Imaging-based hybrid CRISPR screening

By introducing DNA that recognizes sequences, reporter genes and reads sequences into cells and determining their location using readout probes, the problem of difficult to determine cell genotypes in the prior art is solved, and the phenotype and genotypes are achieved The efficient and accurate correlation expands the available space for screening.

CN113994001BActive Publication Date: 2024-12-06PRESIDENT & FELLOWS OF HARVARD COLLEGE
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202080043174.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-01
Filing Date
2020-04-17
Publication Date
2024-12-06
Estimated Expiration
2040-04-17

AI Technical Summary

Technical Problem

Prior art It is difficult to determine the genotype of individual cells whose phenotype has been imaged in a CRISPR-based hybrid library screen, and high-throughput hybrid library screening cannot utilize the cellular structural morphology and the dynamic characteristics of internal molecular tissue.

Method used

By introducing DNA containing recognition sequences, reporter genes and read sequences into the cell, the read probe is used to determine the location of DNA expression, forming a codeword to determine the correspondence between the genotype and phenotype of the cell.

Benefits of technology

Improved decoding accuracy, able to measure genotypes and phenotypes of multiple cells simultaneously, expanding the available phenotype space for screening, allowing high-throughput analysis of the complex morphology and subcellular molecular tissue of cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113994001B_ABST
    Figure CN113994001B_ABST
Patent Text Reader

Abstract

The present invention relates to imaging cells for determining the phenotype and / or genotype of a cell population or for constructing a genotype-phenotype correspondence for high-throughput screening. Cells can be manipulated using CRISPR or other techniques. Nucleic acids can be introduced into cells using lentiviruses. The nucleic acid may contain: a guide portion comprising a DNA or RNA recognition sequence, a reporter gene portion, and an identification portion comprising one or more reading sequences. The guide portion can be used to change the phenotype of the cell, for example, using a sequence that can be targeted with CRISPR or other techniques, such as an sgRNA sequence, and the phenotype of the cell can be determined using various imaging methods. The identification portion can be determined using MERFISH or other suitable techniques. In addition, the association or co-localization between the determination of the reporter gene and the reading sequence can greatly improve the decoding accuracy. Other aspects relate to compositions or devices, kits, etc. for use in the method.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 836,578, entitled “Imaging-Based Pooled CRISPR Screening,” filed by Zhuang et al. on April 19, 2019, and U.S. Provisional Patent Application Serial No. 62 / 841,715, entitled “Imaging-Based Pooled CRISPR Screening,” filed by Zhuang et al. on May 1, 2019. The entire contents of each of these applications are incorporated herein by reference.

[0003] Government funding

[0004] This invention was made with government support under Grant No. MH113094 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field

[0005] The present invention generally relates to imaging cells, for example, for determining the phenotype and / or genotype of a cell population. In some cases, cells can be manipulated, for example, using CRISPR or other technologies. Background Art

[0006] The development of CRISPR-based gene editing systems has greatly enhanced our ability to manipulate genes and explore the fundamental molecular mechanisms of cellular function through genetic perturbations. Facilitated by the ability to generate highly diverse nucleic acid libraries, CRISPR-based pooled library screening can greatly accelerate the discovery of genes involved in cellular processes. However, the phenotypes available in pooled library screening are largely limited to cell viability and marker expression. In recent years, single-cell RNA sequencing and mass cytometry have been combined with CRISPR screening to expand the phenotypic space available for pooled library screening, allowing for genetic screening based on single-cell RNA and protein expression profiles.

[0007] However, high-throughput pooled library screening still fails to exploit many important cellular phenotypes. These include the morphology of cellular structures and the intracellular molecular organization, as well as their dynamics, which can only be measured using techniques such as high-resolution imaging. High-content imaging further allows these properties to be measured simultaneously for many molecular species in a parallel fashion—for example, recent advances in single-cell transcriptome imaging have increased the number of molecular phenotypes that can be imaged down to the genome scale in individual cells in a single experiment. Despite the power of imaging to capture cellular phenotypes, imaging-based pooled library screening remains challenging, primarily due to the difficulty in determining the genotype of individual cells whose phenotypes have been imaged in pooled library screening. Several approaches have been developed to determine genotype by sequencing after physically isolating cells with a specific phenotype. However, to determine the full genotype-phenotype correspondence, full-scale imaging-based pooled library screening approaches are required, in which the genotype and phenotype of individual cells are imaged in situ. Summary of the Invention

[0008] The present invention generally relates to imaging cells, e.g., for determining the phenotype and / or genotype of a cell population. In some cases, cells can be manipulated, e.g., using CRISPR or other techniques. The subject matter of the present disclosure, in some cases, relates to interrelated products, alternative solutions to specific technical problems, and / or a variety of different uses of one or more systems and / or articles.

[0009] In one aspect, the present invention generally relates to a method. According to one set of embodiments, the method comprises: (a) introducing DNA into a plurality of cells, the DNA comprising: a guide portion comprising a recognition sequence, a reporter portion, and an identifier portion comprising a reader sequence; (b) determining the location of RNA molecules expressed by the reporter portion of the introduced DNA in the plurality of cells by determining the reporter portion; (c) determining the reader sequence on the RNA molecules expressed by the introduced DNA comprising the reporter portion and the identifier portion in the plurality of cells by exposing the cells to a readout probe capable of binding to the readout sequence; (d) colocalizing the binding of the readout probe with the location of the RNA molecules expressed by the reporter portion of the introduced DNA; (e) repeating (b), (c), and (d) a plurality of times using different readout sequences; and (f) forming a codeword corresponding to the binding of the colocalized readout probe, wherein the bit value of the codeword is based on the binding of the readout probe to the readout sequence.

[0010] According to another set of embodiments, the method includes: introducing DNA into multiple cells, the DNA comprising: a guide portion comprising a recognition sequence, a reporter gene portion, and an identification portion comprising a reading sequence; determining the position of RNA molecules expressed by the reporter gene portion of the introduced DNA in the multiple cells by determining the reporter gene portion; determining the reading sequence in the multiple cells by exposing the cells to multiple readout probes, each of which can bind to a reading sequence; co-localizing the binding of the readout probes with the position of the RNA molecules expressed by the reporter gene portion of the introduced DNA; and forming a codeword corresponding to the binding of the co-localized readout probes, wherein the bit value of the codeword is based on the binding of the readout probes to the reading sequence.

[0011] In another set of embodiments, the method includes: introducing a nucleic acid into a plurality of cells, wherein the nucleic acid comprises: a guide portion comprising a recognition sequence, a reporter gene portion, and an identification portion comprising a reading sequence; imaging the plurality of cells, wherein the cells exhibit imageable phenotypic differences due to expression of the guide portion; and acquiring a plurality of images of the plurality of cells, wherein the cell images exhibit differences due to differences in the identification portion of the nucleic acid within the cells.

[0012] In another set of embodiments, the method includes: introducing DNA into a plurality of cells using a lentivirus, wherein the DNA comprises: a guide portion comprising a recognition sequence, a reporter gene portion, and an identification portion comprising a reading sequence; determining the phenotypes of the plurality of cells, and determining the genotypes of the plurality of cells, and determining the correspondence between the genotypes and the phenotypes.

[0013] According to yet another set of embodiments, the method includes: introducing DNA into a plurality of cells using a lentivirus, wherein the DNA comprises: a guide portion comprising a recognition sequence and an identification portion comprising a reading sequence; determining the phenotypes of the plurality of cells, determining the genotypes of the plurality of cells, and determining the correspondence between the genotypes and the phenotypes.

[0014] In another aspect, the present invention encompasses methods of making one or more of the embodiments described herein. In yet another aspect, the present invention encompasses methods of using one or more of the embodiments described herein.

[0015] Other advantages and novel features of the present invention will become apparent from the following detailed description of various non-limiting embodiments of the invention considered in conjunction with the accompanying figures. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying drawings, which are schematic and not intended to be drawn to scale. In the drawings, each identical or nearly identical component is generally represented by a single numeral. For clarity, it is not necessary for every component to be labeled in every figure, nor is it necessary for every component of each embodiment of the invention shown, where illustration is not necessary to allow one of ordinary skill in the art to understand the invention. In the drawings:

[0017] Figures 1A-1F Schematic diagram of imaging-based barcode detection for genotype determination according to one embodiment of the present invention;

[0018] Figures 2A-2D FIGURE 1 illustrates a barcode misidentification rate in another embodiment of the present invention;

[0019] Figures 3A-3E Schematic diagram of a lentiviral design in another embodiment of the present invention;

[0020] Figures 4A-4D Schematic diagram of an imaging-based hybrid CRISPR screen in another embodiment of the present invention;

[0021] Figures 5A-5C The diagram shows the genetic factors involved in regulation according to one embodiment of the present invention;

[0022] Figures 6A-6B According to another embodiment of the present invention, certain genes for inhibiting transcription are shown;

[0023] Figure 7 Schematic diagram of a cloning strategy for a library in one embodiment of the present invention;

[0024] Figure 8 FIGURE 2 illustrates colocalization ratio analysis in another embodiment of the present invention;

[0025] Figure 9 Schematic diagram of a cloning strategy for a library in another embodiment of the present invention;

[0026] Figures 10A-10D illustrates the knockdown of certain genes in one embodiment of the present invention; and

[0027] Figure 11 The diagram shows changes in MALAT1 nuclear speckle enrichment in another embodiment of the present invention. DETAILED DESCRIPTION

[0028] The present invention generally relates to imaging cells, for example, for determining the phenotype and / or genotype of a cell population, for example, to construct a genotype-phenotype correspondence for high-throughput screening. In some cases, the cells can be manipulated, for example, using CRISPR or other technologies. In certain embodiments, a nucleic acid can be introduced into the cells, for example, using a lentivirus. The nucleic acid can comprise: a guide portion comprising a DNA or RNA recognition sequence, a reporter gene portion, and an identification portion comprising one or more reading sequences. The guide portion can be used to change the phenotype of the cell, for example, using a sequence that can be targeted using CRISPR or other technologies, such as an sgRNA sequence, and in some cases, the phenotype of the cell can be determined using various imaging methods. The identification portion can be determined using MERFISH or other suitable techniques. In addition, in some cases, the association or co-localization between the determination of the reporter gene and the reading sequence can greatly improve decoding accuracy, for example, by reducing the background signal caused by false identification. Other aspects generally relate to compositions or devices for use in such methods, kits for use in such methods, or the like.

[0029] An example aspect of the present invention generally relates to systems and methods for manipulating the genetic material of a cell (e.g., using CRISPR or other technologies) and determining the phenotype of the cell obtained as a result of the manipulation. The genotype of the cell can also, for example, be determined using a codeword encoding a read sequence, such as used in MERFISH or similar technologies. By determining that the genotype of the cell is changed and how the phenotype of the cell is changed, certain embodiments as discussed herein can be used to understand complex problems, such as about cell morphology, subcellular molecular organization, etc., for example, the spatial structure within a cell (such as a mammalian cell).

[0030] Now refer to Figure 1A Describe exemplary embodiments of the present invention. In this figure, nucleic acid library members can be introduced into cells, such as mammalian cells. In one set of embodiments, the nucleic acid comprises a guide portion (e.g., comprising an sgRNA or another recognition sequence that can be used to identify a target site), a reporter gene portion (e.g., that can directly or indirectly generate a signal such as a fluorescence or immunoprecipitation signal), and an identifier or "barcode" portion (e.g., comprising a reader sequence that can be used to distinguish between various nucleic acids containing different guide portions).

[0031] Various methods can be used to introduce nucleic acid into cells. These methods include, for example, viral delivery (e.g., using slow virus, retrovirus, adenovirus, adeno-associated virus, etc.), electroporation, bombardment delivery, etc. In some cases, slow virus can be useful because it allows nucleic acid to be stably integrated into the genome of the cell. In addition, in certain embodiments, the rate at which nucleic acid is introduced into the cell can be controlled so that most cells contain only one such nucleic acid. For example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the cells can have only one such nucleic acid imported therein.

[0032] In this example, for the lentivirus generated by the mixed library, each lentivirus can contain two library members. During the lentiviral infection process, the guide portion and the identification portion can recombine. Such recombination can lead to incorrect identification of the guide portion based on the measurement of the identification portion. Therefore, in one set of embodiments, the guide portion and the identification portion can be placed in close proximity to each other in the 3'LTR region of the lentivirus, that is, after the polypurine band (PPT) sequence, so that the distance between the guide portion and the identification portion is minimized, for example, for the constant region of the sgRNA of Cas9, it is 100 bases or less. In this way, the recombination rate can be reduced to improve the accurate association between the guide portion and the identification portion. In some cases, the guide portion is replicated within the 5' region of the proviral DNA (e.g., lentivirus). This can enable the guide portion to be integrated into the host cell genome to provide expression of the guide portion.

[0033] After introduction, the cell can be studied to determine the phenotype of the cell and the genotype of the cell (e.g., using an identification moiety). For example, the phenotype can be measured using imaging methods that detect proteins, RNA, or DNA in cells or subcompartments of cells. In certain embodiments, the phenotype can also be associated with cell growth, morphology, or cell-cell interactions. In some cases, the phenotype can be a temporal change, a kinetic of a cell property, or the like. In some cases, the phenotype can include multiple features, i.e., a multidimensional readout.

[0034] The identification portion can be determined, for example, using MERFISH (multiple error-corrected fluorescence in situ hybridization) or other techniques. Those of ordinary skill in the art are familiar with MERFISH and related technologies; see, for example, International Patent Application Publication Nos. WO 2016 / 018960, WO 2016 / 018963, WO 2018 / 089445, WO 2018 / 218150, WO 2018 / 089438. In some cases, in some subsequent embodiments, the identification portion can include various "read sequences" or nucleic acid sequences that can be specifically identified using corresponding nucleic acid probes (e.g., "read probes"). In techniques such as MERFISH, the presence or absence of a read sequence can be encoded as a digit, and the sequence of the read probe can therefore be encoded as a codeword. In addition, in some cases, various error detection and / or correction techniques, such as Hamming codes or Golay codes, can be applied to codewords.

[0035] In some cases, the determination of the reporter gene part can be carried out at intervals with the determination (for example, using one or more read probes) of the various parts of the identification part. In addition, in some embodiments, the position of the reporter gene part and the association between the determination of the identification part or co-location can be used to significantly improve decoding accuracy. For example, binding events or codewords that fully correspond to the position that does not exist with the reporter gene part can be ignored as background noise, non-specific markers, etc. This association or co-location between the reporter gene part and the identification part can significantly improve detection accuracy.

[0036] The above discussion is a non-limiting example of one embodiment of the invention that can be used to image cells (e.g., to determine the phenotype and / or genotype of a cell population). However, other embodiments are possible. Thus, more generally, various aspects of the invention relate to various systems and methods for determining the phenotype and / or genotype of a cell population (e.g., by imaging) and / or manipulating the cells using CRISPR or other techniques.

[0037] According to one aspect, the present invention generally relates to systems and methods for determining the phenotype and / or genotype of a cell population using imaging. In addition, the genome of the cell can, for example, be operated using CRISPR or other technologies. In some cases, a relatively large number of cells can, for example, be studied using suitable imaging techniques (such as those described herein) to determine their phenotype and genotype, for example, after operation. In some embodiments, due to the use of such imaging techniques, a relatively large number of cells can be determined, allowing for relatively large-scale or high-throughput screening, as discussed herein. For example, a specific phenotype of multiple cells can be determined (for example, after editing by CRISPR), and cells with a certain or desired phenotype can also be determined by genotype.

[0038] In some cases, it is possible to determine a relatively large amount of cells. For example, depending on the magnification, a single field of view can include a relatively large amount of cells (for example, at least 10, at least 100, at least 1,000, at least 10,000, at least 100,000 cells, etc.). In addition, the sample can be larger than a single field of view (for example, especially under a relatively large magnification), and multiple images of the different parts of the sample can be obtained manually or automatically (for example, using computer control). This can allow for studying even larger amounts of cells by using more than one field of view. For example, at least 10, at least 100, at least 1,000, at least 10,000, at least 100,000, at least 1,000,000, at least 10,000,000 cells, etc. For example, an overall image of a sample can be combined using multiple fields of view (e.g., fields of view taken simultaneously or nearly simultaneously) to produce an image; for example, at least 2, at least 3, at least 5, at least 7, at least 10, at least 15, at least 20, at least 30, at least 50, at least 75, or at least 100 images (e.g., corresponding to different portions of the sample) can be acquired at different fields of view to produce an overall image. Thus, in some cases, the sample can be substantially larger than a single field of view. For example, a sample can have a field of view of at least about 0.01 cm 2 , at least about 0.03cm 2 , at least about 0.1cm 2 , at least about 0.3cm 2 , at least about 1cm 2 , at least about 3cm 2 , or at least about 10cm 2 Equal area.

[0039] Additionally, in some embodiments, multiple images can be captured for the same field of view. For example, at least 2, at least 3, at least 5, at least 7, at least 10, at least 15, at least 20, at least 30, at least 50, at least 75, or at least 100 images can be acquired for the same field of view.

[0040] In some cases, in one set of embodiments, multiple images can be taken at each field of view imaged within the sample. In some embodiments, different wavelengths can be used. For example, in some cases, images can be collected using different illumination sources and captured using different filters to produce images of different colors that detect the presence of different fluorescent compounds. Thus, in some embodiments, different images can be taken at different wavelengths, for example, to observe images in different colors (e.g., red-green-blue, red-yellow-blue, cyan-magenta-yellow, etc.).

[0041] In some embodiments, these images can be collected at defined time intervals to form time-lapse images of the sample. This can be useful, for example, to determine characteristics that vary over time, such as cell growth. For example, an image (or multiple images) can be acquired at different time points, for example, using a period of about 5 seconds, about 10 seconds, about 15 seconds, about 30 seconds, about 1 minute, about 2 minutes, about 3 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 1 day, etc. Similarly, in some embodiments, images can be collected after different treatments are performed on the same sample.

[0042] In addition, in some embodiments, multiple images can be collected using different imaging modalities, such as super-resolution optical microscopy, conventional epifluorescence microscopy, confocal microscopy, etc., including those described herein. In some cases, these images can be merged to form high-content optical measurements of cell properties.

[0043] The cell can be any suitable cell, for example, a mammalian cell (e.g., a human or non-human cell), a bacterial cell (e.g., an E. coli), a eukaryotic cell, a prokaryotic cell, a yeast cell, or a cell of other types. The cell can be from any suitable source, for example, a cell culture. In some cases, the cell can be taken from a tissue sample, for example, taken from a biopsy, artificial growth or culture, or the like. In some cases, the cell is genetically modified. In some cases, a tissue sample can be analyzed. In certain embodiments, a plurality of cells can be transfected as discussed herein, and the resulting phenotype of the cell is determined.

[0044] In some aspects, nucleic acids are introduced into cells, which can be used to modify the genetic material of the cell, for example, its genome. Technologies such as CRISPR or other related technologies can be used to modify the genetic material of the cell, for example, as guided by the nucleic acid. In some embodiments, this can allow accurate identification of genetic manipulations of cells, and their corresponding phenotypes, using the marker moiety to identify the genotype that leads to the observed phenotype.

[0045] For example, in one group of embodiments, the nucleic acid delivered to the cell may include a guide portion, and / or a reporter gene portion, and / or an identification portion. The guide portion may include an sgRNA or another recognition sequence that can be used to identify a target site (e.g., within the genome of the cell). The reporter gene portion may be capable of directly or indirectly generating a signal, such as a fluorescent signal. For example, the reporter gene portion may encode a fluorescent protein (e.g., GFP), an enzyme that can be used to make another molecule become fluorescent (e.g., luciferase), an enzyme that produces a detectable chemical reactant, and the like. The identification portion may include sequences that can be used to distinguish various nucleic acids that include different guide portions. For example, the identification portion may include one or more sequences (e.g., "reading sequences") that can be read using corresponding nucleic acid probes (e.g., "reading probes").

[0046] In some embodiments, the guide portion and / or reporter gene portion and / or identification portion, if present, can be arranged in any suitable order on the nucleic acid to be introduced into the cell. In some cases, these portions can be relatively close to each other (for example, in the nucleic acid, for example, spaced apart from each other by less than 5,000, less than 3,000, less than 1,000, less than 500, less than 300, less than 100, less than 50, less than 30 or less than the distance of 10 bases). In addition, in some cases, for example, in the nucleic acid, one or more of these portions can at least partially overlap. In addition, in some embodiments, other portions or sequences may also be present in the nucleic acid. For example, one or more of these portions can include promoter sequences, such as those discussed herein.

[0047] In one set of embodiments, the nucleic acid comprises an expression portion or a guide portion. The guide portion may comprise any suitable nucleic acid sequence that is suspected of being able to alter the phenotype of a cell and / or can be used to intentionally alter or manipulate the genome of a cell, for example, to result in an observable phenotypic change in the cell. For example, the guide portion may encode a gene, a protein, a regulatory sequence (e.g., an operator, a promoter such as a CMV promoter, a repressor, a transcription factor binding site, etc.), a sequence encoding a non-coding RNA (e.g., miRNA, siRNA, rRNA, tRNA, lncRNA, snoRNA, snRNA, exRNA, piRNA, tsRNA, rsRNA, shRNA, Cas9 guide RNA, sgRNA, etc.), and the like. In some cases, the guide portion may be part of the same nucleic acid that comprises the identification portion; however, in other cases, the expression portion may be part of a different nucleic acid.

[0048] Thus, for example, the guide portion can include a sequence that recognizes a target region of interest (e.g., a target region of interest on DNA (e.g., on the genome of the cell)), such as an RNA sequence. In some cases, the guide portion can also include a binding sequence, such as a Cas binding sequence that can be recognized by Cas or another nuclease. For example, in some cases, the guide portion can be suitable for allowing CRISPR editing of a genome. For example, the guide portion can include a gRNA (guide RNA) or an sgRNA (single guide RNA). In some embodiments, the sgRNA can include a crispr RNA portion (crRNA), which is a sequence complementary to the target sequence (e.g., complementary to the target DNA), and a tracrRNA portion that can be recognized by a Cas nuclease or another nuclease. In some cases, the crRNA portion can have 17, 18, 19, or 20 nucleotides. A wide variety of different Cas nucleases can be used, such as Cas9 (from Streptococcus pyogenes), Cas14, CasX, CasY, Cas12a, Cas13a, Cas13b, Cas13d, Cas14a, etc. Variant forms of these Cas nucleases are also contemplated, for example, high-fidelity Cas9, eSpCas9, SpCas9-HF1, HypaCas9, FokI-fused dCas9, xCas9, dCas9, etc. Non-limiting examples of suitable binding sequences for Cas are provided below. In addition, one of ordinary skill in the art will be aware of CRISPR and related technologies, and kits that can be used to perform CRISPR experiments are readily commercially available.

[0049] In certain embodiments, there may be more than one possibility for a guide portion. For example, a nucleic acid library may be prepared, e.g., with different crRNA portions, e.g., for binding to different target sequences in a genome. In some cases, there may be at least 10, at least 10, or more possibilities for a guide portion. 2 At least 10 3 At least 10 4 At least 10 5 The invention provides a method for preparing a plurality of distinguishable nucleic acids, for example, the method can bind to different target sites in the genome and / or can cause different changes or manipulations of the genome, etc. Thus, in certain embodiments, one or more identification moieties (such as those described herein) and one or more guide moieties can be used to prepare a plurality of distinguishable nucleic acids. However, it should be understood that the number of possible identification moieties need not equal the number of possible guide moieties, that is, some redundancy can be added, for example, as discussed below.

[0050] In some embodiments, the nucleic acid can include a reporter gene portion, which can, for example, be measured using fluorescence or other detection techniques. For example, the reporter gene portion can include a gene encoding a fluorescent protein, such as GFP (green fluorescent protein), a red fluorescent protein from dsRed, PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PAmCherry, PAtagRFP, mMaple, mMaple2, and mMaple3. Other suitable fluorescent proteins are known to those of ordinary skill in the art. See, for example, U.S. Patent number 7,838,302 or U.S. Patent Application Serial No. 61 / 979,436, the entire contents of each of which are incorporated herein by reference.

[0051] In another set of embodiments, the reporter gene portion can encode an enzyme (e.g., luciferase) that can make another molecule become fluorescent. When expressed in a cell, a suitable substrate (e.g., luciferin) can be added, which can be converted into a fluorescent form when exposed to the enzyme. However, in areas where the nucleic acid is not present, no fluorescence occurs. In this way, the nucleic acid can be located or positioned in a cell (or in a portion of the cell).

[0052] It should be understood that the reporter gene portion need not be determined solely by fluorescence. In other embodiments, other reporter gene portions may be used. For example, in one embodiment, an enzyme that produces a detectable chemical reactant or analog may be encoded within the reporter gene portion. Other examples of reporter genes that may be used include, but are not limited to, proteins that can be detected by immunoprecipitation, immunofluorescence, and the like. Non-limiting examples of suitable proteins include Myc tags or HA tags.

[0053] Any suitable technique can be used to determine the reporter gene portion, and the exact method can depend on the type of reporter gene. Examples include, but are not limited to, in situ hybridization techniques such as smFISH (single molecule fluorescence in situ hybridization), multiplex FISH, CASFISH, or other techniques known to those of ordinary skill in the art. In one embodiment, smFISH is used to locate the reporter gene portion, for example, within the cell.

[0054] In addition, as discussed herein, the position of the marker portion can also be determined and associated or co-localized with the reporter portion, which can, for example, be used to reduce background noise and / or improve decoding accuracy. For example, the reporter portion of the nucleic acid can produce a first signal (e.g., a first fluorescence) and the marker portion can produce a second signal (e.g., a second fluorescence, which can be at the same or a different wavelength as the first fluorescence), and the two can be associated or co-localized with each other.

[0055] In some embodiments, the nucleic acid can include an identification portion or a "barcode" of nucleotides that can be used to distinguish multiple nucleic acids from each other. The identification portion can be present at any suitable position on the nucleic acid. For example, in one embodiment, the identification portion can be present in the 3'UTR of the reporter gene.

[0056] In some cases, other sequences may be present in the identification portion. For example, in some cases, the identification portion may include a promoter or another regulatory sequence (e.g., an operator, a promoter such as a CMV promoter, a repressor, a transcription factor binding site, etc.). A promoter can drive transcription. In some embodiments, the promoter of the identification portion may be the same as or different from the promoter of the guide portion.

[0057] In certain embodiments, a library of marker moieties may be used, e.g., containing at least 10, at least 10 2 At least 10 3 At least 10 4 At least 10 5 At least 10 6 At least 10 7 At least 10 8In some embodiments, the present invention provides a single sequence of at least two, at least three, at least five, at least seven, at least ten, at least fifteen, at least twenty, at least twenty-five, at least thirty, at least forty, or at least fifty variable portions. Each variable portion can include at least two, at least three, at least four, at least five, at least seven, at least ten, at least fifteen, at least twenty, at least twenty-five, at least thirty, at least forty, or at least fifty possibilities.

[0058] Thus, for example, defining an identifier having 22 variable regions with 2 unique possibilities per variable region would define an identifier having 2 22 =4,194,304 members of the identification portion library. As another non-limiting example, the identification portion can be defined as having 10 variable regions and each variable region has 7 unique possibilities, thereby defining a library with 7 10 In some embodiments, the present invention provides a library of marker portions of individual members. It should be understood that the variable portion can include any suitable number of nucleotides, and the different variable portions in the marker portion can independently have the same or different number of nucleotides. Different variable regions also can have the same or different unique possibilities.

[0059] For example, the variable portion can be limited to a length of at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, or more nucleotides, and / or a maximum length of no more than 50, no more than 40, no more than 30, no more than 25, no more than 20, no more than 15, no more than 10, no more than 7, no more than 5, no more than 4, no more than 3, or no more than 2 nucleotides. Combinations of these are also possible, for example, the variable portion can have a length of 5-50nt or 15-25nt, etc.

[0060] Each read sequence position can be considered a "bit" (e.g., a 1 or a 0 in this example), although it should be understood that the number of possibilities for each "bit" is not necessarily limited to just 2, unlike in a computer. In other embodiments, there can be 3 possibilities (i.e., a "trit"), 4 possibilities (i.e., a "quad-bit"), 5 possibilities, etc., instead of just 2 possibilities. For example, various trits are used in the examples below. However, in some, but not all, embodiments, the use of bits (of any number of possibilities) to form the identification portion can allow the use of codewords, error detection codes, error correction codes, etc. within the identification portion, for example, as discussed in detail herein.

[0061] In some cases, the variable portion of the identification portion can be chained together to produce the identification portion. However, in other cases, one or more variable portions can be separated, for example, with the constant portion of Nucleotide at intervals, thereby producing the identification portion. In addition, in some cases, some or all possible variable portions in the library can be unique, for example, to reduce confusion as far as possible. Any method can be used for chaining. For example, a plurality of parts can be used to connect, overlap PCR, oligonucleotide pool synthesis or those of ordinary skill in the art known for nucleic acid connection or chaining together other technologies chain together.

[0062] In certain embodiments, all members of a library are generated and / or used. However, in other embodiments, not all members of a library need be generated and / or used. For example, in some embodiments, a smaller subset of a library may be used, e.g., less than 75%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.3%, or less than 0.1% of all possible members of a library may be generated and / or used, e.g., to reduce or eliminate unclear or unintentional reuse.

[0063] In some embodiments, the genotype of the cell can be determined, for example, using the identification portion to determine. A variety of different techniques for determining the genotype of a cell can be used, for example, FISH, smFISH, MERFISH, in situ hybridization, multiple FISH, CASFISH or other techniques known to those of ordinary skill in the art. In some embodiments, these methods can involve direct hybridization with the identification portion, or direct hybridization with a molecule generated by the portion by the cell. In some cases, it can also involve the combination of separate adapter entities, which then directly bind to the identification portion or the molecule generated by the identification portion. Other non-limiting examples of technology are included in those disclosed in U.S. Patent Application Serial No. 15 / 329,683 or International Patent Application Publication No. WO 2016 / 018960, and the entire contents of each application are incorporated herein by reference.

[0064] In one set of embodiments, determination of the genotype of a cell can be facilitated by determining an identifier portion of a nucleic acid within the cell. For example, a nucleic acid comprising an identifier portion and a guide portion can be introduced into a cell; the guide portion can result in the formation of different phenotypes as discussed above, for example, by allowing editing of a target sequence to occur, for example, on the genome. However, it is also important to know which cells the nucleic acid was introduced into so that the relationship between the observed phenotype (e.g., an altered phenotype) and the genotype that caused those phenotypes can be understood. As discussed herein, by determining the identifier portion within a cell, the identity of the nucleic acid contained within each cell can be determined, thereby also determining a specific guide portion, for example, if the nucleic acid comprises an identifier portion and a guide portion on the same single nucleic acid.

[0065] As a non-limiting example, in one set of embodiments, the cell can be sequentially exposed to nucleic acid probes capable of binding to different portions of the identification portion or to molecules (such as RNA) expressed by the cell from this identification portion, for example, the nucleic acid probe is a nucleic acid probe comprising a target sequence (e.g., particularly in some cases, which is capable of binding to at least a portion of the identification portion) and a reading sequence (e.g., which can be "read" in some manner to determine binding); and the binding of the nucleic acid probe within the cell can be determined. For example, the cell can be exposed to a secondary nucleic acid probe, which can comprise a recognition sequence capable of binding or hybridizing to the reading sequence and can comprise a signaling entity. By determining the signaling entity within an image (and in some cases, inactivating the signaling entity between images and exposing to different nucleic acid probes), the identification portion of the cell can be determined.

[0066] As discussed herein, various nucleic acid probes can be used to determine one or more nucleic acids in a cell. The probe can comprise a nucleic acid (or an entity that can hybridize with nucleic acids, for example, specific hybridization), such as DNA, RNA, LNA (locked nucleic acid), PNA (peptide nucleic acid), or a combination thereof. In some cases, other components can also be present in the nucleic acid probe, for example, as discussed below. In some embodiments, the nucleic acid probe can be formed by other components, for example, proteins or other small molecules, or can represent a combination of these components and nucleic acids (such as DNA, RNA, LNA, PNA, etc.).

[0067] Nucleic acid probes can be introduced into cells using any suitable method. In some cases, the cells can be sufficiently permeabilized so that the nucleic acid probe can be introduced into the cells by flowing a fluid containing the nucleic acid probe around the cells. In some cases, the cells can be sufficiently permeabilized as part of a fixation process; in other embodiments, cells can be sufficiently permeabilized by exposure to certain chemicals such as ethanol, methanol, Triton, etc. Additionally, in some embodiments, techniques such as electroporation or microinjection can be used to introduce nucleic acid probes into cells.

[0068] Determination of intracellular nucleic acid can be qualitative and / or quantitative. In addition, the determination can also be spatial, for example, the position of intracellular nucleic acid can be determined in two dimensions or three dimensions. In some embodiments, the position, number and / or concentration of intracellular nucleic acid can be determined.

[0069] As mentioned, in certain embodiments, the association or co-localization between the reporter gene position and the detection read sequence when reading the codeword can significantly improve decoding accuracy, for example, by reducing the misidentification of background signals introduced by non-specific labels. In some cases, for example, the codeword readout portion can only include one sequence for readout, making it more difficult to identify the readout signal, for example, relative to the background. For example, in some cases, the reporter gene portion can be determined as discussed herein, for example, locally or spatially, and the portion of the identifier sequence can be determined as discussed herein. In some cases, the apparent portion of the identifier sequence that is not co-localized with the reporter gene portion can be eliminated from further consideration. For example, the apparent identifier sequence can be an incorrect signal, background noise, etc. In addition, in some cases, the reporter gene portion can be determined between different determinations of the identifier sequence. Such an approach can improve accuracy, for example, by reducing errors caused by sample movement, platform offset, etc. Therefore, the association or co-localization between the reporter gene position and the detection read sequence can be used to determine whether the hypothetical signal of the read sequence is the read sequence or background noise, etc. (therefore not worthy of further consideration).

[0070] It will be appreciated that while the number of guide moieties and / or identifier moieties can have a relatively large number of possibilities (e.g., millions), this is readily achievable by one of ordinary skill in the art using technology such as computers and automated nucleic acid synthesis instruments (many of which are commercially available) and techniques such as solid phase synthesis and / or isothermal assembly, and / or error-prone PCR and / or ligation or otherwise assembly by, for example, combinatorial overlapping PCR of multiple variable regions. Similarly, a correspondingly relatively large number of unique identifier moieties can be associated with such a large number of possibilities for guide moieties, e.g., by using a relatively small number of suitable variable regions and a unique "position" that can be generated for each variable region. Thus, nucleic acid libraries (e.g., each containing an identifier moiety and a guide moiety) can be prepared, e.g., containing at least 10, at least 10 2 At least 10 3 At least 10 4 At least 10 5 At least 10 6 At least 10 7 At least 10 8 The only member.

[0071] In some aspects, nucleic acid from a nucleic acid library can be introduced into a cell. Any suitable technique can be used to introduce the nucleic acid. For example, in one group of embodiments, nucleic acid can be delivered to a cell using a virus, such as a slow virus, a retrovirus, adenovirus, or an adeno-associated virus. In some cases, the virus can be capable of transfecting or delivering the nucleic acid to the genome of the cell, and in some cases, stably within the genome.

[0072] For example, in one set of embodiments, a lentiviral delivery system can be used to introduce nucleic acids into cells. The lentiviral system can allow a certain number of nucleic acids to be introduced into the cells to be controlled. For example, by controlling the titer of the lentivirus used for transduction, the number of library members delivered to a single cell can be controlled to be 1, or more than 1. In some embodiments, the guide portion and the identification portion can be placed in close proximity to each other within the 3'LTR region of the lentivirus, that is, after the polypurine band (PPT) sequence of the lentivirus, so that the distance between the guide portion and the identification portion is minimized, for example, for the constant region of the sgRNA of Cas9, it is 100 bases or less. In certain embodiments, the distance can also be less than 500 bases, less than 300 bases, less than 200 bases, less than 100 bases, less than 50 bases, less than 30 bases, or less than 10 bases. Such a lentiviral construct can reduce the genomic distance between the guide portion and the identification portion. This can lead to a reduction in recombination effects and can allow the guide portion to be more accurately identified by measuring the identification portion. Those skilled in the art are familiar with lentiviral and other viral delivery systems for introducing nucleic acids into cells. Many kits capable of such delivery of nucleic acids into cells using viruses are readily commercially available.

[0073] In addition, in some embodiments, other techniques can be used to introduce nucleic acids into cells. For example, the nucleic acid can be incorporated into a plasmid, which can be taken up by the cell. Other methods for introducing nucleic acids into cells include, but are not limited to, calcium phosphate (e.g., tricalcium phosphate), electroporation, cell extrusion, mixing cationic lipids with materials that produce liposomes (liposomes fuse with cell membranes), etc. Other non-limiting examples of suitable methods include dendrimers, cationic polymers, lipofection, FuGENE, sonoporation, optical transfection, protoplast fusion, impalefection, gene guns, magnetic transfection, particle bombardment, viral infection, etc.

[0074] In certain embodiments, the nucleic acid can be introduced into or transfected into the cell so that at least 50% of the cells only introduce 0 or 1 nucleic acid therein. In some cases, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% etc. cells can only introduce 0 and / or 1 nucleic acid therein. This can, for example, be achieved using slow viruses such as those described above, suitable dilution techniques, cell sorting techniques, or by using other techniques such as microfluidic droplets. In other cases, the percentage of transfected cells can be smaller, such as less than 50%, less than 20%, less than 10%, less than 1%. In some embodiments, the cells wherein these nucleic acids are not introduced can be removed. The non-limiting example of cell removal includes processing with chemicals such as antibiotics, for example, killing untransfected cells or preventing untransfected cells from dividing. In another example, some or all of the cells not containing the introduced nucleic acid can be removed from the sample, for example, using fluorescence-activated cell sorting and / or other suitable cell sorting or microfluidic techniques.

[0075] In certain embodiments, the identification portion and the guide portion can be combined in a single source, for example, a nucleic acid contained in a single virus. In other embodiments, these portions can be provided to the cell in separate sources, for example, two different viral delivery vehicles. Other examples of introducing nucleic acids into cells are disclosed herein, and the methods of introduction can be the same or different.

[0076] The merging of the identification portion and the guide portion can be determined, whether on the same or different vectors (e.g., viruses), for example, randomly or deterministically. For example, a specified CRISPR edit can be assigned to a specified barcode and expressed in the cell. In some embodiments, the specific association between the identification portion and the guide portion can be measured using any of a variety of techniques. For example, PCR can be used to amplify a nucleic acid portion comprising both the identification portion and the guide portion, and then sequencing methods, including next-generation sequencing, can be used to identify which identification region appears with which guide portion by direct sequencing of this PCR product. Those of ordinary skill in the art are aware of other techniques that can be used to sequence nucleic acids (e.g., containing the identification portion and the guide portion). Any technology can be used for sequencing, for example, Sanger sequencing, high-throughput sequencing, next-generation sequencing, nanopore sequencing, ligation sequencing, synthesis sequencing, etc. Those of ordinary skill in the art are aware of different techniques for sequencing nucleic acids.

[0077] Cells can be analyzed in certain aspects to determine their phenotype. In some cases, in some embodiments, the phenotype can be changed, for example, by using CRISPR or other technologies, for example, by interacting with the genome of the cell, as discussed herein. Any suitable technique can be used to determine the phenotype, for example, using optical techniques, by analyzing cell behavior, etc. Specific examples include, but are not limited to, microscopes or other optical techniques such as light microscopes, fluorescence microscopes, confocal microscopes, near-field microscopes, two-photon microscopes, or phase contrast microscopes, or other technologies described herein. In some cases, super-resolution techniques can be used, including any of those described herein. In some embodiments, phenotypes can be detected by other technologies, such as atomic force microscopes or patch clamps. In addition, in some embodiments, proteins can be used to determine the phenotype. For example, proteins can be determined using fluorescence, immunofluorescence, etc. Specific non-limiting examples include fluorescent labeling methods such as fluorescent proteins or organic dyes. In some cases, microscopes and another technology can be used in combination to determine the phenotype.

[0078] Examples of phenotypes that can be determined include, but are not limited to, the morphology of the cell (e.g., shape, size, visual appearance, organelles, subcompartments, state (e.g., during the cell cycle), etc.), certain characteristics of cell movement (e.g., speed, persistence, chemotactic behavior, etc.), certain characteristics of cell-to-cell interactions (e.g., cell-cell adhesion, cell-cell avoidance, cell-cell interactions, etc.), or certain subcellular characteristics (e.g., location of a protein or nucleic acid, diffusion of a protein or nucleic acid, binding of two or more proteins and / or nucleic acids, etc.). Morphology can include whole-cell morphology or subcompartment morphology. In one embodiment, smFISH is used to determine the phenotype of a cell.

[0079] In some cases, the phenotype can be determined dynamically, e.g., over time in a cell.

[0080] In certain embodiments, the cells are present on a substrate, e.g., a substrate suitable for culturing and / or imaging cells. For example, the substrate can be glass, silicon, plastic (e.g., polystyrene, polypropylene, polycarbonate, etc.), or the like. In some cases, at least a portion of the substrate can be at least partially light-transmissive. The substrate can also be untreated or treated in some manner to promote cell attachment.

[0081] In some embodiments, the phenotype that can be determined includes all or at least a portion of the transcriptome of the cell. A variety of techniques can be used to determine the transcriptome, including, but not limited to, smFISH, MERFISH or other techniques such as those described herein. Also referring to U.S. Patent Application Serial No. 15 / 329,683 or International Patent Application Publication No. WO 2016 / 018960, the entire contents of each of which are incorporated herein by reference. In some cases, the transcriptome can be determined spatially within one or more cells.

[0082] In addition, in some cases, the phenotype that can be determined includes all or at least a portion of the chromosome of the cell, and / or can be combined with the chromosome of the cell or otherwise associate with an agent such as protein or RNA. For example, the concentration, spatial position, activity, association of the agent of chromosome and / or other associations etc. can be determined according to some embodiments of the present invention. In some cases, chromosome can be determined in one or more cells in space. The limiting examples of the technology that can be used to determine chromosome include multiple DNA FISH or CASFISH. As another example, the epigenetic modification of cell can be determined.

[0083] Additionally, in some cases, the phenotype that can be determined includes all or at least a portion of the cell's proteome. A variety of techniques can be used to determine the proteome, including antibody labeling, sequential antibody labeling, multiplex antibody imaging, or other multiplex protein imaging techniques. For example, the concentration, spatial location, activity, association, etc. of proteins and / or other associated agents can be determined.

[0084] In certain embodiments, one or more markers in a cell can be determined to determine the phenotype. For example, the marker can indicate a certain cell protein, nucleic acid, morphological feature, etc., or the marker can indicate cell behavior. In addition, the marker can be a marker that can be visually determined in some cases. For example, the marker can be fluorescent, or can change the fluorescence of another fluorescent entity in the cell (for example, by enhancing or quenching). In some embodiments, the marker can also be a dye or can change color. Therefore, the difference in intensity, wavelength, frequency, position, distribution, etc. between cells in the image can be determined to determine the phenotype of the cell. In some cases, other methods for determining the marker can also be used; for example, the marker can be radioactive. Many such markers are commercially available.

[0085] In addition, it should be understood that these measurements are not mutually exclusive. Any combination of these measurements can be carried out in a single sample. And in some embodiments such measurement can be repeated, for example, for same sample. For example, the measurement can be repeated to ensure correctness or reduce potential error (for example, measurement error), or after being exposed to various stimulations or conditions, the measurement is repeated, such as with different nutritional sources, small molecules or other suitable agents that can interact with cells.

[0086] In some cases, the phenotype of a cell can be altered by applying a guide portion, for example, as discussed above, the guide portion can be expressed by the cell in some form to change its phenotype. For example, a guide portion can be used to induce changes in the genome of a cell, for example, by CRISPR or other suitable techniques, including those described herein. As another example, a guide portion encoding a protein can be added to a cell, and the cell can express the protein. If different proteins are encoded in different cells, the cells can exhibit different phenotypes, which can be determined as described above. Thus, for example, multiple cells can be transfected or otherwise introduced with multiple different guide portions, and the cells are then studied to determine the effects of the different guide portions on their phenotypes.

[0087] Therefore, some aspects generally relate to nucleic acid probes introduced into cells (or other samples). The probe can include any one of a variety of entities that can hybridize with nucleic acid (e.g., target site), typically by Watson-Crick base pairing, such as DNA, RNA, LNA, PNA, etc., depending on the application. The nucleic acid probe typically includes a target sequence that can be combined with at least a portion of the target (e.g., target site). In some cases, the combination can be specific binding (e.g., by complementary binding). When introduced into cells or other systems, the target sequence can be combined with a specific target (e.g., mRNA, or other nucleic acids, as discussed herein). The nucleic acid probe can also include one or more read sequences, as discussed below.

[0088] In some cases, more than one type of nucleic acid probe can be applied to a sample, for example, sequentially or simultaneously. For example, at least 2, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000 or at least 30,000 distinguishable nucleic acid probes can be applied to a sample. In some cases, the nucleic acid probes can be added sequentially. However, in some cases, more than one nucleic acid probe can be added simultaneously.

[0089] The nucleic acid probe can include one or more target sequences that can be positioned at any position within the nucleic acid probe. The target sequence can include a region that is substantially complementary to a portion of a target, such as a target nucleic acid. For example, in some cases, the portion can be at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary, for example, to produce specific binding. Typically, complementarity is determined based on Watson-Crick nucleotide base pairing.

[0090] In some cases, the target sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides in length. In some cases, the target sequence may be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides in length. Any combination of these is also possible, for example, the target sequence can have a length of 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0091] The target sequence of nucleic acid probe can be determined with reference to the target suspected to be present in the cell or other sample.For example, the target nucleic acid of protein can be determined using the sequence of protein, for example, by determining the nucleic acid that forms the protein by expression.In some cases, only a part of the nucleic acid encoding the protein is used, for example, with a length as discussed above.In addition, in some cases, more than one target sequence that can be used to identify a specific target can be used.For example, multiple probes can be used, which can be combined or hybridized with the same or different regions of the same target in sequence and / or simultaneously.Hybridization typically refers to an annealing process, by which the single-stranded nucleic acids complementary to each other are associated to form double-stranded nucleic acids by Watson-Crick nucleotide base pairing (for example, hydrogen bonding, guanine-cytosine and adenine-thymine).

[0092] In some embodiments, nucleic acid probes can also include one or more "reading" sequences, as described above. The reading sequence can be used to identify the nucleic acid probe, for example, by associating with a signaling entity, as described below. In some embodiments, the nucleic acid probe can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more, 20 or more, 24 or more, 32 or more, 40 or more, 48 or more, 50 or more, 64 or more, 75 or more, 100 or more, 128 or more reading sequences. The reading sequence can be positioned at any position in the nucleic acid probe. If there is more than one reading sequence, the reading sequences can be positioned next to each other, and / or spaced apart by other sequences.

[0093] The read sequences can be of any length. If more than one read sequence is used, the read sequences can independently be of the same or different lengths. For example, the read sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides in length. In some cases, the length of the read sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides. Any combination of these is also possible, for example, the read sequence can have a length of 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0094] In some embodiments, the read sequence can be arbitrary or random. In some cases, the read sequence can be selected to reduce or minimize homology with other components of the cell or other sample, for example, so that the read sequence itself does not bind or hybridize with other nucleic acids suspected to be in the cell or other sample. In some cases, the homology can be less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%. In some cases, there can be less than 20 base pairs, less than 18 base pairs, less than 15 base pairs, less than 14 base pairs, less than 13 base pairs, less than 12 base pairs, less than 11 base pairs, or less than 10 base pairs of homology. In some cases, such base pairs are continuous.

[0095] In one set of embodiments, a set of nucleic acid probes may comprise a specific number of read sequences, which in some cases may be less than the number of targets of the nucleic acid probes. One of ordinary skill in the art will appreciate that if there is one signaling entity and n read sequences, then generally 2 can be uniquely identified. n-1 different nucleic acid targets. However, it is not necessary to use all possible combinations. For example, a group of nucleic acid probes can target 12 different nucleic acid sequences, yet contain no more than 8 read sequences. As another example, a group of nucleic acids can target 140 different nucleic acid species, yet contain no more than 16 read sequences. Different nucleic acid sequence targets can be individually identified by using different combinations of read sequences within each probe. For example, each probe can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, etc. or more read sequences. In some cases, a group of nucleic acid probes can each contain the same number of read sequences, although in other cases, different numbers of read sequences can be present on various probes.

[0096] As a non-limiting example, a first nucleic acid probe can comprise a first target sequence, a first read sequence, and a second read sequence, while a second, different nucleic acid probe can comprise a second target sequence, the same first read sequence, but with a third read sequence in place of the second read sequence. Such probes can thus be distinguished by determining the presence of various read sequences or various read sequences associated with a given probe or position, as discussed herein. For example, the probes can be serially identified and encoded using "codewords," as discussed below. Optionally, the codewords can also be subject to error detection and / or correction.

[0097] In addition, in certain embodiments, a set of nucleic acid probes (and their corresponding complementary sites on the encoded probes) can be prepared using only 2 or only 3 of the 4 natural nucleotide bases, such as excluding all "G" or excluding all "C" within the set of probes. In certain embodiments, sequences lacking "G" or "C" can form very little secondary structure and can promote more uniform and faster hybridization. Thus, in some cases, the nucleic acid probes can contain only A, T, and G; only A, T, and C; only A, C, and G; or only T, C, and G.

[0098] In one aspect, the read sequence on the nucleic acid probe can be able to bind to (e.g., specifically bind to) the corresponding recognition sequence on the primary amplification nucleic acid. Therefore, when the nucleic acid probe identifies the target (e.g., DNA or RNA target) in the biological sample, the primary amplification nucleic acid can also associate with the target via the nucleic acid probe utilizing the interaction (e.g., complementary binding) between the read sequence of the nucleic acid probe and the corresponding recognition sequence on the primary amplification nucleic acid. For example, the recognition sequence can identify the target read sequence, but does not substantially identify or bind to other non-target read sequences. The primary amplification nucleic acid can also include any one of a variety of entities that can hybridize with nucleic acids, for example, DNA, RNA, LNA, and / or PNA, etc., depending on the application. For example, these entities can form some or all of the recognition sequence. Therefore, the recognition sequence can identify nucleic acid sequences, such as DNA or RNA.

[0099] In some cases, the recognition sequence can be substantially complementary to the target read sequence. In some cases, the sequences can be at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary. Typically, complementarity is determined based on Watson-Crick nucleotide base pairing. The structure of the target read sequence can include those described above.

[0100] In some cases, the recognition sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides in length. In some cases, the length of the recognition sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides. Any combination of these is also possible, for example, the recognition sequence can have a length of 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0101] In some embodiments, primary amplified nucleic acid can also include one or more read sequences that can be combined with secondary amplified nucleic acid, as described below. For example, primary amplified nucleic acid can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more, 20 or more, 32 or more, 40 or more, 50 or more, 64 or more, 75 or more, 100 or more, 128 or more read sequences. The read sequence can be positioned at any position in the primary amplified nucleic acid. If there is more than one read sequence, the read sequence can be positioned next to each other, and / or spaced apart with other sequences. In one embodiment, the primary amplified nucleic acid includes a recognition sequence at the first end and a plurality of read sequences at the second end.

[0102] In some cases, the length of the read sequence within the primary amplified nucleic acid can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides. In some cases, the read sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides in length. Combinations of any of these are also possible, for example, the read sequence can have a length of 10-20 nucleotides, 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0103] Any number of read sequences can be present in a primary amplified nucleic acid. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more read sequences can be present in a primary amplified nucleic acid. If more than one read sequence is present in a primary amplified nucleic acid, the read sequences can be the same or different. In some cases, for example, the read sequences can all be the same.

[0104] In some embodiments, a set of primary amplified nucleic acids can be prepared using only two or only three of the four natural nucleotide bases, such as excluding all "G" or excluding all "C" within the set of nucleic acids. In certain embodiments, sequences lacking "G" or "C" can form very little secondary structure and can promote more uniform and faster hybridization. Thus, in some cases, the primary amplified nucleic acids can contain only A, T, and G; only A, T, and C; only A, C, and G; or only T, C, and G.

[0105] In some cases, more than one type of primary amplified nucleic acid can be applied to a sample, e.g., sequentially or simultaneously. For example, at least 2, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000, or at least 30,000 distinguishable primary amplified nucleic acids can be applied to a sample. In some cases, the primary amplified nucleic acids can be added sequentially. However, in some cases, more than one primary amplified nucleic acid can be added simultaneously.

[0106] In one group of embodiments, the read sequence on the primary amplified nucleic acid can be capable of binding to (e.g., specifically binding to) a corresponding recognition sequence on a secondary amplified nucleic acid. Thus, when a nucleic acid probe identifies a target (e.g., a DNA or RNA target) in a biological sample, the secondary amplified nucleic acid can also associate with the target via the primary amplified nucleic acid utilizing the interaction (e.g., complementary binding) between the read sequence of the primary amplified nucleic acid and the corresponding recognition sequence on the secondary amplified nucleic acid. For example, the recognition sequence on the secondary amplified nucleic acid can recognize the read sequence on the primary amplified nucleic acid, but substantially does not recognize or bind to other non-target read sequences. The secondary amplified nucleic acid can also include any one of a variety of entities capable of hybridizing with nucleic acids, such as DNA, RNA, LNA, and / or PNA, etc., depending on the application. For example, these entities can form some or all of the recognition sequence.

[0107] In some cases, the recognition sequence on the secondary amplified nucleic acid can be substantially complementary to the read sequence on the primary amplified nucleic acid. In some cases, the sequences can be at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary.

[0108] In some cases, the length of the recognition sequence on the secondary amplified nucleic acid can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides. In some cases, the length of the recognition sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides. Any combination of these is also possible, for example, the recognition sequence can have a length of 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0109] In some embodiments, the secondary amplified nucleic acid can also include one or more read sequences that can be combined with a signaling entity, as discussed herein. For example, the secondary amplified nucleic acid can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more, 20 or more, 32 or more, 40 or more, 50 or more, 64 or more, 75 or more, 100 or more, 128 or more read sequences that can be combined with a signaling entity. The read sequence can be positioned at any position within the secondary amplified nucleic acid. If there is more than one read sequence, the read sequence can be positioned next to each other, and / or spaced apart by other sequences. In one embodiment, the secondary amplified nucleic acid includes a recognition sequence at the first end and multiple read sequences at the second end. This structure can also be the same or different from the structure of the primary amplified nucleic acid.

[0110] In some cases, the length of the read sequence within the secondary amplified nucleic acid can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides. In some cases, the length of the read sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides. Combinations of any of these are also possible, for example, the read sequence within the secondary amplified nucleic acid can have a length of 10-20 nucleotides, 10-30 nucleotides, 20-40 nucleotides, 5-50 nucleotides, 10-200 nucleotides, or 25-35 nucleotides, 10-300 nucleotides, etc.

[0111] Any number of read sequences can be present in the secondary amplified nucleic acid. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more read sequences can be present in the secondary amplified nucleic acid. If more than one read sequence is present in the secondary amplified nucleic acid, the read sequences can be the same or different. In some cases, for example, the read sequences can all be the same. Additionally, the same or different number of read sequences can be independently present in the primary amplified nucleic acid and the secondary amplified nucleic acid.

[0112] The set of secondary amplified nucleic acids can be prepared using only two or only three of the four natural nucleotide bases, in certain embodiments, such as excluding all "G" or excluding all "C" within the set of nucleic acids. In certain embodiments, sequences lacking "G" or "C" can form very little secondary structure and can promote more uniform and faster hybridization. Thus, in some cases, the secondary amplified nucleic acids can contain only A, T, and G; only A, T, and C; only A, C, and G; or only T, C, and G.

[0113] In some cases, more than one type of secondary amplified nucleic acid can be applied to a sample, e.g., sequentially or simultaneously. For example, at least 2, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000, or at least 30,000 distinguishable secondary amplified nucleic acids can be applied to a sample. In some cases, the secondary amplified nucleic acids can be added sequentially. However, in some cases, more than one secondary amplified nucleic acid can be added simultaneously.

[0114] In addition, in certain embodiments, this pattern can be repeated before the signaling entity, for example, using tertiary amplified nucleic acids, quaternary nucleic acids, etc., similar to the discussion above. Thus, the signaling entity can be bound to the last amplified nucleic acid. Thus, as non-limiting examples, the encoding nucleic acid probe can be bound to the target, the primary amplified nucleic acid can be bound to the encoding nucleic acid probe, the secondary amplified nucleic acid can be bound to the primary amplified nucleic acid, the tertiary amplified nucleic acid can be bound to the secondary amplified nucleic acid, and the signaling entity can be bound to the tertiary amplified nucleic acid, or the encoding nucleic acid probe can be bound to the target, the primary amplified nucleic acid can be bound to the encoding nucleic acid probe, the secondary amplified nucleic acid can be bound to the primary amplified nucleic acid, the tertiary amplified nucleic acid can be bound to the secondary amplified nucleic acid, the quaternary amplified nucleic acid can be bound to the tertiary amplified nucleic acid, and the signaling entity can be bound to the quaternary amplified nucleic acid, etc. Thus, in all embodiments, the last amplified nucleic acid need not necessarily be the secondary amplified nucleic acid.

[0115] In some aspects, cells can be immobilized or fixed to a substrate, e.g., prior to determining the genotype, as discussed below. In some cases, the immobilization or fixing of the cells can be performed after determining the phenotype. This can be useful, for example, in accordance with certain embodiments, for correlating the phenotype of a cell within an image with the genotype of a subsequent cell (e.g., determined as discussed below). In some embodiments, the cells can also be fixed prior to measuring the phenotype, rather than after measuring the phenotype and before measuring the genotype.

[0116] Those of ordinary skill in the art know the systems and methods for fixing cells or otherwise immobilizing cells on substrates. As non-limiting examples, cells can be fixed using chemicals such as formaldehyde, paraformaldehyde, glutaraldehyde, ethanol, methanol, acetone, acetic acid, etc. In one embodiment, cells can be fixed using an organic solvent (HOPE) mediated by Hepes-glutamic acid buffer. Also referring to U.S. Patent Application Serial No. 62 / 419,033, the full content of which is incorporated herein by reference.

[0117] Certain aspects of the present invention relate to assay samples, which can include cell cultures, cell suspensions, biological tissues, biopsies, organisms, and the like. In some cases, the sample can also be cell-free but contain nucleic acids. If the sample comprises cells, the cells can be human cells, or any other suitable cell type, such as mammalian cells, fish cells, insect cells, plant cells, and the like. In some cases, more than one type of cell can be present.

[0118] In a sample, the target to be measured may include nucleic acids, proteins, and the like. The nucleic acids to be measured may include, for example, DNA (e.g., genomic DNA), RNA, or other nucleic acids present in cells (or other samples). The nucleic acids may be endogenous to the cells, or may be added to the cells. For example, the nucleic acids may be viral nucleic acids, or may be artificially created. In some cases, the nucleic acids to be measured may be expressed by the cells. In some embodiments, the nucleic acids are RNA. The RNA may be coding and / or non-coding RNA. For example, the RNA may encode a protein. Non-limiting examples of RNA that can be studied in cells include mRNA, siRNA, rRNA, miRNA, tRNA, lncRNA, snoRNA, snRNA, exRNA, piRNA, and the like.

[0119] In some cases, a majority of nucleic acids within a cell can be studied. For example, in some cases, sufficient RNA present in a cell can be assayed to generate a partial or complete transcriptome of the cell. In some cases, at least four types of mRNA are assayed within a cell. In some cases, at least three, at least four, at least seven, at least eight, at least 12, at least 14, at least 15, at least 16, at least 22, at least 30, at least 31, at least 32, at least 50, at least 63, at least 64, at least 72, at least 75, at least 100, at least 127, at least 128, at least 140, at least 255, at least 256 ... At least 0, at least 1,000, at least 1,500, at least 2,000, at least 2,500, at least 3,000, at least 4,000, at least 5,000, at least 7,500, at least 10,000, at least 12,000, at least 15,000, at least 20,000, at least 25,000, at least 30,000, at least 40,000, at least 50,000, at least 75,000, or at least 100,000 types of mRNA.

[0120] In some cases, the transcriptome of a cell can be measured. It should be understood that the transcriptome generally encompasses all RNA molecules produced in the cell, not just mRNA. Thus, for example, in some cases, the transcriptome can also include rRNA, tRNA, siRNA, etc. In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the cell's transcriptome can be measured.

[0121] In some embodiments, other targets to be measured can include targets connected to nucleic acids, proteins, etc. For example, in one group of embodiments, a binding entity capable of recognizing a target can be conjugated to a nucleic acid probe. The binding entity can be any entity that can recognize a target (e.g., specific or non-specific recognition). Non-limiting examples include enzymes, antibodies, receptors, complementary nucleic acid chains, aptamers, etc. For example, an antibody connected to an oligonucleotide can be used to measure a target. The target can be bound to an antibody connected to an oligonucleotide, and the oligonucleotide can be measured as discussed herein.

[0122] The determination of targets such as nucleic acids within cells or other samples can be qualitative and / or quantitative. Additionally, the determination can also be spatial, for example, the position of nucleic acids or other targets within cells or other samples can be determined in two or three dimensions. In some embodiments, the position, number, and / or concentration of nucleic acids or other targets within cells or other samples can be determined.

[0123] In some cases, a majority of the genome of a cell can be assayed. The genomic segments assayed can be genomically continuous or discontinuous. For example, in some cases, at least 4 genomic segments within a cell are assayed. In some cases, at least 3, at least 4, at least 7, at least 8, at least 12, at least 14, at least 15, at least 16, at least 22, at least 30, at least 31, at least 32, at least 50, at least 63, at least 64, at least 72, at least 75, at least 100, at least 127, at least 128, at least 140, at least 255, at least 256, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 100, at least 127, at least 128, at least 140, at least 255, at least 256, at least 257, at least 260, at least 270, at least 271, at least 272, at least 273, at least 274, at least 275 00, at least 1,000, at least 1,500, at least 2,000, at least 2,500, at least 3,000, at least 4,000, at least 5,000, at least 7,500, at least 10,000, at least 12,000, at least 15,000, at least 20,000, at least 25,000, at least 30,000, at least 40,000, at least 50,000, at least 75,000, or at least 100,000 genomic segments.

[0124] In some cases, the entire genome of a cell can be assayed, it being understood that a genome generally encompasses all DNA molecules produced within a cell, not just chromosomal DNA. Thus, for example, in some cases, a genome can include, in addition to (or instead of) chromosomal DNA, mitochondrial DNA, chloroplast DNA, plasmid DNA, and the like. In some embodiments, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or 100% of the genome of a cell can be assayed.

[0125] As discussed herein, according to some aspects, a variety of nucleic acid probes can be used to measure one or more targets in a cell or other sample. The probe can include nucleic acid (or an entity that can be hybridized with nucleic acid, for example, an entity of specific hybridization), such as DNA, RNA, LNA (locked nucleic acid), PNA (peptide nucleic acid), and / or a combination thereof. In some cases, other components can also be present in the nucleic acid probe, for example, as discussed herein. In addition, any suitable method can be used to introduce the nucleic acid probe into the cell.

[0126] In one embodiment, the present invention provides the nucleic acid probe of the present invention.Other components may also be present in the nucleic acid probe or also be present in the amplified nucleic acid.For example, in one group of embodiments, one or more primer sequences may be present, for example, to promote enzyme amplification.One of ordinary skill in the art knows the primer sequences that are suitable for applications such as amplification (for example, using PCR or other suitable technologies).Many such primer sequences are commercially available.Other examples of the sequence that may be present in the primary nucleic acid probe include, but are not limited to, promoter sequences, operons, identifier sequences, nonsense sequences, etc.

[0127] In some embodiments, primers are single-stranded or partially double-stranded nucleic acids (e.g., DNA), and primers serve as the starting point for nucleic acid synthesis, allowing polymerases such as nucleic acid polymerases to extend primers and replicate complementary chains. Primers are (e.g., designed to) complement and hybridize with target nucleic acids. In some embodiments, primers are synthetic primers. In some embodiments, primers are non-natural primers. Primers typically have a length of 10-50 nucleotides. For example, primers can have a length of 10-40, 10-30, 10-20, 25-50, 15-40, 15-30, 20-50, 20-40, or 20-30 nucleotides. In some embodiments, primers have a length of 18-24 nucleotides.

[0128] In some embodiments, one or more signaling entities can be combined with an identification entity on a secondary amplified nucleic acid (or other final amplified nucleic acid). Non-limiting examples of signaling entities include fluorescent entities (fluorophores) or phosphorescent entities, for example, as discussed below. The signaling entity can then be determined, for example, to determine the nucleic acid probe or the target. In some cases, the determination can be spatial, for example, two-dimensionally or three-dimensionally. In addition, in some cases, the determination can be quantitative, for example, the amount or concentration of the signaling entity and / or target can be determined.

[0129] In one set of embodiments, the signaling entity can be attached to the secondary amplified nucleic acid (or other last amplified nucleic acid). The signaling entity can be attached to the secondary amplified nucleic acid (or other last amplified nucleic acid) before or after the secondary amplified nucleic acid associates with the target in the sample. For example, the signaling entity can be attached to the secondary amplified nucleic acid initially or after the secondary amplified nucleic acid has been applied to the sample. In some cases, the signaling entity is added and then reacted to attach it to the amplified nucleic acid.

[0130] In one group of embodiments, the signaling entity can be attached to the nucleotide sequence by a key, and the key can be cleaved to release the signaling entity. For example, after determining the distribution of nucleic acid probes in the sample, the signaling entity can be released or inactivated, followed by another round of nucleic acid probes and / or amplified nucleic acids. Therefore, in some embodiments, the key can be a cleavable key, such as a disulfide bond or a photocleavable key. Examples of photocleavable keys are discussed in detail herein. In some cases, such a key can be cleaved, for example, after being exposed to a reducing agent or light (e.g., ultraviolet light). Other details are shown below. Other examples of systems and methods for inactivating and / or removing signaling entities are discussed in more detail herein.

[0131] In certain embodiments, the use of primary and secondary amplified nucleic acids suggests that there is a maximum number of signaling entities that can bind to a given nucleic acid probe. For example, there can be a maximum number of primary amplified nucleic acids that can bind to a nucleic acid probe, for example, due to the maximum number of secondary amplified nucleic acids that can bind to a limited number of primary amplified nucleic acids and / or due to the maximum number of primary amplified nucleic acids that can bind to a limited number of read sequences on the nucleic acid probe. Although each potential position need not actually be filled with a signaling entity, this structure suggests that there is a saturation limit for the signaling entities, beyond which any other signaling entities that may happen to be present cannot associate with the nucleic acid probe or its target.

[0132] Thus, certain embodiments of the present invention generally relate to systems and methods for amplifying a signal indicative of a nucleic acid probe or its target, wherein the signal is saturable, i.e., such that there is a saturation upper limit to the number of signaling entities that can associate with the nucleic acid probe or its target. Typically, this number is greater than 1. For example, the upper limit of signaling entities can be at least 2, at least 3, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 400, at least 500, etc. In some cases, the upper limit can be less than 500, less than 400, less than 300, less than 250, less than 200, less than 175, less than 150, less than 125, less than 100, less than 75, less than 50, less than 40, less than 30, less than 25, less than 20, less than 15, less than 10, less than 5, etc. In some cases, this upper limit can be defined as the maximum number of the signaling entity that can be combined with secondary amplification nucleic acid, multiplied by the maximum number of the secondary amplification nucleic acid that can be combined with primary amplification nucleic acid, multiplied by the maximum number of the primary amplification nucleic acid that can be combined with the nucleic acid probe combined with target.On the contrary, the technology such as rolling circle amplification or hairpin expansion (hairpin unfolding) allows to amplify signal in an uncontrolled manner, that is, when there are enough reagents, amplification can proceed, and does not have predetermined terminal point or saturation limit.Therefore, such technology does not have a theoretical upper limit for the number of the signaling entity that can associate with nucleic acid probe or its target.

[0133] However, it should be understood that the average number of signaling entities bound to a nucleic acid probe or its target is not necessarily the same as its upper limit, i.e., the signaling entities may not actually be at full saturation (although they may be fully saturated). For example, the saturation amount (or the number of signaling entities bound relative to the maximum number that can be bound) may be less than 97%, less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, etc., and / or at least 50%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, etc. In some cases, allowing more time for binding to occur and / or increasing the concentration of the reagent can increase the saturation amount.

[0134] Because there is a potential upper limit to the number of signaling entities that can actually bind to a nucleic acid probe or its target, in contrast to uncontrolled amplification, binding events distributed within a sample, e.g., spatially distributed, can exhibit substantially uniform size and / or brightness, such as those discussed above. For example, due to a specific number of secondary amplified nucleic acids that can bind to a primary amplified nucleic acid, it is found that the secondary amplified nucleic acids cannot exceed a fixed distance from the nucleic acid probe or its target, which can limit the "spot size" or diameter of fluorescence (indicative of binding) from the signaling entity.

[0135] In certain embodiments, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the binding events may exhibit substantially the same brightness, size (e.g., apparent diameter), color, etc., which may make it easier to distinguish the binding events from other events, such as nonspecific binding, etc.

[0136] In addition, as previously mentioned, some aspects of the present invention use the code space of encoding various binding events, and optionally error detection and / or error correction can be used to determine the combination of nucleic acid probes with their targets. In some cases, one group of nucleic acid probes can include certain "read sequences" that can be combined with certain amplified nucleic acids, as discussed herein, and the position of the nucleic acid probe or target can be determined in a sample using a signaling entity associated with the amplified nucleic acid, for example, in certain code spaces, for example, as discussed herein. Also referring to International Patent Application Publication Nos. WO 2016 / 018960 and WO 2016 / 018963, the entire contents of which are each incorporated herein by reference. As mentioned, in some cases, a group of read sequences in the nucleic acid probe can be combined together in various combinations, for example, so that a relatively large amount of different nucleic acid probes can be determined using a relatively small number of read sequences, as discussed herein.

[0137] Thus, in some cases, a set of nucleic acid probes can each comprise a specific number of read sequences, some of which are shared between different nucleic acid probes, such that the entire set of nucleic acid probes can comprise a specific number of read sequences. A set of nucleic acid probes can have any suitable number of read sequences. For example, a set of nucleic acid probes can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or the like read sequences. In some embodiments, more than 20 are also possible. Additionally, in some cases, a set of nucleic acid probes can have a total of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 20 or more, 24 or more, 32 or more, 40 or more, 50 or more, 60 or more, 64 or more, 100 or more, 128 or more, etc. possible read sequences, although some or all of the probes can each contain more than one read sequence, as discussed herein. Additionally, in some embodiments, a set of nucleic acid probes can have no more than 100, no more than 80, no more than 64, no more than 60, no more than 50, no more than 40, no more than 32, no more than 24, no more than 20, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, or no more than 2 read sequences present. Combinations of any of these are also possible, for example, a set of nucleic acid probes can contain a total of 10-15 read sequences.

[0138] As a non-limiting example of a method for combinatorially identifying a relatively large number of nucleic acid probes from a relatively small number of read sequences contained within a nucleic acid probe, in a set of 6 different types of nucleic acid probes, each type of nucleic acid probe comprising one or more read sequences, the total number of read sequences within the set can be no greater than 4. It should be understood that although 4 read sequences are used in this example for ease of explanation, in other embodiments, a larger number of nucleic acid probes can be implemented, for example, using 5, 8, 10, 16, 32, or more read sequences, or any other suitable number of read sequences described herein, depending on the application. For example, if each nucleic acid probe comprises two different read sequences, then by using 4 such read sequences (A, B, C, and D), up to 6 probes can be individually identified. It should be noted that in this example, the order of the read sequences on the nucleic acid probes is not critical, i.e., "AB" and "BA" can be considered synonymous (although in other embodiments, the order of the read sequences can be critical, and "AB" and "BA" may not necessarily be synonymous). Similarly, if five read sequences (A, B, C, D, and E) are used in a set of nucleic acid probes, up to ten probes (e.g., AB, AC, AD, AE, BC, BD, BE, CD, CE, DE) can be individually identified. For example, one of ordinary skill in the art will appreciate that for k read sequences in a set of n read sequences per probe, up to ten probes can be individually identified. Different probes are provided, assuming that the order of the read sequences is not important; because not all probe sequences need to have the same number of read sequences, and not all combinations of read sequences are necessarily used in every embodiment, in some embodiments, more or less than this number of different probes can be used. In addition, it should be understood that in some embodiments, the number of read sequences on each probe is not necessarily the same. For example, some probes may contain 2 read sequences, while other probes may contain 3 read sequences.

[0139] In some aspects, the binding pattern of the read sequence and / or nucleic acid probe within the sample can be used to define an error detection code and / or error correction code, for example, to reduce or prevent the misidentification or error of nucleic acid. Thus, for example, if the indication is that there is binding (for example, as determined using a signaling entity), the position can be identified with a "1"; on the contrary, if the indication is not bound, the position can be identified with a "0" (or in some cases, vice versa). Then, multiple rounds of binding assays (for example, using different nucleic acid probes) can be used to establish a "code word", for example, for this spatial position. In some embodiments, the code word can be subject to error detection and / or correction. For example, the code word can be organized so that for the binding pattern of the read sequence or the specified nucleic acid probe of a specified group, if no match is found, the match can be identified as an error, and, optionally, error correction can be applied to the sequence to determine the correct target for the nucleic acid probe. In some cases, the code word can have fewer "letters" or positions, that is, the total number of nucleic acids encoded by the code word, for example, wherein each code word encodes a different nucleic acid.

[0140] Such error detection and / or error correction codes can take a variety of forms. Various such codes have been previously developed in other fields such as the telecommunications industry, such as Golay codes or Hamming codes. In one set of embodiments, the binding patterns of the read sequences or nucleic acid probes are assigned so that not every possible combination is assigned.

[0141] For example, if 4 read sequences are possible and the nucleic acid probe contains 2 read sequences, then up to 6 nucleic acid probes can be identified; however, the number of nucleic acid probes used can be less than 6. Similarly, for k read sequences in a group with n read sequences on each nucleic acid probe, Different probes, but the number of nucleic acid probes used can be greater or less than Additionally, these may be assigned randomly, or in a specific manner to increase the ability to detect and / or correct errors.

[0142] As another example, if multiple rounds of nucleic acid probes are used, the rounds can be chosen arbitrarily. If, in each round, each target can have two possible outcomes, such as being detected or not detected, there may be 2 for n rounds of probes. n different targets, but the number of targets actually used can be less than 2 n For example, if in each round each target can have more than two possible outcomes, such as being detected in different color channels, then for n rounds there may be more than 2 n (For example, 3 n , 4 n, ...) different targets. In some cases, the number of targets actually used can be any number less than this number. In addition, these can be randomly assigned, or assigned in a specific way to increase the ability to detect and / or correct errors.

[0143] The codeword can be used to define various code spaces. For example, in one set of embodiments, the codeword or nucleic acid probe can be allocated in the code space so that the allocation interval is Hamming distance, and the number of erroneous "readings" is measured in a specified pattern, and the erroneous "readings" cause the nucleic acid probe to be misinterpreted as different valid nucleic acid probes. In some cases, the Hamming distance can be at least 2, at least 3, at least 4, at least 5, at least 6, etc. In addition, in one set of embodiments, the allocation can be formed as a Hamming code, for example, a Hamming (7, 4) code, a Hamming (15, 11) code, a Hamming (31, 26) code, a Hamming (63, 57) code, a Hamming (127, 120) code, etc. In another set of embodiments, the distribution can form a SECDED code, such as a SECDED (8, 4) code, a SECDED (16, 4) code, a SCEDED (16, 11) code, a SCEDED (22, 16) code, a SCEDED (39, 32) code, a SCEDED (72, 64) code, etc. In yet another set of embodiments, the distribution can form an extended binary Golay code, an optimal binary Golay code, or a ternary Golay code. In another set of embodiments, the distribution can represent a subset of possible values ​​obtained by any of the codes described above.

[0144] For example, an error detection code can be formed by limiting the number of codewords used to less than 10%, less than 5%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, or less than 0.001% of the total number of possible codewords, such that an incorrect codeword is unlikely to exist as another used codeword. Thus, any detected codeword that does not match a used codeword is more likely to be incorrect.

[0145] For example, an error correction code can be formed by using only binary words that contain a fixed or constant number of "1" bits (or "0" bits) to encode the target. For example, the code space can include only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, etc. "1" bits (or "0" bits), for example, all codes have the same number of "1" bits or "0" bits, etc. In another set of embodiments, the allocation can represent a subset of the possible values ​​obtained by the code described above to solve the problem of asymmetric readout errors. For example, in some cases, a code in which the number of "1" bits can be fixed for all binary code words used can eliminate measurement bias for code words with different numbers of "1"s when the ratio of measuring a "0" bit as a "1" or measuring a "1" bit as a "0" is different.

[0146] Therefore, in some embodiments, once a code word is determined (e.g., as discussed herein), the code word can be compared to a known nucleic acid code word. If a match is found, the nucleic acid target can be identified or determined. If no match is found, the error in reading the code word can be identified. In some cases, error correction can also be applied to determine the correct code word, thereby obtaining the correct identity of the nucleic acid target. In some cases, the code word can be selected so that assuming only one error exists, only one possible correct code word can be obtained, so the nucleic acid target may only have one correct identity. In some cases, this can also be extended to a larger code word space or Hamming distance; for example, a code word can be selected so that if there are 2, 3, or 4 errors (or more errors in some cases), only one possible correct code word can be obtained, so the nucleic acid target may only have one correct identity.

[0147] The error correction code may be a binary error correction code, or it may be based on other numbering systems, such as a ternary or quaternary error correction code. For example, in one set of embodiments, more than one type of signaling entity may be used and assigned different numbers within the error correction code. Thus, as a non-limiting example, a first signaling entity (or in some cases more than one signaling entity) may be assigned a "1," a second signaling entity (or in some cases more than one signaling entity) may be assigned a "2" ("0" indicating that no signaling entity is present), and the codewords are assigned to define a ternary error correction code. Similarly, a third signaling entity may additionally be assigned a "3" to form a ternary error correction code, and so on. Non-limiting examples of such codes include Reed-Solomon erasure codes and generalizations thereof.

[0148] In addition, in some embodiments, described code can also be selected by the random selection of the subset of all possible code words.For example, the random subset of the binary code word that can be selected to be n codes of length.In some cases, these code words can be spaced with Hamming distance, that is, must be flipped thereby one is transformed into another so that some code words used keep the number of positions of some error robustness or error correction capability.In some embodiments, the random subset of the code word used can be measured and error robustness and error correction can be selectively applied to the code word that satisfies the constraint required by these characteristics using the mode such as next generation sequencing.

[0149] As discussed herein, in some aspects, a signaling entity is determined, for example, by imaging, to determine a nucleic acid probe and / or form a codeword. Examples of signaling entities include those discussed herein. In some cases, the signaling entity within a sample can be, for example, spatially, measured using a variety of techniques. In some embodiments, the signaling entity can be fluorescent, and techniques for measuring fluorescence within a sample, such as fluorescence microscopy or confocal microscopy, can be used to spatially identify the position of the signaling entity within the cell. In some cases, the position of the entity within the sample can be determined in two dimensions or even three dimensions. In addition, in some embodiments, more than one signaling entity can be measured at one time (e.g., with signaling entities of different colors or emissions), and / or measured sequentially.

[0150] In addition, in some embodiments, the confidence level of target (for example, nucleic acid target) can be determined.For example, the confidence level can be determined using the ratio of the number of exact matches and the number of matches with one or more errors.In some cases, the matching of only having a confidence ratio greater than a specific value can be used.For example, in certain embodiments, the confidence ratio of only matching is greater than about 0.01, greater than about 0.03, greater than about 0.05, greater than about 0.1, greater than about 0.3, greater than about 0.5, greater than about 1, greater than about 3, greater than about 5, greater than about 10, greater than about 30, greater than about 50, greater than about 100, greater than about 300, greater than about 500, greater than about 1000 or any other suitable value, and the matching is just acceptable. Additionally, in some embodiments, a match is accepted only if the confidence ratio of the target is greater than about 0.01, about 0.03, about 0.05, about 0.1, about 0.3, about 0.5, about 1, about 3, about 5, about 10, about 30, about 50, about 100, about 300, about 500, about 1000, or any other suitable value relative to the internal standard or false positive control.

[0151] In some embodiments, the spatial position of an entity (and therefore, a nucleic acid probe that can associate with the entity) can be determined with a relatively high resolution. For example, the position can be determined with a spatial resolution of greater than about 100 microns, greater than about 30 microns, greater than about 10 microns, greater than about 3 microns, greater than about 1 micron, greater than about 800 nm, greater than about 600 nm, greater than about 500 nm, greater than about 400 nm, greater than about 300 nm, greater than about 200 nm, greater than about 100 nm, greater than about 90 nm, greater than about 80 nm, greater than about 70 nm, greater than about 60 nm, greater than about 50 nm, greater than about 40 nm, greater than about 30 nm, greater than about 20 nm, or greater than about 10 nm.

[0152] There are various techniques capable of optically determining the spatial position of an entity or imaging the spatial position of an entity, for example, using fluorescence microscopy. In some embodiments, more than one color can be used. In some cases, the spatial position can be determined with super-resolution, or with a resolution higher than the wavelength of light or the diffraction limit. Non-limiting examples include STORM (stochastic optical reconstruction microscopy), STED (stimulated emission depletion microscopy), NSOM (near-field scanning optical microscopy), 4Pi microscopy, SIM (structured illumination microscopy), SMI (spatial modulated light illumination) microscopy, RESOLFT (reversible saturated optical linear fluorescence transition microscopy), GSD (ground state loss microscopy), SSIM (saturated structured illumination microscopy), SPDM (spectral precision distance microscopy), photoactivated localization microscopy (PALM), fluorescence photoactivated localization microscopy (FPALM), LIMON (3D light micro-nanomicroscopy), super-resolution optical wave imaging (SOFI), etc. See, for example, U.S. Patent No. 7,838,302 to Zhuang et al., issued on November 23, 2010, entitled “Sub-Diffraction Limit Image Resolution and Other Imaging Techniques”; U.S. Patent No. 8,564,792 to Zhuang et al., issued on October 22, 2013, entitled “Sub-diffraction Limit Image Resolution in Three Dimensions”; or International Patent Application Publication No. WO 2013 / 090360 to Zhuang et al., published on June 20, 2013, entitled “High Resolution Dual-Objective Microscopy”, the entire contents of each of which are incorporated herein by reference.

[0153] As an illustrative, non-limiting example, in one set of embodiments, a sample can be imaged using a high numerical aperture, oil immersion objective having a 100X magnification and light collected on an electron-multiplying CCD camera. In another embodiment, the sample can be imaged using a high numerical aperture, oil immersion lens having a 40X magnification and light collected using a wide-field scientific-grade CMOS camera. Using different combinations of objectives and cameras, in various non-limiting embodiments, a single field of view can correspond to an area of ​​no less than 40x40 microns, 80x80 microns, 120x120 microns, 240x240 microns, 340x340 microns, or 500x500 microns, etc. Similarly, in some embodiments, a single camera pixel can correspond to an area of ​​no less than 80x80 nm, 120x120 nm, 160x160 nm, 240x240 nm, or 300x300 nm, etc., of the sample. In another embodiment, the sample can be imaged using a low numerical aperture, 10X magnification air lens and light collected using an sCMOS camera. In other embodiments, the sample can be optically sectioned by illumination with a single or multiple scanning diffraction-limited focal spots generated by a scanning mirror or rotating disk and collected through a single or multiple pinholes. In another embodiment, the sample can also be illuminated by thin-sheet light generated by any of a variety of methods known to those skilled in the art.

[0154] In one embodiment, the sample can be illuminated by a single Gaussian mode laser line. In some embodiments, the illumination spectrum can be planarized by passing these laser lines through a multimode optical fiber that is vibrated by a piezoelectric or other mechanical device. In some embodiments, the illumination spectrum can be planarized by passing a single mode Gaussian beam through a variety of refractive beam shapers, such as a piShaper or a series of stacked Powell prisms. In yet another set of embodiments, the Gaussian beam can be passed through a variety of different diffusing elements, such as frosted glass or engineered diffusers, which in some cases can be rotated at high speed to remove residual laser speckle. In yet another embodiment, the laser illumination light can be passed through a series of microlens arrays to produce overlapping images of the illumination light that approximate a planar illumination field.

[0155] In some embodiments, the centroid of the spatial location of the entity can be determined. For example, the centroid of the signaling entity can be determined within an image or a series of images using an image analysis algorithm known to those skilled in the art. In some cases, the algorithm can be selected to determine non-overlapping single emitters and / or partially overlapping single emitters in a sample. Non-limiting examples of suitable techniques include maximum likelihood algorithms, least squares algorithms, Bayesian algorithms, compressed sensing algorithms, and the like. In some cases, combinations of these techniques can also be used.

[0156] In addition, in some cases, the signaling entity can be inactivated. For example, in some embodiments, a first secondary nucleic acid probe that can associate with a signaling entity (e.g., using an amplified nucleic acid) can be applied to a sample, the first secondary nucleic acid probe can recognize a first read sequence (e.g., on the nucleic acid probe), and then the signaling entity can be inactivated before a second secondary nucleic acid probe is applied to the sample, e.g., the second secondary nucleic acid probe can associate with the signaling entity (e.g., using an amplified nucleic acid). If multiple signaling entities are used, the same or different techniques can be used to inactivate the signaling entity, and some or all of the multiple signaling entities can be inactivated, e.g., sequentially or simultaneously.

[0157] Inactivation can be caused by removing the signaling entity (e.g., from the sample or from the nucleic acid probe, etc.), and / or by chemically altering the signaling entity in some manner (e.g., by photobleaching the signaling entity, bleaching or chemically altering the structure of the signaling entity, e.g., by reduction, etc.). For example, in one set of embodiments, the fluorescent signaling entity can be inactivated by chemical or optical techniques such as oxidation, photobleaching, chemical bleaching, stringent washing or enzymatic digestion or by reaction by exposure to an enzyme, dissociation of the signaling entity from other components (e.g., probe), chemical reaction of the signaling entity (e.g., chemical reaction with a reactant that can alter the structure of the signaling entity), etc. For example, bleaching can occur by exposure to oxygen, a reducing agent, or the signaling entity can be chemically cleaved from the nucleic acid probe (e.g., using tris(2-carboxyethyl)phosphine) and washed away by a fluid stream.

[0158] In some embodiments, various nucleic acid probes (including primary and / or secondary nucleic acid probes) can be associated with one or more signaling entities, for example, using amplified nucleic acids, as discussed herein. If more than one nucleic acid probe is used, the signaling entities can be the same or different. In certain embodiments, the signaling entity is any entity capable of emitting light. For example, in one embodiment, the signaling entity is fluorescent. In other embodiments, the signaling entity can be phosphorescent, radioactive, absorptive, etc. In some cases, the signaling entity is any entity that can be determined with relatively high resolution within a sample, for example, with a resolution higher than the wavelength or diffraction limit of visible light. The signaling entity can be, for example, a dye, a small molecule, a peptide or a protein, etc. In some cases, the signaling entity can be a single molecule. If multiple secondary nucleic acid probes are used, the nucleic acid probes can be associated with the same or different signaling entities or contain the same or different signaling entities.

[0159] Non-limiting examples of signaling entities include fluorescent entities (fluorophores) or phosphorescent entities, for example, cyanine dyes (e.g., Cy2, Cy3, Cy3B, Cy5, Cy5.5, Cy7, etc.), Alexa Fluor dyes, Atto dyes, light-convertible dyes, photoactivated dyes, fluorescent dyes, metal nanoparticles, semiconductor nanoparticles or "quantum dots", fluorescent proteins such as GFP (green fluorescent protein), or photoactivated fluorescent proteins such as PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PAmCherry, PAtagRFP, mMaple, mMaple2, and mMaple3. Other suitable signaling entities are known to those of ordinary skill in the art. See, for example, U.S. Patent No. 7,838,302 or International Patent Application Publication No. WO 2015 / 160690, the entire contents of each of which are incorporated herein by reference.

[0160] In one set of embodiments, the signaling entity may be attached to the oligonucleotide sequence via a bond that can be cleaved to release the signaling entity. In one set of embodiments, the fluorophore may be conjugated to the oligonucleotide via a cleavable bond, such as a photocleavable bond. Non-limiting examples of photocleavable bonds include, but are not limited to, 1-(2-nitrophenyl)ethyl, 2-nitrobenzyl, biotin phosphoramidite, acrylic acid phosphoramidite, diethylaminocoumarin, 1-(4,5-dimethoxy-2-nitrophenyl)ethyl, cyclododecyl(dimethoxy-2-nitrophenyl)ethyl, 4-aminomethyl-3-nitrobenzyl, (4-nitro-3-(1-chlorocarbonyloxyethyl)phenyl)methyl-S-acetylthioate, (4-nitro-3-(1-chlorocarbonyloxyethyl)phenyl)methyl-3-(2-pyridyldithiopropionate), 3-(4,4'-dimethoxytrimethyl)-1-(2-nitrophenyl)-propane-1,3-dithioate

[00155] Phosphoramidite, 1-[2-nitro-5-(6-trifluoroacetylhexanamidomethyl)phenyl]-ethyl-[2-cyano-ethyl-(N,N-diisopropyl)]-phosphoramidite, 1-[2-nitro-5-(6-(4,4'-dimethoxytrimethyloxy)butanamidomethyl)phenyl]-ethyl-[2-cyanoethyl-(N,N-diisopropyl)]-phosphoramidite, 1-[2-nitro-5-(6-(N-(4,4'-dimethoxytrimethyloxy)butanamidomethyl)phenyl]-ethyl-[2-cyanoethyl-(N,N-diisopropyl)]-phosphoramidite, or similar linkers. The oligonucleotide sequence can be, for example, a primary or secondary (or other) amplification nucleic acid, such as those discussed herein.

[0161] In another set of embodiments, the fluorophore can be conjugated to the oligonucleotide via a disulfide bond. The disulfide bond can be cleaved by a variety of reducing agents, such as, but not limited to, dithiothreitol, dithioerythritol, β-mercaptoethanol, sodium borohydride, thioredoxin, glutaredoxin, trypsinogen, hydrazine, diisobutylaluminum hydride, oxalic acid, formic acid, ascorbic acid, phosphorous acid, tin chloride, glutathione, thioglycolate, 2,3-dimercaptopropanol, 2-mercaptoethylamine, 2-aminoethanol, tris(2-carboxyethyl)phosphine, di(2-mercaptoethyl)sulfone, N,N'-dimethyl-N,N'-di(mercaptoacetyl)hydrazine, 3-mercaptopropionate, dimethylformamide, thiopropyl-agarose, tri-n-butylphosphine, cysteine, ferric sulfate, sodium sulfite, phosphite, hypophosphite, phosphorothioate, etc., and / or any combination of these. The oligonucleotide sequence can be, for example, a primary or secondary (or other) amplification nucleic acid, such as those discussed herein.

[0162] In another embodiment, the fluorophore can be conjugated to the oligonucleotide by one or more thiophosphate-modified nucleotides (wherein the sulfur modification replaces the bridge oxygen and / or non-bridge oxygen). In certain embodiments, the fluorophore can be cleaved from the oligonucleotide by adding a compound, such as but not limited to iodoethanol, iodine mixed in ethanol, silver nitrate, or mercuric chloride. In another set of embodiments, the signaling entity can be chemically inactivated by reduction or oxidation. For example, in one embodiment, a chromophore such as Cy5 or Cy7 can be reduced to a stable non-fluorescent state using sodium borohydride. In another set of embodiments, the fluorophore can be conjugated to the oligonucleotide by an azo bond, which can be cleaved using 2-[(2-N-arylamino)phenylazo]pyridine. In another set of embodiments, the fluorophore can be conjugated to the oligonucleotide by a suitable nucleic acid segment, which can be cleaved when appropriately exposed to a DNA enzyme, such as an exonuclease or an endonuclease. Examples include, but are not limited to, deoxyribonuclease I or deoxyribonuclease II. In one group of embodiments, the cracking can occur by restriction endonucleases. Non-limiting examples of potential suitable restriction endonucleases include BamHI, BsrI, NotI, XmaI, PspAI, DpnI, MboI, MnlI, Eco57I, Ksp632I, DraIII, AhaII, SmaI, MluI, HpaI, ApaI, BclI, BstEII, TaqI, EcoRI, SacI, HindII, HaeII, DraII, Tsp509I, Sau3AI, PacI, etc. More than 3000 kinds of restriction enzymes have been studied in detail, and more than 600 kinds of these are commercially available. In another group of embodiments, the fluorophore can be conjugated to biotin, and the oligonucleotide is conjugated to avidin or streptavidin. The interaction between biotin and avidin or streptavidin allows the fluorophore to be conjugated to the oligonucleotide, and when fully exposed to excess additives, the free biotin can "compete out" the connection, thereby causing cleavage to occur. Additionally, in another set of embodiments, the probe can be removed using a corresponding "toe-hold-probe", which comprises the same sequence as the probe and an additional number of bases homologous to the encoded probe (e.g., 1-20 additional bases, e.g., 5 additional bases). These probes can remove the labeled readout probe by strand displacement interactions. The oligonucleotide sequence can be, for example, a primary or secondary (or other) amplified nucleic acid, such as those discussed herein.

[0163] As used herein, the term "light" generally refers to electromagnetic radiation having any suitable wavelength (or equivalently, frequency). For example, in some embodiments, light can include wavelengths in the optical or visible range (e.g., having a wavelength of about 400 nm to about 700 nm, i.e., "visible light"), infrared wavelengths (e.g., having a wavelength of about 300 microns to 700 nm), ultraviolet wavelengths (e.g., having a wavelength of about 400 nm to about 10 nm), etc. In some cases, as discussed in detail below, more than one entity can be used, i.e., chemically different or unique entities, e.g., structurally different or unique entities. However, in other cases, the entities can be chemically identical or at least substantially chemically identical.

[0164] In one set of embodiments, the signaling entity is "switchable," i.e., the entity can be switched between two or more states, at least one of which emits light of a desired wavelength. In the other state or states, the entity may not emit light, or may emit light of a different wavelength. For example, an entity can be "activated" to a first state capable of producing light of a desired wavelength and "deactivated" to a second state incapable of emitting light of the same wavelength. An entity is "photoactivatable" if it can be activated by incident light of a suitable wavelength. As a non-limiting example, Cy5 can be switched between a fluorescent and dark state in a controlled and reversible manner by light of different wavelengths, i.e., 633 nm (or 642 nm, 647 nm, 656 nm) red light can switch or inactivate Cy5 to a stable dark state, while 405 nm green light can switch or activate Cy5 back to a fluorescent state. In some cases, the entity can reversibly switch between two or more states, for example, upon exposure to a suitable stimulus. For example, a first stimulus (e.g., light of a first wavelength) can be used to activate a convertible entity, while a second stimulus (e.g., light of a second wavelength) can be used to deactivate the convertible entity, e.g., to a non-emissive state. Any suitable method can be used to activate the entity. For example, in one embodiment, incident light of a suitable wavelength can be used to activate the entity to emit light, i.e., the entity is "photoconvertible." Thus, the photoconvertible entity can be converted between different light-emitting or non-emissive states by, for example, incident light of different wavelengths. The light can be monochromatic (e.g., generated using a laser) or polychromatic. In another embodiment, the entity can be activated after being stimulated by an electric and / or magnetic field. In other embodiments, the entity can be activated after being exposed to a suitable chemical environment, e.g., by adjusting the pH, or by inducing a reversible chemical reaction involving the entity. Similarly, any suitable method can be used to deactivate the entity, and the methods for activating and deactivating the entity do not have to be the same. For example, the entity can be deactivated after being exposed to incident light of a suitable wavelength, or the entity can be deactivated by being left for a sufficient period of time.

[0165] Typically, a "switchable" entity can be identified by one of ordinary skill in the art by determining conditions under which the entity in the first state can emit light when exposed to an excitation wavelength, converting the entity from a first state to a second state, for example, after exposure to light of a switching wavelength, and then showing that the entity in the second state can no longer emit light (or emits light of much reduced intensity) when exposed to the excitation wavelength.

[0166] In one set of embodiments, as discussed, the convertible entity can convert upon exposure to light. In some cases, the light used to activate the convertible entity can come from an external source, for example, a light source such as a laser light source, another light-emitting entity in close proximity to the convertible entity, etc. In some cases, the second light-emitting entity can be a fluorescent entity, and in certain embodiments, the second light-emitting entity can itself be a convertible entity.

[0167] In some embodiments, the switchable entity includes a first light-emitting moiety (e.g., a fluorophore) and a second moiety that activates or "converts" the first moiety. For example, upon exposure to light, the second moiety of the switchable entity can activate the first moiety, causing the first moiety to emit light. Examples of activator moieties include, but are not limited to, Alexa Fluor 405 (Invitrogen), Alexa Fluor 488 (Invitrogen), Cy2 (GE Healthcare), Cy3 (GE Healthcare), Cy3B (GE Healthcare), Cy3.5 (GE Healthcare), or other suitable dyes. Examples of light-emitting moieties include, but are not limited to, Cy5, Cy5.5 (GE Healthcare), Cy7 (GE Healthcare), Alexa Fluor 647 (Invitrogen), Alexa Fluor 680 (Invitrogen), Alexa Fluor 700 (Invitrogen), Alexa Fluor 750 (Invitrogen), Alexa Fluor 790 (Invitrogen), DiD, DiR, YOYO-3 (Invitrogen), YO-PRO-3 (Invitrogen), TOT-3 (Invitrogen), TO-PRO-3 (Invitrogen), or other suitable dyes.These can be linked together, e.g., covalently, e.g., directly, or through a linker, e.g., to form compounds such as, but not limited to, Cy5-Alexa Fluor 405, Cy5-Alexa Fluor 488, Cy5-Cy2, Cy5-Cy3, Cy5-Cy3.5, Cy5.5-Alexa Fluor 405, Cy5.5-Alexa Fluor 488, Cy5.5-Cy2, Cy5.5-Cy3, Cy5.5-Cy3.5, Cy7-Alexa Fluor 405, Cy7-Alexa Fluor 488, Cy7-Cy2, Cy7-Cy3, Cy7-Cy3.5, Alexa Fluor 647-Alexa Fluor 405, Alexa Fluor 647-Alexa Fluor 488, Alexa Fluor 647-Cy2, Alexa Fluor In some embodiments, the Alexa Fluor 750-Alexa Fluor 405, Alexa Fluor 750-Alexa Fluor 488, Alexa Fluor 750-Cy2, Alexa Fluor 750-Cy3, or Alexa Fluor 750-Cy3.5. Those skilled in the art will appreciate the structures of these and other compounds, many of which are commercially available. The moieties may be covalently linked or connected by joints such as those described in detail below. Other light emitting or activator moieties may include moieties having two quaternary ammonium nitrogen atoms connected by polymethylene chains, wherein each nitrogen is independently a part of a heteroaromatic moiety such as pyrrole, imidazole, thiazole, pyridine, quinoline, indole, benzothiazole, etc., or a part of a non-aromatic amine. In some cases, there may be 5, 6, 7, 8, 9 or more carbon atoms between the two nitrogen atoms.

[0168] In some cases, the light emitting portion and the activator portion, when separated from each other, can each be a fluorophore, i.e., an entity that can emit light of a specific emission wavelength when exposed to a stimulus (e.g., an excitation wavelength). However, when forming a convertible entity comprising a first fluorophore and a second fluorophore, the first fluorophore forms the first light emitting portion and the second fluorophore forms the activator portion, which activates or "converts" the first portion in response to the stimulus. For example, the convertible entity can comprise a first fluorophore directly bonded to a second fluorophore, or the first or second entity can be connected by a linker or a common entity. Whether a pair of light emitting portion and activator portion produces a suitable convertible entity can be tested by methods known to those of ordinary skill in the art. For example, light of various wavelengths can be used to stimulate the pair, and the emitted light from the light emitting portion can be measured to determine whether the pair forms a suitable conversion.

[0169] As a non-limiting example, Cy3 and Cy5 can be linked together to form such an entity. In this example, Cy3 is an activator portion capable of activating Cy5 (light emitting portion). Therefore, light at or near the maximum absorption of the activation or second portion of the entity (e.g., for Cy3, close to 532nm light) can enable the portion to activate the first light emitting portion, thereby enabling the first portion to emit light (e.g., for Cy5, close to 647nm). See, for example, U.S. Patent No. 7,838,302, the entire contents of which are incorporated herein by reference. In some cases, the first light emitting portion can be subsequently inactivated by any suitable technique (e.g., by directing 647nm red light to the Cy5 portion of the molecule).

[0170] Other non-limiting examples of potentially suitable activator moieties include 1,5IAEDANS, 1,8-ANS, 4-methylumbelliferone, 5-carboxy-2,7-dichlorofluorescein, 5-carboxyfluorescein (5-FAM), 5-carboxynaphthylfluorescein, 5-carboxytetramethylrhodamine (5-TAMRA), 5-FAM (5-carboxyfluorescein), 5-HAT (hydroxytryptamine), 5-hydroxytryptamine (HAT), 5-ROX (carboxy-X-rhodamine), 5-TAMRA (5-carboxytetramethylrhodamine), 6-carboxyrhodamine 6G, 6-CR 6G, 6-JOE, 7-amino-4-methylcoumarin, 7-aminoactinomycin D (7-AAD), 7-hydroxy-4-methylcoumarin, 9-amino-6-chloro-2-methoxyacridine, ABQ, acid fuchsin, ACMA (9-amino-6-chloro-2-methoxyacridine), acridine orange, acridine red, acridine yellow, acriflavine, acriflavine Feulgen SITSA, Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 635, Alizarin aminocarboxylate complex, Alizarin Red, AMC, AMCA-S, AMCA (aminomethylcoumarin), AMCA-X, Aminactinomycin D, Aminocumarin, Aminomethylcoumarin (AMCA), Aniline Blue, Anthrocylstearate, APTRA-BTC, APTS, Astrazon Brilliant Red 4G, Basic Orange R, Basic Red 6B, Basic Yellow 7GLL, Atabrine, ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 520, ATTO 532, ATTO 550, ATTO 565, ATTO 590, ATTO 594, ATTO 610, ATTO 611X, ATTO 620, ATTO 633, ATTO 635, ATTO 647, ATTO 647N, ATTO 655, ATTO 680, ATTO 700, ATTO 725, ATTO740, ATTO-TAG CBQCA, ATTO-TAG FQ, Auramine, Aurophosphine G, Aurophosphine,BAO 9 (diaminophenyloxadiazole), BCECF (high pH), BCECF (low pH), Berberine sulfate, Bimane, Dibenzamide, Dibenzamide (Hoechst), Di-BTC, Blancophor FFG, Blancophor SV, BOBO-1, BOBO-3, Bodipy 492 / 515, Bodipy 493 / 503, Bodipy 500 / 510, Bodipy 505 / 515, Bodipy 530 / 550, Bodipy 542 / 563, Bodipy 558 / 568, Bodipy 564 / 570, Bodipy 576 / 589, Bodipy 581 / 591, Bodipy 630 / 650-X, Bodipy 650 / 665-X, Bodipy 665 / 676, Bodipy Fl, Bodipy FL ATP, Bodipy Fl-Ceramide, Bodipy R6G, Bodipy TMR, Bodipy TMR-X Conjugate, Bodipy TMR-X, SE, Bodipy TR, Bodipy TRATP, Bodipy TR-X SE, BO-PRO-1, BO-PRO-3, Brilliant Sulphoflavin FF, BTC, BTC-5N, Calcein, Calcein Blue, Calcium Crimson, Calcium Green, Calcium Green-1Ca, 2+ Dye, Calcium Green-2Ca 2+ , calcium green-5N Ca 2+ , Calcium Green-C18 Ca 2+ , Calcium Orange, Calcofluor White, Carboxy-X-Rhodamine (5-ROX), Cascade Blue, Cascade Yellow, Catecholamine, CCF2 (GeneBlazer), CFDA, Chromomycin A, Chromomycin A, CL-NERF, CMFDA, Coumarin Phalloidin, CPM Methylcoumarin, CTC, CTC Methyl Cy2, Cy3.1 8, Cy3.5, Cy3, Cy5.1 8, Cyclic AMP Fluoro Sensor (FiCRhR), Dabcyl, Dansyl, Dansylamide (Dansyl Amine), Dansylcadaverine, Dansyl chloride, Dansyl DHPE, Dansyl fluoride, DAPI, Dapoxyl, Dapoxyl 2, Dapoxyl 3'DCFDA, DCFH (dichlorodihydrofluorescein diacetate), DDAO, DHR (dihydrorhodamine 123), di-4-ANEPPS, di-8-ANEPPS (non-ratio), DiA (4-Di-16-ASP), dichlorodihydrofluorescein diacetate (DCFH), DiD – lipophilic tracer, DiD (DiIC18 (5)), DIDS, dihydrorhodamine 123 (DHR), DiI (DiIC18 (3)), dinitrophenol, DiO (DiOC18 (3)), DiR, DiR (DiIC18 (7)), DM-NERF (high pH), DNP, dopamine, DTAF, DY-630-NHS, DY-635-NHS, DyLight 405, DyLight 488, DyLight 549, DyLight633, DyLight 649, DyLight 680, DyLight 800, ELF 97, Eosin, Erythrosine, Erythrosine ITC, Ethidium bromide, Ethidium bromide homodimer-1 (EthD-1), Acridine Orange, EukoLight, Europium (III) chloride, Fast Blue, FDA, Feulgen (pararosaniline), FIF (formaldehyde-induced fluorescence), FITC, Flazo Orange, Fluo-3, Fluo-4, Fluorescein (FITC), Fluorescein diacetate, Fluoro-Emerald, Fluoro-Gold (hydroxy Hydroxystilbamidine), Fluor-Ruby, FluorX, FM 1-43, FM 4-46, Fura Red (high pH), FuraRed / Fluo-3, Fura-2, Fura-2 / BCECF, Genacryl Brilliant Red B, Genacryl Brilliant Yellow 10GF, Genacryl Pink 3G, Genacryl Yellow 5GF, GeneBlazer (CCF2), Gloxalic Acid, Granular Blue, Hematoporphyrin, Hoechst 33258, Hoechst 33342, Hoechst 34580, HPTS, Hydroxycoumarin, Hydroxy FluoroGold, Serotonin, Indo-1, High Calcium, Indo-1, Low Calcium, Indole Dicarbocyanine (DiD), Indole Tricarbocyanine (DiR), Intrawhite Cf, JC-1, JO-JO-1, JO-PRO-1, LaserPro, Laurodan, LDS 751 (DNA), LDS 751 (RNA), Leucophor PAF, Leucophor SF, Leucophor WS, Lissamine Rhodamine, Lissamine Rhodamine B, Calcein / Ethifradiin Homodimer, LOLO-1, LO-PRO-1, Fluorescent Yellow, Lyso Tracker Blue, LysoTracker Blue-White, Lyso Tracker Green, Lyso Tracker Red, Lyso Tracker Yellow, LysoSensor Blue, LysoSensor Green, LysoSensor Yellow / Blue, Mag Green, Magdala Red (Root Bark Red B), Mag-Fura Red, Mag-Fura-2, Mag-Fura-5, Mag-Indo-1, Magnesium Green, Magnesium Orange, Malachite Green, Marina Blue, Maxilon Brilliant Flavin 10GFF, Maxilon Brilliant Flavin 8GFF, Merocyanine, Methoxycoumarin, Mitotracker Green FM, Mitotracker Orange, Mitotracker Red, Mithramycin, Monobromodiamine, Monobromodiamine (mBBr-GSH), Monochlorodiamine, MPS (Methyl Green Pyronitrile), NBD, NBD Amine, Nile Red, Nitrobenzoxadidole, Norepinephrine, Nuclear Fast Red, Nuclear Yellow, Nylosan Brilliant Flavin E8G, Oregon Green, Oregon Green 488-X, OregonGreen, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, Pararosaniline (Feulgen), PBFI, Phlox B (Sudan Red), Phorwite AR, Phorwite BKL, Phorwite Rev, Phorwite RPA, Phosphine 3R, PKH26 (Sigma), PKH67, PMIA, Pontochrome Blue Black, POPO-1,POPO-3, PO-PRO-1, PO-PRO-3, Primulin, Reactive Yellow, Propidium Iodide (PI), PyMPO, Pyrene, Pyronine, Pyronine B, PyrozalBrilliant Flavin 7GF, QSY 7, Quinacridone Mustard, Resorufin, RH 414, Rhod-2, Rhodamine, Rhodamine 110, Rhodamine 123, Rhodamine 5GLD, Rhodamine 6G, Rhodamine B, Rhodamine B 200, Rhodamine B extra, Rhodamine BB, Rhodamine BG, Rhodamine Green, Rhodamine Phallicidine, Rhodamine Phalloidin, Rhodamine Red, Rhodamine WT, Rose Bengal, S65A, S65C, S65L, S65T, SBFI, 5-HT, Sevron Brilliant Red 2B, Sevron Brilliant Red 4G, Sevron Brilliant Red B, Sevron Orange, Sevron Yellow L, SITS, SITS (primulin), SITS (stilbene isothiosulfonic acid), SNAFL calcein, SNAFL-1, SNAFL-2, SNARF calcein, SNARF1, SodiumGreen, SpectrumAqua, SpectrumGreen, SpectrumOrange, Spectrum Red, SPQ (6-methoxy-N-(3-sulfopropyl)quinolinium), Stilbene, Sulforhodamine B can C, Sulforhodamine Extra, SYTO 11, SYTO 12, SYTO 13, SYTO 14, SYTO 15, SYTO 16, SYTO 17, SYTO 18, SYTO 20, SYTO 21, SYTO 22, SYTO 23, SYTO 24, SYTO 25, SYTO 40, SYTO 41, SYTO 42, SYTO 43, SYTO 44, SYTO 45, SYTO 59, SYTO 60, SYTO 61, SYTO 62, SYTO 63, SYTO 64, SYTO 80, SYTO 81, SYTO 82, SYTO 83, SYTO 84, SYTO 85, SYTOX Blue, SYTOX Green, SYTOX Orange, Tetracycline, Tetramethylrhodamine (TAMRA), Texas Red, Texas Red-X conjugate, Thiadicarbocyanine (DiSC3), Thiazine Red R, Thiazine Orange, Thioflavin 5, Thioflavin S, Thioflavin TCN, Thiolyte, Thiazoline Orange, Tinopol CBS (fluorescent brightener), TMR, TO-PRO-1, TO-PRO-3, TO-PRO-5, TOTO-1, TOTO-3,TRITC (tetramethylrhodamine isothiocyanate), True Blue, TruRed, Ultralite, Uranine B, Uvitex SFC, WW 781, X-rhodamine, XRITC, Xylene Orange, Y66F, Y66H, Y66W, YO-PRO-1, YO-PRO-3, YOYO-1, YOYO-3, SYBR Green, Thiazole Orange (inter-chelating dye), or a combination thereof.

[0171] Another aspect of the present invention relates to computer-implemented methods. For example, a computer and / or automated system can be provided that can automatically and / or repeatedly perform any of the methods described herein. As used herein, an "automated" device refers to a device that can operate without human guidance, that is, an automated device can perform a function over a period of time after anyone has completed taking any action to facilitate a function (e.g., by inputting instructions to a computer to start the process). Typically, the automated device can perform repeated functions on time after this point. In some cases, the processing steps can also be recorded on a machine-readable medium.

[0172] For example, in some cases, a computer can be used to control the imaging of a sample, for example, using fluorescence microscopy, STORM or other super-resolution techniques such as those described herein. In some cases, a computer can also control operations such as drift correction, physical registration, hybridization and cluster alignment in image analysis, cluster decoding (e.g., fluorescence cluster decoding), error detection or correction (e.g., as described herein), noise reduction, identifying foreground features from background features (such as noise or debris in an image), etc. As an example, a computer can be used to control the activation and / or excitation of a signaling entity within a sample, and / or the acquisition of an image of a signaling entity. In one set of embodiments, a sample can be excited using light having various wavelengths and / or intensities, and the order of the wavelengths of the light used to excite the sample can be associated with an image obtained for a sample containing the signaling entity using a computer. For example, a computer can apply light having various wavelengths and / or intensities to a sample so as to produce a different average number of signaling entities in each target area (e.g., one activated entity per position, two activated entities per position, etc.). In some cases, this information can be used to construct an image of the signaling entity and / or determine the location of the signaling entity, in some cases at high resolution, as described above.

[0173] In some aspects, the sample is placed on a microscope. In some cases, the microscope can include one or more channels, such as microfluidic channels, to guide or control fluid to the sample or to flow out from the sample. For example, in one embodiment, nucleic acid probes such as those discussed herein can be introduced into the sample and / or removed from the sample by making fluid flow to the sample or flow out from the sample through one or more channels. In some cases, one or more chambers or reservoirs can also be present for retaining fluid, for example, in communication with the channel and / or with the sample fluid. Those of ordinary skill in the art are familiar with channels, including microfluidic channels, for moving fluid to the sample or removing fluid from the sample.

[0174] The following documents are each incorporated herein by reference in their entirety: U.S. Patent No. 10,240,146, entitled “Probe Library Construction”; U.S. Patent Application Publication No. 2017 / 0220733, entitled “Systems and Methods for Determining Nucleic Acids”; U.S. Patent Application Serial No. 62 / 779,333, entitled “Amplification Methods and Systems for MERFISH and Other Applications”; International Patent Application Publication No. WO 2016 / 018960, entitled “Systems and Methods for Determining Nucleic Acids”; International Patent Application Publication No. WO 2016 / 018963, entitled “Probe Library Construction”; International Patent Application Publication No. WO 2018 / 089445, entitled “Matrix imprinting and Clearing”; International Patent Application Publication No. WO 2018 / 218150, entitled “Systems and Methods for High-Throughput Image-Based and International Patent Application Publication No. WO 2018 / 089438, entitled “Multiplexed Imaging Using MERFISH and Expansion Microscopy.” In addition, the entire contents of each of the following are also incorporated herein by reference: U.S. Provisional Patent Application Serial No. 62 / 836,578, entitled “Imaging-Based Pooled CRISPR Screening,” filed by Zhuang et al. on April 19, 2019, and U.S. Provisional Patent Application Serial No. 62 / 841,715, entitled “Imaging-Based Pooled CRISPR Screening,” filed by Zhuang et al. on May 1, 2019.

[0175] The following examples are intended to illustrate certain embodiments of the invention, but are not intended to represent the full scope of the invention.

[0176] Example 1

[0177] Mixed library CRISPR screening provides a powerful means to discover genetic factors involved in cellular processes in a high-throughput manner. However, the phenotypes available from mixed library screening are limited. Complex phenotypes, such as cell morphology and subcellular molecular organization, and their dynamics, require imaging-based readouts, which are currently not available using mixed library CRISPR screening. These embodiments show all mixed library CRISPR screening methods based on imaging, which combine high-content phenotypic imaging in single cells with high-throughput guide RNA (sgRNA) identification. In one such method, sgRNA is co-delivered to cells, where the corresponding barcode is placed in the 3' untranslated region (3'UTR) of the reporter gene using a lentiviral delivery system that has reduced recombination-induced sgRNA-barcode mismatches. Multiple error robust fluorescence in situ hybridization (MERFISH) can be used to read out the barcode, so sgRNA can be identified with high accuracy. See, for example, International Patent Application Publication Nos. WO 2016 / 018960, WO 2016 / 018963, WO 2018 / 089445, WO 2018 / 218150, WO 2018 / 089438, and WO 2018 / 089438, the entire contents of which are incorporated herein by reference. These embodiments use this approach to screen 162 sgRNAs targeting 54 RNA-binding proteins for the effect of RNA localization to the nuclear compartment, and to discover previously unknown regulatory factors for nuclear RNA localization. Notably, these screenings revealed both positive and negative regulators for long noncoding RNA (lncRNA), MALAT1 nuclear speckle localization, suggesting that lncRNA is located in the dynamic regulatory role of subcellular compartments.

[0178] These examples develop an imaging-based pooled library CRISPR screening approach that allows for the phenotype and genotype of individual cells to be read out through high-resolution, high-content imaging. This approach promises to significantly expand the phenotypic space accessible through pooled genetic screening by allowing the detection of complex cellular phenotypes, such as cell morphology, subcellular organization of different molecular species, and their dynamics. This approach was applied to screen for genetic factors involved in nuclear RNA localization, identifying both positive and negative regulators that control lncRNA localization to nuclear speckles.

[0179] These examples illustrate an all-imaging-based mixed library CRISPR screening approach in mammalian cells. This approach allows for high-content phenotypic imaging of multiple molecular targets in single cells and more accurate identification of the genotype of each cell, the latter being achieved by associating each sgRNA with a unique barcode and reading out the barcode using multiple error robust fluorescence in situ hybridization (MERFISH). To illustrate the power of this approach, genetic screening of factors that regulate RNA localization in nuclear compartments was performed. Various nuclear RNAs, such as small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and long non-coding RNAs (lncRNAs), are associated with nuclear compartments such as nucleoli and nuclear speckles formed by liquid-liquid phase separation. Understanding the spatial regulation of these RNAs is important for understanding how they organize diverse nuclear activities and functions, including transcriptional regulation, transcriptional processing, and genomic stability. The effects of 162 sgRNAs (targeting 54 genes) were screened for localization of six RNA targets, including: lncRNA MALAT1, U2 snRNA, and noncoding RNA 7SK, all of which are known to localize to nuclear speckles; nascent preribosomal RNA and noncoding RNA MRP, both of which are known to localize to the nucleolus; and polyadenylated RNA. These results revealed several regulators of nuclear RNA localization. Specifically, two positive regulators that are critical for the nuclear speckle localization of MALAT1 and a negative regulator that reduces MALAT1 nuclear speckle localization were identified, suggesting that lncRNA localization is dynamically regulated.

[0180] Example 2

[0181] This example illustrates high-throughput, high-precision barcode imaging in mammalian cells. In situ imaging-based mixed library screening has been performed in bacteria in recent years, where the genotype of a single cell is identified by multiplexed FISH imaging of barcodes associated with gene variants. Because bacterial cells are small, the diffusion signal from the barcode RNA in a single cell is strong enough to be easily measured. However, mammalian cells are about a thousand times larger than bacteria, making it difficult to achieve a high enough concentration of barcode RNA to allow reliable measurement. Therefore, new barcode expression and detection schemes are needed for mammalian cells to increase the barcode signal and reduce the background.

[0182] To achieve this goal, two independent promoters were used to express the sgRNA and reporter gene in the same vector and a 12-digit ternary barcode was incorporated into the 3' untranslated region (3'UTR) of the reporter gene ( Figure 1AEach digit of the ternary barcode (hereafter referred to as a trit) is made from one of three different readout sequences (30 nucleotides (nt) long) specific to that digit, corresponding to the three possible trit values ​​0, 1, and 2. For example, 12 trits have a total encoding of 3 12 = 531,441 barcodes. Because there are a total of 36 different three-bit sequences (3 different sequences for each of the 12 three-bit sequences), the barcodes are read using sequential rounds of hybridization to form images with 36 pseudo-color channels (18 rounds of hybridization, each with 2-color imaging, one pseudo-color channel for each three-bit sequence), providing highly multiplexed detection. To increase the signal from the barcodes, a branched DNA amplification scheme is used to amplify the signal of each three-bit sequence ( Figure 1A To reduce background interference, the reporter gene mRNA sequence was co-stained, and both the reporter gene sequence and the barcode sequence were detected using single-molecule FISH (smFISH), so that only the barcode signal co-localized with the reporter gene signal was considered ( Figure 1A For each specific triple, a numerical value (0, 1, or 2) was assigned to the triple based on the pseudo-colored channel that exhibited the highest proportion of reporter mRNA smFISH signals colocalized with the triple. This detection scheme reduces background signals generated by nonspecific binding of barcoded FISH probes, which is important for decoding accuracy as shown in the following sections.

[0183] To test this barcoding scheme, a library of vectors was cloned, each containing a shared reporter gene (luciferase-mCherry) and a unique barcode ( Figure 1B ; see below and Figure 7 Although the total number of possible barcodes exceeds 500,000, the library is limited to only ~2000 vectors (for error detection purposes, as described below), and the barcodes in the library are determined by sequencing. The library is delivered to the genome of U-2OS cells using lentivirus at a low multiplicity of infection (MOI) so that most infected cells receive only one barcode. The barcode signal of a single cell is measured using a multiplex detection protocol as described above.

[0184] After each round of hybridization, bright barcode signals were observed that colocalized with the smFISH signals of the reporter gene (luciferase-mCherry) mRNA ( Figure 1C For each three-bit assay, the three three-bit values ​​were probed separately (in different pseudo-color channels as described earlier), and three distinct cell populations were observed, representing cells expressing the barcodes for the three different three-bit values ​​( Figure 1D ; see below and Figure 8 A k-means clustering algorithm was used to separate the three cell populations, with each population assigned a three-bit value based on which of the three pseudo-color channels assigned to that three-bit showed the highest proportion of reporter mRNA spots colocalizing with the three-bit signal. Detection of 12 three-bits using 36 pseudo-color channels allowed the assignment of a barcode to each cell. The barcodes decoded for the majority of cells (~57%) matched the ~2000 barcodes in the library determined by sequencing ( Figure 1E ), cells with mismatched barcodes were discarded. To assess the improvement in barcode detection accuracy using this reporter gene colocalization approach, the barcode for each cell was also assigned based on the number of FISH spots detected for individual barcode signals (without considering colocalization with reporter gene signals). It was found that in this case no decoded barcode matched the actual barcode in the library ( Figure 1F ), which is presumably caused by background signals introduced by nonspecific FISH labeling, indicating that the use of reporter gene co-localization greatly improves decoding accuracy.

[0185] Using a bottleneck strategy (i.e., limiting the total number of vectors in the library to ~2000, which is only <0.4% of the total possible number of 12-bit ternary barcodes) allows for error detection, because a read error at any bit is most likely to generate an invalid barcode that is not present in the library. Quantitatively, because only 0.4% of all possible barcodes are present in the library, the probability that any incorrectly detected barcode matches a barcode in the library is only 0.4%. Therefore, of the 57% of barcodes that are exact matches, only 0.3% are likely to be due to barcode misidentification (see detailed calculations below).

[0186] Figure 1 shows imaging-based barcode detection for genotyping in mammalian cells. Figure 1A The purpose is to show a strategy for high-precision imaging-based barcode detection for genotyping. sgRNA and a reporter gene with an imaging-based barcode are co-delivered to the genome of the host cell. The reporter gene portion of the mRNA is detected by single-molecule FISH (smFISH), and the barcode is detected by MERFISH, using successive rounds of hybridization to detect each bit (three bits) of the ternary barcode. The barcode signal is amplified using a 4×4 branched DNA amplification scheme. Figure 1B Shown are the construct designs of reporter gene-barcode libraries used to probe barcode identification accuracy. Figure 1CThe upper figure shows an example image showing the reporter mRNA smFISH signal and the signal for each of the three three-digit values ​​(0, 1, and 2) for a single three-digit barcode. The lower figure shows a magnified view of the white box area of ​​the upper figure, where the reporter gene signal is shown on the left and the overlap between the reporter gene signal and the barcode three-digit signal is shown on the right. For this cell, the three-digit value 1 has a high colocalization ratio, while the three-digit values ​​0 and 2 do not have a high colocalization ratio. The scale bar is 10 microns. Figure 1D Shown are the colocalization ratios of three triple values ​​of three measurements of example pairs for all cells.Each spot in the mapping corresponds to individual cells.Colocalization is than the number of the reporter gene smFISH spot that is defined as colocalization with three signal spots divided by the sum of reporter gene smFISH spot in the cell.Based on its colocalization, than using the k-means clustering algorithm, cell is divided into three clusters (shown with different shades).Each cluster corresponds to the cell with specific triple value. Figure 1E Shown are histograms of the number of cells with varying numbers of mismatched triplets in the decoded barcodes compared to valid barcodes in the library. Barcodes were decoded as described above using colocalization of reporter and triplet signals. Figure 1F and Figure 1E Same as , but employs barcodes that are decoded using only the number of measured three-way signal spots, without taking into account the colocalization of the reporter gene signal and the three-way signal.

[0187] Figure 7 The library cloning strategy used to evaluate the accuracy of imaging-based barcode detection is shown. Briefly, barcodes and UMIs (unique molecular identifiers) were first assembled from single DNA oligonucleotides via two-step overlapping PCR (see below). The shading of the different oligonucleotides represents different three-bit sequences. This barcode-UMI library was then inserted into a digested lentiviral plasmid backbone to form a barcode-UMI lentiviral vector library. A reporter gene cassette was further inserted into the barcode-UMI lentiviral vector library to form the final reporter gene-barcode library.

[0188] Figure 8 Shown are all 12 three-dimensional colocalization ratio analysis.To all 12 three-dimensional display the colocalization ratio of three numerical values ​​of single three-dimensional measurement to all cells.Based on its colocalization ratio, cells are divided into three clusters (shown with different shadings) using k-means clustering algorithm.Each cluster corresponds to the cell with a three-dimensional numerical value.

[0189] Example 3

[0190] To further verify the low false positive rate, in this example, two reporter gene-barcode libraries were designed, each expressing the reporter gene luciferase-mCherry ( Figure 2A ), and the two libraries were cloned separately. Each library was reduced to contain <0.2% of all possible barcodes, making it very unlikely that the same barcode would appear in both libraries, and the identity of the barcode associated with each epitope-tagged reporter gene was determined by sequencing. The two libraries were introduced into U-2OS cells separately, and then the cells from the two libraries were mixed together in approximately equal numbers. The phenotype of each cell, i.e., the expression of HA or Myc tags, was analyzed using immunofluorescence imaging ( Figure 2B ), using successive rounds of hybridization to image the barcode associated with each cell as described above. The rationale is that determining the phenotype of each cell will allow the barcode identity of that cell to be deduced from the sequencing results, which will then be compared with the barcode determined by imaging to allow the identification of a small fraction of misidentified barcodes.

[0191] Judging by barcode-phenotype mismatch, only ∼1% of cells had incorrectly labeled barcodes ( Figure 2C and 2D Even this small error is likely due to errors in cell segmentation, which in turn leads to errors in phenotypic determination, further supporting the very low barcode misidentification rate in these experiments.

[0192] FIG2 illustrates the evaluation of the misidentification rate using barcodes with known phenotype-barcode correspondences. Figure 2A The diagram shows the construct used to evaluate barcode detection accuracy. The reporter gene luciferase-mCherry is tagged with either an HA or Myc tag to define two phenotypes, as well as a nuclear localization signal to concentrate HA and Myc signals in the nucleus, facilitating detection. The barcode is placed in the 3' UTR of the reporter gene, and sequencing confirms the correspondence between the barcode and the HA or Myc tag. The reporter gene is driven by a CMV promoter. Figure 2B The images shown show HA and Myc immunostaining signals in two different channels. Nuclei with strong HA signals have weak Myc signals, and vice versa. Cell borders are highlighted. Nuclear borders of HA-expressing and Myc-expressing cells are also labeled, respectively. Scale bar: 50 μm. Figure 2CIt is a scatter plot of the HA and Myc immunostaining intensity of a single cell. Shown are cells that are determined to be assigned to the HA or Myc library based on the barcodes of imaging. Cells that are classified as HA or Myc immunostaining positive are shown by triangles or circles (see below). Among 1105 cells with the barcode corresponding to HA, only 10 were observed to be Myc immunostaining positive, and among 1034 cells with the barcode corresponding to Myc, only 9 were observed to be HA immunostaining positive, indicating that the barcode error identification rate is low. The HA and Myc immunostaining signals of a small number of cells (197 in 2336 cells) were all below the threshold or their HA and Myc immunostaining signals were all above the threshold, so they were not clearly identified as HA positive or Myc positive (see below). These cells were eliminated from the analysis. Figure 2D Shown are histograms of the ratio of HA intensity to Myc intensity for individual cells decoded by barcode imaging to contain either an HA-tagged reporter or a Myc-tagged reporter.

[0193] Example 4

[0194] This example illustrates a lentiviral delivery system with reduced recombination effects for accurate sgRNA labeling. Another challenge for sgRNA labeling by hybrid barcode imaging comes from the viral system used to deliver the sgRNA-reporter gene-barcode vector into mammalian cells. Lentivirus is a preferred delivery system for mammalian cells because it allows stable genomic integration of the vector and the introduction of one sgRNA per cell by transfection at a low MOI (although other delivery systems can also be used in other cases). However, lentivirus has two single-stranded RNA genomes and is prone to recombination, which can lead to mispairing of sgRNA and barcode during viral transduction. The recombination rate of lentivirus is ~1 event per kilobase (kb). Because in these experiments, the sgRNA and reporter gene-barcode combination were expressed under the control of two independent promoters, the barcode and sgRNA sequences were separated by a large genomic distance (>1 kb) in these examples, so the probability of recombination-induced barcode-sgRNA mispairing can be huge.

[0195] This example describes a strategy modified from the CROP-seq method to overcome this recombination problem. Specifically, the reporter gene (puro-T2A-mCherry) was placed under the control of a strong Pol II promoter (EF1α, EF1-α), the sgRNA was placed under the control of an independent promoter (hU6), and the barcode was placed downstream of the polypurine band (PPT) in the lentiviral genome ( Figure 3AIn this way, the protospacer sequence (~20 nt sequence for specific gene targeting) and barcode sequence of sgRNA can be separated by a minimum genomic distance (~100 bases). Although the expression of sgRNA downstream of the reporter gene can be impaired by the interference of the strong EF1α (EF1-alpha) promoter expressing the reporter gene, the sgRNA expression cassette is copied to the 5'LTR of the proviral genome during genomic integration, forming an additional functional unit for expressing sgRNA without interference from the EF1α (EF1-alpha) promoter ( Figure 3A ). Transcription of the reporter gene terminates only at the 3' end of the 3'LTR, so the barcode should be expressed in the reporter gene mRNA 3'UTR for imaging-based barcode labeling ( Figure 3A ).

[0196] To evaluate whether this construct design can support functional lentiviral infection and sgRNA expression, a library containing both sgRNAs targeting genes essential for cell survival and non-targeting control sgRNAs was constructed. Efficient sgRNA expression can lead to cell depletion of sgRNAs targeting essential genes. 159 sgRNAs targeting 53 essential ribosomal proteins (3 sgRNAs per gene) and 51 non-targeting sgRNAs as controls were selected (Dataset S1), and a lentiviral library containing these 210 sgRNAs, as well as a reporter gene (puro-T2A-mCherry) and a barcode was generated by mixed cloning ( Figure 3A (See below and Figure S3). This lentiviral library was then used to infect U-2OS cells stably expressing Cas9-BFP. On day 2 after lentiviral infection, cells infected with the library and expressing high levels of Cas9 were selected based on mCherry and BFP fluorescence, respectively. These cells were retained for experiments at different time points after infection. The abundance of cells expressing various sgRNAs was determined by genomic DNA sequencing.

[0197] As expected, cells containing sgRNAs targeting essential genes were significantly depleted compared to cells containing non-targeting sgRNAs, and the extent of depletion depended on the length of time after lentiviral infection ( Figure 3B ), indicating that this viral system can support the expression of functional sgRNAs. In addition, the abundance of cells containing different sgRNAs was measured by imaging-based barcoding, as described above. The abundance of cells containing individual sgRNAs measured by imaging-based barcoding correlated well with the abundance of cells measured by direct sgRNA protospacer sequencing ( Figure 3C ), further supporting accurate barcode detection.

[0198] Next, this experiment was used to evaluate the recombination rate of the constructs. If recombination occurs, the barcode assigned to the sgRNA of the essential gene can recombine with the non-targeting sgRNA, which should result in a higher cell abundance measured by barcode imaging than by protospacer sequencing. Similarly, the barcode assigned to the non-targeting sgRNA can recombine with the sgRNA targeting the essential gene, resulting in a lower cell abundance measured by barcode imaging. Therefore, for both cells containing sgRNAs targeting essential genes and cells containing non-targeting sgRNAs, the fold change in relative cell abundance between day 2 and day 21 after lentiviral transduction was measured.

[0199] As expected, the relative abundance of cells containing sgRNAs targeting essential genes was greatly reduced on day 21 compared to day 2, whereas the relative abundance of cells containing non-targeting sgRNAs was greatly increased on day 21 ( Figure 3D Compared with the results obtained by sgRNA sequencing, the fold changes determined by barcode imaging were slightly smaller due to recombination ( Figure 3D This difference allowed quantification of the recombination-induced mispairing rate (see below), which was determined to be ∼8% between the sgRNA protospacer and the barcode ( Figure 3E ).

[0200] Additionally, recombination-induced mispairing between the sgRNA protospacer sequence and a unique molecular identifier (UMI, a 20-nt sequence placed ~500 bases downstream of the protospacer sequence) was measured ( Figure 3A As expected, due to the larger genomic distance between the UMI and the protospacer (~500 nt), the recombination-induced mispairing rate in the region between the protospacer and the UMI was larger, ~16% ( ) compared to the genomic distance between the barcode and the protospacer (~100 nt). Figure 3D and 3E). Notably, for random pairing of barcodes, the probability that these barcodes share the same sequence at any given three-position position is approximately 1 / 3, because there are three possible sequences for any given three positions, and because the barcodes in the reduced library are a randomly selected subset of all possible barcodes. Therefore, it is estimated that recombination in the barcode region should be roughly 1 / 3 of the recombination rate of fully homologous sequences of the same length. Based on the ~8% recombination rate measured for the ~100-nt genomic region between the barcode and the protospacer sequence (the common sequence of the sgRNA), the recombination rate in the ~400-nt barcode region is estimated to be approximately (400 / 100) x 8% / 3 = 10.7%, resulting in a recombination rate of ~8% + 10.7% = 18.7% for the genomic region between the protospacer sequence and the UMI, which is consistent with the measured value of ~16%. Furthermore, because the barcode library is reduced in size, recombination occurring within the barcode region is likely to generate new barcodes that match valid barcodes in the library, making barcode misidentification less likely.

[0201] In summary, the low error rate (<1%) in barcode imaging and the low mismatch rate (~8%) between sgRNA and barcode induced by recombination allow for high accuracy in sgRNA identification by barcode imaging, which further allows for full-imaging-based mixed library CRISPR screening. It is worth noting that although the remaining 8% mismatch rate between sgRNA and barcode can potentially generate false positives and false negatives in the screening, the error rate will be negligible because hundreds of cells carrying the same sgRNA are generally probed to determine which sgRNA has a statistically significant effect; moreover, three sgRNAs targeting each gene are probed, and only if two of the three sgRNAs show a statistically significant effect will the gene be considered a hit. Any remaining false positives can be easily identified by validation experiments.

[0202] Figure 3A Illustration of the design of a lentiviral delivery method with low recombination-induced sgRNA-barcode mismatch rate. Figure 3A Shown is the lentiviral construct used to deliver sgRNA and a barcode for sgRNA labeling. The sgRNA cassette (hU6 promoter and sgRNA) and barcode array are placed downstream of the polypurine band (PPT). A strong Pol II promoter (EF1α, EF1-alpha) drives expression of the reporter gene puro-T2A-mCherry. Following genomic integration, the sgRNA cassette is copied into the 5' LTR for sgRNA expression, while the barcode and reporter gene are expressed in the 3' UTR for barcode imaging. UMI: Unique Molecular Identifier. Figure 3BProtospacer counts for each sgRNA at days 8, 21, and 28 after lentiviral transduction are plotted against protospacer counts measured at day 2 after transduction. Protospacer counts at days 8, 21, and 28 were normalized by a factor such that the average counts for non-targeting sgRNAs for these conditions were the same as the average counts for non-targeting sgRNAs at day 2. Protospacer counts were determined by sequencing. As expected, cells expressing sgRNAs targeting essential ribosomal genes were strongly depleted over time, such that counts for sgRNAs targeting essential genes were greatly reduced compared to non-targeting control sgRNAs. Figure 3C Shown is the correlation between the number of cells expressing certain sgRNAs, measured by imaging-based barcode detection, and the sgRNA counts measured by protospacer sequencing, at day 21 after lentiviral transduction. sgRNAs targeting essential genes are generally labeled in red, and non-targeting control sgRNAs are generally labeled in blue. Figure 3D Figure 2 is a violin plot showing the median fold change in relative sgRNA abundance between days 2 and 21 after lentiviral transduction, as measured by protospacer sequencing, imaging-based barcode detection, and UMI sequencing. The relative abundance of a particular sgRNA is defined as the fraction of total sgRNA reads corresponding to that specific sgRNA (i.e., the number of protospacer (or UMI) reads determined by sequencing for that specific sgRNA normalized to the total number of protospacer (or UMI) reads for all sgRNAs, or the number of cells expressing the barcode corresponding to that sgRNA normalized to the total number of cells determined by imaging). As expected, the relative abundance of sgRNAs targeting essential genes decreases over time, while the relative abundance of non-targeting sgRNAs increases. Due to recombination, the fold change determined by barcode imaging is slightly smaller than that determined by protospacer sequencing, and the fold change determined by UMI sequencing is slightly smaller than that determined by barcode imaging. Figure 3E Shown are the median mispairing rates between protospacers and barcodes and between protospacers and UMIs due to recombination, measured at days 21 and 28 after lentiviral transduction. Error bars indicate 95% confidence intervals.

[0203] Example 5

[0204] This example illustrates a mixed CRISPR screen for factors that regulate nuclear RNA localization. To demonstrate the efficacy of this screening approach, potential regulators of RNA localization were screened in the nucleus ( Figure 4A). 54 candidate genes involved in nuclear RNA regulation were selected, including hnRNP family proteins, DExD / H box RNA helicases, and genes involved in RNA modification (Dataset S2). A library of 167 sgRNAs was designed, containing three sgRNAs for each of the 54 genes and five non-targeting sgRNAs as controls. A lentiviral library containing these sgRNAs, a reporter gene (puro-T2A-mCherry), and a barcode was generated by mixed cloning (see below and Figure 9 To demonstrate the ability of this method to evaluate complex phenotypes, the spatial distribution of five specific RNA species (lncRNA MALAT1, U2 snRNA, 7SK, MRP, and nascent preribosomes, as well as RNA containing polyadenylation) was imaged using FISH. In addition, the nuclear speckle protein SON was also included in the phenotypic imaging using immunolabeling with oligonucleotide-conjugated antibodies. These RNA and protein targets were imaged using sequential rounds of hybridization, as well as barcode imaging, with 3-4 different color channels ( Figure 4A ) (See below for details of the imaging step).

[0205] As expected, the protein SON showed a clustered distribution marking nuclear speckles, while MRP and pre-ribosome signals marked subnucleolar compartments ( Figure 4B Based on these images, the boundaries of these structures were identified, and their number, the area they covered, and their average signal intensity (i.e., the total signal located within the identified cluster boundaries divided by the total area covered by these clusters) were determined in individual cells. Next, the enrichment of MALAT1, U2, 7SK, and polyadenylated RNA in nuclear speckles identified by SON staining was quantified (see below).

[0206] For each of these feature quantifications, the values ​​determined for cells carrying the targeting sgRNA were compared to the values ​​measured from cells carrying a non-targeting control sgRNA to determine the fold change. Four biological replicates of the experiment were performed, and a total of ∼30,000 cells were decoded, with hits determined based on the following criteria: at least two of the three sgRNAs targeting a gene exhibited a statistically significant fold change (Dataset S3).

[0207] As a positive control, a statistically significant decrease in cluster signal intensity, cluster area, and cluster number associated with SON staining was detected in cells expressing sgRNA targeting SON ( Figure 4C In addition, sgRNAs targeting several DExD / H-box RNA helicases (DDX10, DDX18, DDX21, DDX24, DDX52, and DDX56) resulted in statistically significant changes in various features of nascent preribosome staining ( Figure 4D), consistent with the known functions of these genes in ribosome biogenesis. Notably, the magnitude of the changes in these phenotypic traits was moderate ( Figure 4C and 4D ), potentially because not all cells expressing the sgRNA are genome-edited. Thus, these quantifications allow identification of genetic perturbations with statistically significant effects, but the magnitude of phenotypic changes is less informative. It was also noted that perturbation of several genes in the hnRNP family resulted in significant changes in pre-ribosome and MRP signaling in the nucleolus (Dataset S3), potentially due to indirect effects.

[0208] Figure 4 shows an imaging-based hybrid CRISPR screen for regulators of nuclear RNA localization. Figure 4A The scheme of screening based on imaging is shown. Cells infected with lentivirus expressing sgRNA, barcode and reporter gene are fixed and imaged. In 18 rounds of hybridization (1-18 rounds), 647-nm and 750-nm color channels are used to image the barcode by MERFISH. In order to increase the accuracy of barcode imaging, 561-nm color channel is used to image reporter gene mRNA in each round (1-18 rounds), to allow the co-localization between barcode and reporter gene mRNA signal to be determined. In the first 7 rounds (1-7 rounds), 7 proteins and RNA targets for phenotypic measurement are imaged in 488-nm color channel. The mosaic on the left side comprises 900 visual fields from a single screening. Figure 4B Phenotypic images of SON, MRP, pre-ribosomes, MALAT1, U2 snRNA, 7SK, and polyadenylated RNA are shown. SON marks nuclear speckles, while pre-ribosomes and MRP mark subnuclear structures. Cluster number, cluster area, and cluster intensity were quantified for SON, ribosomes, and MRP. The enrichment of MALAT1, U2 snRNA, 7SK, and polyadenylated RNA in nuclear speckles was quantified. Scale bar: 20 μm. Figure 4C Volcano plot showing the effect of each sgRNA on SON cluster intensity, cluster area, and cluster number. Figure 4D Volcano plot showing the effect of each sgRNA on pre-ribosome cluster intensity, cluster area, and cluster number. Figure 4C and 4DThe fold change induced by each sgRNA was calculated as the mean of all cells containing that sgRNA divided by the mean of all cells containing non-targeting sgRNAs. The horizontal dashed line indicates the p-value (0.05) used to determine the screen hit. The data points for the indicated hits (i.e., two of the three sgRNAs targeting that gene showed a statistically significant fold change (p < 0.05)) are shown in shades matching the shade of the gene name shown in the legend, with data points for sgRNAs targeting other genes shown in gray. Data points for non-targeting sgRNAs are shown in black.

[0209] Figure 9 The cloning strategy for the lentiviral sgRNA-barcode delivery library is shown. Briefly, barcodes and UMIs were first assembled from single DNA oligonucleotides using two-step overlapping PCR, and then assembled with protospacer sequences and sgRNA constant region sequences using overlapping PCR to form the sgRNA-barcode-UMI cassette library. The shading of the different oligonucleotides represents different three-bit sequences. This library was then inserted into a digested lentiviral backbone containing a reporter gene, with the hU6 promoter at a site downstream of the polypurine threonine band (PTT).

[0210] Example 6

[0211] This example illustrates a novel factor involved in regulating the nuclear speckle localization of MALAT1. This screening revealed genes involved in regulating the nuclear speckle localization of different RNA species (data set S3). Compared with 7SK, U2 snRNA and RNA comprising polyadenylation, more genes regulating the localization of MALAT1 were identified. This discussion focused on MALAT1. Notably, two groups of genes ( Figure 5A ; Dataset S3), all but one gene (hnRNPH3) were validated by siRNA-mediated knockdown ( Figure 5B and 5C ). Due to the lack of effective antibodies for this protein, the effectiveness of siRNA against hnRNPH3 has not been confirmed. Depletion of the first set of genes (DHX15, DDX42, hnRNPK, and hnRNPH1) resulted in a statistically significant reduction in the enrichment of MALAT1 in nuclear speckles ( Figures 5A-5C), suggesting that these genes upregulate the nuclear speckle localization of MALAT1. DHX15 and DDX42 are involved in spliceosome recycling and assembly, respectively, consistent with the involvement of mRNA splicing factors in the recruitment of MALAT1 to nuclear speckles. The hnRNP family proteins hnRNPH1 and hnRNPK have not been previously reported to upregulate the nuclear speckle localization of MALAT1. These two genes were also found to affect the localization of other RNA species, including U2 snRNA, polyadenylated RNA, preribosomal RNA, and MRP (Dataset S3), suggesting a global effect of perturbation of these two genes.

[0212] Surprisingly, we also identified three factors, hnRNPA1, hnRNPL, and PCBP1, that negatively regulate the nuclear speckle localization of MALAT1. Their depletion by sgRNA or siRNA induced a statistically significant increase in MALAT1 enrichment in nuclear speckles ( Figures 5A-5C The fold increase in MALAT1 enrichment induced by siRNA may be an underestimate due to incomplete knockdown. Combined knockdown of all three factors further increased MALAT1 enrichment in nuclear speckles (see below). Figure 10A ), interestingly, this also led to the enlargement of some nuclear speckles (see below, Figure 10B and 10C The composition of each nuclear speckle (measured by the ratio of MALAT1 and SON levels in nuclear speckles) also became more diverse in the triple knockdown samples: some speckles had a reduced MALAT1 / SON ratio, while some had an increased ratio (see below, Figure 10D These results indicate that enhanced nuclear speckle localization of MALAT1 following knockdown of the three negative regulators is associated with altered nuclear speckle morphology and composition. This suggests a role for MALAT1 in regulating nuclear speckle structure, consistent with the observation that MALAT1 knockdown leads to reduced nuclear speckle size.

[0213] FIG5 shows the genetic factors involved in regulating MALAT1 nuclear speckle localization. Figure 5A A volcano plot of the effect of each sgRNA on MALAT1 nuclear speckle enrichment is shown. Fold changes are calculated as described in Figure 4. The horizontal dashed line represents the p-value (0.05) used to determine the hit of the screening. The hits confirmed by siRNA knockdown are highlighted in the shadow matching the shadow of the gene name shown in the legend, and the data points of sgRNAs targeting other genes are shown in gray. The data points of non-targeting sgRNAs are shown in black. Figure 5BBox plots are shown showing the effects of siRNA knockdown on MALAT1 localization for seven hit genes, alongside data for a control non-targeting siRNA. The middle line shows the median, the boxes indicate the 25th-75th percentile quartiles, and the whiskers indicate the maximum and minimum values. 100-300 cells were quantified for each condition. Student's t-tests were performed for each condition compared to the control. ****, p < 0.0001. Figure 5C Images showing MALAT1 localization after siRNA knockdown of seven target genes are shown. Data from a control non-targeting siRNA are also shown. MALAT1 staining is shown in the upper image, and SON staining is shown in the lower image. Scale bar is 10 μm.

[0214] FIG10 shows that triple knockdown of hnRNPA1, hnRNPL, and PCBP1 affects the morphology and composition of nuclear speckles. Figure 10A Shown are box plots showing the effects of control siRNA and single and triple knockdown (KD) of HNRNPA1, HNRNPL, and PCBP1 on MALAT1 localization. Box plot elements are as described in Figure 5. 100-300 cells were quantified for each condition. Student's t-tests were performed between each single KD and non-targeting control, as well as between triple KD and single KD of hnRNPA1, hnRNPL, or PCBP1. ****, p<0.0001. Figure 10B Shown are example images of cells showing the enlargement of some MALAT1-positive nuclear puncta (highlighted by arrows) after triple KD of hnRNPA1, hnRNPL and PCBP1 compared to cells transfected with control non-targeting siRNA. Scale bar is 10 μm. Figure 10C The distribution of nuclear speckle sizes is shown, showing that triple KD of hnRNPA1, hnRNPL, and PCBP1 increases nuclear speckle size. The difference between the two distributions was tested using a two-sample Kolmogorov-Smirnov test. Figure 10D The distribution of log2(MALAT1 / SON intensity ratio) in each nuclear spot is shown for control siRNA and hnRNPA1, hnRNPL and PCBP1 triple KD samples. ˜300 cells and ˜7000 spots were measured for control and triple KD conditions, respectively.

[0215] Example 7

[0216] It has been previously shown that nuclear speckle localization of MALAT1 may be impaired following transcriptional inhibition. However, the genetic factors involved in this process are largely unknown. Therefore, it was tested whether these negative regulators have a role in this process. To this end, in this example, the drug 5,6-dichloro-1-β(beta)-D-ribofuranosylbenzimidazole (DRB) was added to inhibit transcription, and a substantial reduction in MALAT1 enrichment in nuclear speckles was observed. Single knockdown of hnRNPA1, hnRNPL, and PCBP1 was largely unable to rescue DRB-induced dissociation of MALAT1 from nuclear speckles ( Figure 6A and 11 On the other hand, double knockdown of two of the three factors or triple knockdown of all three factors largely rescued this DRB-induced dissociation effect ( Figure 6A 、 6B and 11, see also below), suggesting that these hnRNP family proteins are required for transcriptional repression-induced MALAT1 dissociation from nuclear speckles, and that these factors may play multiple roles in this process. These results provide a potential mechanism for the dissociation of MALAT1 from nuclear speckles by transcriptional repression. During transcriptional repression, RNA-binding proteins such as hnRNPA1 and hnRNPL are freed from nascent mRNA transcripts, allowing them to bind to other RNA species. Therefore, it is possible that free hnRNPA1 and hnRNPL can bind to MALAT1 and compete for factors that recruit MALAT1 to nuclear speckles, thereby preventing MALAT1 from localizing to nuclear speckles during transcriptional repression.

[0217] FIG6 shows that hnRNPA1, hnRNPL, and PCBP1 are required for transcriptional repression-induced dissociation of MALAT1 from nuclear speckles. Figure 6A Shown is the quantitative enrichment of MALAT1 nuclear speckle of the cell of being transfected by different siRNA combinations in the presence or absence of transcription inhibitor DRB process (50 micromoles, 1h).To each condition quantitative 100-300 cell.The MALAT1 of transcription inhibition induction can not be rescued by single knockout low hnRNPA1, hnRNPL and PCBP1 from the dissociation of nuclear speckle, but can be knocked out and triple knocked out and rescued by the double of these factors. Figure 6B Images are shown showing that MALAT1 dissociates from nuclear speckles upon transcriptional inhibition in cells transfected with control siRNA, whereas transcriptional inhibition fails to dissociate MALAT1 from nuclear speckles in cells co-transfected with siRNA targeting hnRNPA1, hnRNPL, and PCBP1. Scale bar: 10 μm.

[0218] Figure 11Shown are the fold changes in MALAT1 nuclear speckle enrichment after transcriptional inhibition under different knockdown conditions. The bar graph shows the fold change in MALAT1 nuclear speckle enrichment after transcriptional inhibition under various knockdown conditions. This fold change is defined as the MALAT1 nuclear speckle enrichment after transcriptional inhibition divided by the enrichment before transcriptional inhibition after the same siRNA treatment. Shown are control siRNA, single knockdown of hnRNPA1, hnRNPL, and PCBP1, and double and triple knockdown of hnRNPA1, hnRNPL, and PCBP1. Error bars: SD. Student's t-test was performed for each condition relative to the control. **, p < 0.01, ****, p < 0.0001, ns, not significant. n = 3, 30–100 cells per experiment.

[0219] Example 8

[0220] These embodiments develop an imaging-based mixed library CRISPR screening method that allows the establishment of genotype-phenotype correspondences for individual cells and allows high-throughput screening of mammalian cells based on complex phenotypes that were previously unavailable for mixed library screening. sgRNA identification by MERFISH-based barcode detection allows this imaging-based screening and demonstrates a barcode misidentification rate as low as ~1%. A lentiviral delivery scheme was designed in which the mispairing rate of recombination-induced sgRNA and barcode was reduced (mispairing rate <10%). In summary, these provide highly accurate sgRNA identification by barcode imaging. These methods greatly expand the phenotypic space available for mixed library screening. Compared to imaging-based screening using an array format (in which a single gene perturbation is measured individually in a single well), the main advantage of performing mixed screening is that the reagents for gene perturbation, i.e., DNA plasmids and lentiviruses, can be prepared in a mixed manner using standard molecular biology procedures, requiring less labor and cost, which is particularly beneficial for large-scale custom-designed libraries. The preparation of reagents for array screening generally requires expensive multi-well robotic processing systems and more complex operating procedures. Another advantage of the hybrid approach is that the changes in experimental conditions for different perturbations can be minimized because all genetic perturbations are measured in the same experiment. This is particularly desirable when cells should be treated with concentration- or time-sensitive conditions. Moreover, the hybrid format can also simplify multiple phenotypic measurements, which require consecutive rounds of staining and signal removal by buffer exchange. On the other hand, when there is no particular need for reagents to generate individual genetic perturbations and when the phenotypic measurements are not very sensitive to changes in sample processing conditions, array screening may be preferred because the MERFISH barcode readout process significantly increases the complexity of the imaging procedure.

[0221] Current 12-bit ternary barcode libraries contain over 500,000 barcodes. Even with a strict 1% bottleneck strategy for error-robust barcode detection, over 5,000 different sgRNAs can be included in each library, a capacity that can be easily increased by adding more bits to the barcodes. The current limitation on the number of sgRNAs that can be screened is the time required to image a large number of cells. This imaging system utilizes a high-magnification (60X) objective to read out the FISH signal from individual mRNA molecules for barcode detection, limiting the number of cells that can be imaged per field of view. However, imaging speed can be significantly improved by: 1) using greater magnification for barcode signals, allowing faster frame rates to be captured per field of view and / or by using lower-magnification objectives, allowing more cells to be imaged per field of view; and 2) using multiple cameras for detection, allowing simultaneous detection of fluorescence signals in different color channels. With these improvements, a more than 10-fold increase in the number of cells and genotypes that can be screened per experiment could be achieved.

[0222] To demonstrate the efficacy of this approach for screening complex phenotypes in mammalian cells, the subcellular localization of seven different molecular species, including six RNAs and one protein, was imaged. These screening experiments revealed previously unknown regulators of nuclear RNA localization. Interestingly, both positive and negative regulators of the nuclear speckle localization of the lncRNA MALAT1 were identified. Positive regulators included the DExD / H box RNA helicases DHX15 and DDX42, and the hnRNP family genes hnRNPH1 and hnRNPK; while negative regulators included hnRNPA1, hnRNPL, and PCBP1. RNAs can localize to cellular compartments formed by phase separation through at least two mechanisms: 1) RNAs can act as scaffolds that nucleate phase separation, such as mRNAs in P bodies and stress granules and pre-ribosomal RNAs in the nucleolus; 2) RNAs can be recruited to phase separation bodies as clients, which has been shown to be responsible for the localization of MALAT1 to nuclear speckles. It is possible that the negative regulators discovered in this screen can compete with factors that recruit MALAT1 to nuclear speckles, thereby preventing MALAT1's nuclear speckle localization. The role of these negative regulators in the dissociation of MALAT1 from nuclear speckles induced by transcriptional repression was also identified. These results suggest that lncRNA localization can be dynamically regulated by protein factors.

[0223] These results demonstrate the ability of this imaging-based screening method to reveal molecular factors involved in cellular processes that can only be assessed by high-resolution imaging. This screening method can be widely applied to investigate genetic factors that control or regulate a large number of phenotypes, including morphological characteristics, dynamics of molecular organization and cellular structure, and cell-cell interactions. This screening method can also be combined with highly multiplexed DNA, RNA and protein imaging methods, including genome-scale imaging methods, to dissect factors involved in gene regulation and other genomic functions in a high-throughput manner.

[0224] Example 9

[0225] This example illustrates various materials and methods used in these examples.

[0226] The cloning of the reporter gene-barcode library and the sgRNA-reporter gene-barcode library was carried out in a mixed manner using oligonucleotides ordered from IDT (data sets S1, S2 and S4). These libraries were cloned into the lentiviral vector pFUGW as described below. The identity of the barcodes present in the library and the barcode-sgRNA correspondence were established using high-throughput sequencing. Lenti-XTM Packaging Single Shots (VSV-G) (Takara, 631276) were used to prepare lentivirus in LentiX cells (Takara, 632180). U-2OS cells were infected with the lentiviral library at a low multiplicity of infection (MOI) such that only 10-20% of the cells were infected. Infected cells were sorted based on mCherry expression and Cas9-BFP expression. The sorted cells were fixed, permeabilized and stained for imaging according to the detailed method discussed below.

[0227] A custom microscope built around a Nikon Ti-U microscope body with a Nikon CFI Plan Apo Lambda 60x oil-immersion objective lens with a 1.4NA was used for imaging. For sequential rounds of hybridization and imaging, a peristaltic pump (Gilson, MINIPULS 3) pumped liquids (TCEP buffer for staining lysis, hybridization buffer containing readout probes, or hybridization buffer for sample washes) into a Bioptech's FCS2 flow chamber with a sample coverslip. Three valves (Hamilton, MVP, and HVXM 8-5) were used to select the input fluid (details below). Barcode decoding and phenotypic quantification based on the acquired images are also described in detail below.

[0228] Cell culture. U-2OS cells were cultured at 37°C in EMEM medium (ATCC, HTB-96) supplemented with 10% FBS (Sigma, F4135-1L) and 1% Pen / Strep (Invitrogen, 15140122) antibiotics. U-2OS cells stably expressing Cas9-BFP were generated by lentiviral transduction, followed by FACS sorting using the BFP signal. To generate a lentiviral vector for Cas9-BFP, the Cas9-BFP sequence was PCR amplified from pLentiCas9-BFP (Addgene #78545) and cloned into the pFUGW backbone with the SVVF promoter. Two nuclear localization signal sequences were added to enhance the nuclear localization of Cas9.

[0229] Vector library cloning. Each 12-bit barcode consists of 12 30-nt sequences, each 30-nt sequence represents a trinucleotide, with the nucleotide 'A' separating adjacent trinucleotides. Oligonucleotides encoding each pair of 30-nt sequences adjacent in a forward and reverse alternating manner were ordered from IDT (i.e., trit1+trit2, trit2+trit3 reverse complement, trit3+trit4, trit4+trit5 reverse complement, ..., trit9+trit10, trit10+trit11 reverse complement, trit11+trit12, see Dataset S4). Each trinucleotide has three different values, identified by three distinct 30-nt sequences, so each pair of adjacent 30-nt sequences has 9 possible different sequences, requiring a total of 11x9=99 oligonucleotides to cover all possible adjacent 30-nt sequence pairs. At both ends of the barcode (represented by oligonucleotides 1-9 and 91-99), two constant primer binding sequences were added for PCR amplification purposes. The sequences of these 99 oligonucleotides are recorded in Dataset S4. The entire barcode library was assembled by two-step overlapping PCR. First, the 12 bits were divided into three segments, each of which was generated by the following reaction: Segment 1. Oligonucleotides 1-36 as templates, oligonucleotides 1-9 as forward primers, and oligonucleotides 28-36 as reverse primers; Segment 2. Oligonucleotides 37-72 as templates, oligonucleotides 37-45 as forward primers, and oligonucleotides 64-72 as reverse primers; Segment 3. Oligonucleotides 73-99 as templates, oligonucleotides 73-81 as forward primers, and oligonucleotide 100 as reverse primers. The three PCR products were gel purified. Then, the three segments were mixed and overlapping PCR was performed using forward primer oligonucleotide 101 and reverse primer oligonucleotide 102. The reverse primer in this step contains a 20-base random sequence region that serves as a unique molecular identifier (UMI) for the sequencing step. The sequences of oligonucleotides 100-102 are also recorded in data set S4. All PCR reactions were performed using real-time qPCR equipment to monitor the reaction, so that the reaction was stopped in the logarithmic growth phase to reduce the library bias caused by PCR bias. The PCR products were assembled into modified pFUGW backbones by isothermal assembly. The assembled library was electroporated into Endura competent cells (Lucigen, 60242-2), which were then grown overnight under ampicillin selection to amplify the library. The amplified library was purified by mini prep. This library was named pFUGW_barcode_UMI_backbone library.

[0230] The pFUGW_barcode_UMI_main chain library is then used to generate a library that also contains a reporter gene (luciferase-mCherry) for barcode imaging. First, a reporter gene cassette containing a CMV promoter and a reporter gene open reading frame is generated in an intermediate vector. The open reading frame contains luciferase-mCherry, 2X HA or 2X Myc tags at the N-terminus and a nuclear localization signal at the C-terminus. Oligonucleotides 103 and 104 (sequences are provided in data set S4) are used to PCR amplify the reporter gene cassette from the intermediate vector. The pFUGW_barcode_UMI_main chain library is then digested with BstXI and treated with alkaline phosphatase, and assembled with the reporter gene cassette PCR product using isothermal assembly. The assembled library is electroporated into Endura competent cells, which are then grown overnight under ampicillin selection for amplification. The cells are then diluted to include the desired number of constructs in each library. These shrunken libraries are then purified by mini prep. These libraries are named reporter gene_barcode libraries.

[0231] Cloning of sgRNA-barcode library. The following strategy was used to clone the sgRNA-barcode library: first, a prototype spacer sequence-sgRNA constant region-barcode box library was generated by multi-step overlapping PCR; this library was then inserted into a lentiviral vector by isothermal assembly, in which the U6 promoter was placed downstream of the PPT sequence. To generate the prototype spacer sequence-sgRNA constant region-barcode box library, the barcode segment was first generated using a similar method as described in the "Cloning of barcode libraries for quantitative barcode decoding accuracy" section. The only difference was that the constant (primer) region at the 5' end was changed by replacing oligonucleotides 1-9 with oligonucleotides 105-113 because the barcode was placed in close proximity to the sgRNA. The sgRNA constant region was PCR amplified using oligonucleotides 114 and 115. The prototype spacer sequence library was ordered from IDT, where the constant region was used for PCR amplification on both sides of the prototype spacer sequence. In this work, two protospacer libraries were generated, one for essential ribosomal genes and a non-targeting sgRNA control to measure the recombination rate between sgRNA and barcode (dataset S1), and the other for targeting genes that potentially regulate RNA localization in the nucleus (dataset S2). The protospacer library was PCR amplified using oligonucleotides 116 and 117, and the PCR products were gel purified. The protospacer, sgRNA constant region, and barcode PCR products were then mixed and overlap PCR was performed using oligonucleotides 116 and 118 as primers. Reverse primer oligonucleotide 118 contained a 20-base random sequence region that served as a unique molecular identifier (UMI) for the sequencing step. The sequences of oligonucleotides 105-118 are also recorded in data set S4. All PCR reactions were performed using a real-time qPCR instrument to monitor the reactions, so that the reactions were stopped in the logarithmic growth phase. The PCR products were assembled into a modified pFUGW backbone by isothermal assembly, in which the U6 promoter was placed downstream of the PPT sequence. The assembled library is electroporated into Endura competent cells, which are then grown overnight on ampicillin selection plates for amplification. A specific number of colonies (~3800 for essential ribosomal gene libraries and ~2500 for RNA positioning screening libraries) are scraped from the plates with LB buffer and cultured overnight in 200 mL LB buffer. The library is purified by mini prep. These libraries are named sgRNA_barcode libraries.

[0232] Sequencing library preparation and analysis. To determine the identity of the barcodes present in the library and establish the correspondence between sgRNAs and barcodes, the library was analyzed using high-throughput sequencing. It was found that PCR amplification of the barcode region can lead to barcode recombination due to homology between barcodes. Therefore, a ligation-based approach was used to install sequencing adapters into the barcode library. In this approach, the region to be sequenced was digested from the library and then ligated to the adapter using T4 ligase.

[0233] To determine the barcodes in the reporter gene-barcode library, the library was digested with BstXI and BamHI at 37°C for 2-3 hours, and the resulting fragments were purified using the Zymo DNA purification kit (ZD4002). To generate adapters with sticky ends for ligation, oligonucleotides 119-124 (sequences provided in Dataset S4) were mixed at 0.5 micromolar each, subjected to 5 cycles of PCR, and the products were purified using the Zymo DNA purification kit to generate double-stranded sequences with 5' and 3' adapters separated by BstXI and BamHI digestion sites. The purified products were digested with BstXI and BamHI at 37°C for 2-3 hours and then purified. The resulting mixture, containing adapters with sticky ends for ligation, was mixed with the purified library fragment mixture described above. T4 ligase was added and the reaction was maintained at room temperature for 2-4 hours. The reaction mixture was directly subjected to 2% agarose gel electrophoresis, and the band corresponding to a size of ~400 bp was excised and purified. The purified DNA samples were used for concentration measurement and high-throughput sequencing using the V2-MISeq kit (Illumina, MS-103-1003).

[0234] To determine the sgRNA-barcode correspondence of the sgRNA-barcode library, two sequencing libraries were generated because the length from the protospacer sequence to the end of the barcode was greater than 500 bp, which exceeded the optimal length range for high-quality sequencing using the V2-MISeq kit. In one library, BstXI and BamHI were used to generate junction sites located 5' of the protospacer sequence and 3' of the UMI, respectively. Sequencing of this library covered the protospacer sequence region, a portion of the barcode region, and the UMI region because sequencing from either end of this library may not reach the middle of the barcode. In the second library, KpnI and BamHI were used to generate junction sites (the KpnI site was immediately after the sgRNA and before the barcode). Sequencing of this library covered the entire barcode region and the UMI region. The UMI sequence was used to identify the protospacer sequence and barcode in the same construct from these two libraries. Oligonucleotides 125-130 and oligonucleotides 131-136 (sequences provided in Dataset S4) were used to generate aptamers for the first and second libraries, respectively. The procedure was the same as that described for generating sequencing libraries for the reporter-barcode library.

[0235] UMIs, protospacer sequences, and barcode sequences were extracted from sequencing reads. The reads were then grouped by shared UMIs and barcodes to generate a codebook for sgRNA-barcode mapping. Reads with incorrect protospacer sequences or barcodes assigned to multiple sgRNAs were removed from further analysis.

[0236] To determine the distribution of protospacer sequences and UMIs from cell populations at different time points after lentiviral transduction in the experiment using sequencing to determine recombination rates, sequencing libraries were prepared by PCR amplification from purified genomic DNA using oligonucleotides 137-140 and oligonucleotides 141-144 (sequences provided in Dataset S4) as forward and reverse primers, respectively.

[0237] Lenti-X cells (Takara, 632180) were used for lentiviral preparation and transduction. TM Packaging Single Shots (VSV-G) (Takara, 631276) was used to prepare lentivirus. The prepared virus was prepared using Lenti-X TMThe virus was concentrated in a concentrate (Takara, 631231) and stored at -80 ° C. For transfection, the amount of virus was controlled so that 10-30% of the cells were transduced to ensure that most infected cells were infected with only 1 virus particle. Viral transduction was performed using 10 μg / ml polybrene (Sigma, TR-1003-G). Compared with the construct without insertion after PPT, the viral titer of the construct with the U6-sgRNA-barcode array placed after PPT did not show a significant reduction, indicating that the insertion did not impair lentiviral transduction.

[0238] siRNA knockdown. All siRNAs were purchased from Dharmacon, and siRNA knockdown was performed according to Dharmacon's experimental procedure. In brief, U-2OS cells were seeded on imaging coverslips in 12-well plates at 30,000 cells / well. For siRNA transfection, 1.5 microliters of 20 micromolar siRNA were added to 100 microliters of serum-free, antibiotic-free culture medium in one test tube, and 1 microliter of Dharmacon transfection reagent (Dharmacon, T-2001-01) was added to 100 microliters of serum-free culture medium in another test tube. The two test tubes were incubated for 5 minutes, then gently mixed and incubated for another 20 minutes at room temperature. 800 microliters of antibiotic-free serum-containing culture medium were mixed into 200 microliters of the above-mentioned siRNA and transfection reagent mixture to generate 1 mL of transfection culture medium. Cell culture medium was replaced with 1 mL of transfection culture medium. Cells were incubated at 37°C for 72 hours before phenotypic measurement.

[0239] Imaging coverslips were silanized. Imaging coverslips were first cleaned with 1M KOH and pure methanol, washed with 70% ethanol, and dried in an oven. For silanization, coverslips were soaked in silanization buffer (500 mL distilled water, 1500 microliters of Bind-silane (Sigma, GE17-1330-01), pH adjusted to 3.5 with glacial acetic acid) at room temperature for 1 hour. The coverslips were then washed with water and stored dry. Before inoculating cells, silanized coverslips were coated with 1% poly-D-lysine (Sigma, P0899) in a 60 mm diameter cell culture dish for 30 minutes, followed by a 1 hour wash with water.

[0240] Imaging sample preparation. U-2OS cells were seeded on coverslips two days before fixation. For phenotypic imaging in experiments screening for factors involved in regulating nuclear RNA localization, U-2OS cells were fixed six days after lentiviral transduction. Samples were fixed with 4% paraformaldehyde (EMS, 15714) in PBS for 15 minutes and permeabilized in 0.5% Triton-X (Sigma, X100) for 30 minutes. Next, samples were incubated in blocking buffer (500 μl blocking buffer: 50 μl 10x PBS, 200 μl RNase-free BSA (ThermoFisher, AM2618), 50 μl 25 mg / ml yeast tRNA (ThermoFisher, 15401029), 5 μl mouse RNase inhibitor (NEB, M0314L), 1 μl 25% Triton-X, and RNase-free water to 500 μl) for 1 hour and stained with a 1:100 primary antibody, anti-SON (Abcam, ab121759), in blocking buffer for 1 hour at room temperature. Samples were washed three times with 1x PBS and incubated with a 1:300 oligonucleotide-labeled secondary antibody for 1 hour. The oligonucleotide-labeled secondary antibody can later be detected by a readout probe based on sequence complementarity to the oligonucleotide sequence on the antibody. Samples were washed three times with 1x PBS and postfixed with 4% PFA for 30 minutes. The samples were then equilibrated in 30% formamide in 2x SSC for 5 minutes before FISH staining. The FISH hybridization buffer contained 30% formamide (ThermoFisher, AM9342), 60% stellaris RNA FISH hybridization buffer (Biosearch, SMF-HB1-10), 10% 25 mg / mL yeast tRNA, and 1:100 mouse RNase inhibitor. The samples were stained overnight at 37°C with 300nM FISH probes for reporter genes, 300nM FISH probes for RNA phenotype (i.e., 6 RNA species) imaging, and 100nM primary amplification probes for barcode imaging. The FISH probes for reporter genes each contained a 30-nt target sequence that could bind to the reporter gene mRNA and 3 20-nt readout sequences that allowed binding to complementary fluorescently labeled readout probes. Each FISH probe for each RNA target used in phenotypic imaging contains a 30-nt targeting sequence that binds to the RNA target and one or two 20-nt readout sequences that allow binding to complementary fluorescently labeled readout probes. Each primary amplification probe used for barcode imaging contains a 30-nt targeting sequence that binds to one of the 30-nt three-bit sequences on the barcode and four additional 30-nt identical sequences that allow binding to the secondary amplification probes ( Figure 1A). The samples were then washed twice in 30% formamide in 2x SSC and stained with 100 nM of a secondary amplification probe for barcode imaging in 10% hybridization buffer (10% formamide, 80% Stellaris RNA FISH hybridization buffer, 10% 25 mg / mL yeast tRNA, and 1:100 mouse RNase inhibitor) at 37°C for 1 hour. Each secondary amplification probe contains a 30-nt target sequence that can bind to the primary amplification probe and 4 additional 20-nt identical readout sequences that allow binding to complementary fluorescently labeled readout probes. Therefore, this amplification protocol allows for a maximum of 16-fold signal amplification. Samples labeled with FISH probes for phenotypic imaging and reporter gene mRNA imaging and primary and secondary amplification probes for barcode imaging were washed twice in 30% formamide in 2xSSC and then embedded in 4% polyacrylamide gels, followed by incubation with protein digestion buffer (for 50 mL digestion buffer: 5 mL 8 M guanidine-HCl (ThermoFisher, 24115), 2.5 mL 1 M Tris pH 8.0 (ThermoFisher, 15569025), 100 microliters 0.5 M EDTA (ThermoFisher, 15575020), 0.25 mL Triton-X and 1:100 proteinase K (ThermoFisher, AM2548)) at 37°C overnight to remove proteins and lipids from the samples. This step is hereinafter referred to as the sample wash step. Proteinase K cleavage causes protein digestion (including digestion of mCherry protein), so the mCherry fluorescent signal disappears after digestion and does not interfere with FISH signal detection using a 561nm channel. FISH probes for RNA, 7SK, MRP, U2 snRNA containing poly(A) and oligonucleotides connected to the secondary antibody for SON staining are conjugated with acrydite. During the sample cleaning step, they can be cross-linked with polyacrylamide gel and these probes and the RNA they bind are retained in the gel. The FISH probes for MALAT1 and pre-ribosomes are not labeled with acrydite because the sizes of both MALAT1 and pre-ribosomes are large and therefore retained in the gel during sample cleaning. Reporter gene mRNA is connected to the gel by an acrydite-labeled poly-T probe (the probe can be bound to the poly(A) tail of the reporter gene mRNA), thereby allowing the FISH probes for reporter genes and the FISH probes for barcode imaging to remain in the gel during cleaning. The sample cleaning step significantly reduces the background signal caused by the non-specific binding of cell autofluorescence and FISH probes to proteins and lipids. The samples were then washed with 2x SSC and placed in 2x SSC for imaging. The sequences of the FISH probes used are listed in Dataset S5.

[0241] For experiments measuring barcode labeling errors using two known phenotypes (expression of HA- or Myc-tagged reporter genes), U-2OS cells were fixed 6 days after transduction. The tags were stained with primary antibodies (anti-Myc (Abcam, ab9132) and anti-HA (Abcam, ab9110)), followed by staining with Alexa 405-labeled anti-mouse secondary antibodies (Abcam, ab175658) and Alexa 488-labeled anti-rabbit secondary antibodies (Invitrogen, A21206). Before gel embedding, samples were incubated in 25 mM Mg-NHS (Sigma, 730300) in 2x SSC for 1 hour to allow the Mg-NHS-labeled antibodies to bind to the gel during gel polymerization. After sample washing, the antibodies were fragmented and the dyes were bound to the gel via cross-linked antibody fragments. The dyes Alexa 405 and Alexa 488 were able to withstand polymerization during gel embedding. The remainder of the sample preparation, including immunostaining and barcode staining, was as described above.

[0242] Antibody labeling is carried out by oligonucleotide. Use the following strategy to label antibodies with oligonucleotide. Antibody is first mixed with DBCO-NHS, DBCO-NHS is conjugated to antibody by DBCO, and then DBCO-labeled antibody is mixed with azide-labeled oligonucleotide so that oligonucleotide is conjugated to the antibody. Specifically, first use 50KD protein concentrator (Millipore, UFC510024) to exchange 100 micrograms of anti-rabbit antibody (ThermoFisher, 31210) into 100 microliters of PBS by buffer. NaHCO 3 and DBCO-NHS ester (Kerafast, FCC310) are added to the antibody solution so that their final concentrations are 50mM and 100mM respectively. Make the reaction continue 1 hour at room temperature to prepare DBCO-labeled antibody, remove excess DBCO by using 50KD protein concentrator to exchange buffer with PBS. PBS buffer was then added to the DBCO-labeled antibody to bring the solution volume to 100 μL, and 25 μL of azide-labeled oligonucleotide (100 μM, Dataset S3) was added. The reaction was allowed to proceed overnight at 4°C. After the reaction was complete, excess oligonucleotide was removed by buffer exchange with PBS, and the final oligonucleotide-labeled antibody was aliquoted and stored at -80°C.

[0243] Imaging settings and continuous imaging. Imaging settings are as described above. See, for example, U.S. Patent Application Publication No. 2017-0220733 or International Patent Application Publication No. WO 2018 / 089438, the entire contents of each of which are incorporated herein by reference. In brief, a peristaltic pump (Gilson, MINIPULS 3) pumps liquid into a Bioptech 's FCS2 flow chamber with a sample coverslip, and three valves (Hamilton, MVP, and HVXM 8-5) are used to select the input fluid. A custom microscope built around a Nikon Ti-U microscope body is used for imaging, and the Nikon Ti-U microscope body is equipped with a Nikon CFI PlanApo Lambda 60x oil immersion objective lens with 1.4NA. Solid-state single-mode lasers (405 nm laser, Obis 405 nm LX 200 mW, Coherent; 488 nm laser, Genesis MX488-1000, Coherent; 560 nm laser, 2RU-VFL-P-2000-560-B1R, MPB Communications; 647 nm laser, 2RU-VFL-P-1500-647-B1R, MPB Communication; and 750 nm laser, 2RU-VFL-P-500-750-B1R, MPB Communications) were used for illumination. Acousto-optical tunable filters (AOTFs) were used to control the intensity of the 488 nm, 560 nm, and 647 nm lasers. The 405 nm laser was modulated by a direct digital signal, and the 750 nm laser was switched by a mechanical shutter. A custom dichroic (Chroma, zy405 / 488 / 561 / 647 / 752RP-UF1) and emission filter (Chroma, ZET405 / 488 / 461 / 647-656 / 752m) were used to separate the excitation illumination from the fluorescence emission. The emission light was imaged onto a Hamamatsu digital CMOS camera. During acquisition, the sample was transferred using an automated XY stage (Ludl, BioPrecision2) and maintained in focus using a homemade autofocus system.

[0244] For the experiment that needs higher imaging flux, 40x object lens (CFI60 Plan Fluor 40x oil immersion objective lens) is used to obtain the more cell of every visual field (FOV).Use four camera systems to separately and simultaneously gather the signal from 750nm, 647nm, 561nm and 488nm fluorophore.In detail, four camera mounts (QuadCam LS 1.0x, 89North) are installed on Nikon Ti-U microscope body, and 4 Hamamatsu digital CMOS cameras are installed on this mount.4 dichroic filters (T495lpxr, T562lpxr, T647lpxr, T760lpxr, Chroma Tech) and 4 single-band emission filters (ET 450 / 50m, ET 525 / 50m, ET 605 / 75m and ET 705 / 70m, Chroma Tech) that 4 are separated from the signal of different fluorophores are installed on camera mount. In order to make the signal alignment from 4 cameras, multicolor beads (FP-0257-2, Spherotech) are imaged and by the cp2tform function in MatLab, the signal from 647nm, 561nm and 488nm color channel is aligned with the signal from 750nm color channel.Cp2tform derives polynomial spatial transformation to x, y and z coordinates, and applies this transformation to bar code and phenotypic signal.In order to image nucleus on four cameras, 1:1000 647nm Nucred dye (R37106, ThermoFisher) is used to replace DAPI.

[0245] Before loading onto the flow cell, the sample was stained with an Atto565-labeled 20-nt readout probe (dataset S5) that has a sequence complementary to the readout sequence on the FISH probe used for reporter gene mRNA imaging. The staining was performed in hybridization buffer (10% ethylene carbonate (Sigma, E26258) in 2x SSC) at a readout probe concentration of 3 nM. The readout probe for the reporter gene was introduced only once, but imaging was performed repeatedly during all hybridization rounds. Readout probes for seven molecular targets (SON proteins and six RNA targets) for phenotypic imaging and readout probes for barcode imaging were introduced in successive rounds of hybridization. For phenotypic and barcode imaging, 3 nM of a 20-nt readout probe complementary to the oligonucleotide sequence on the SON antibody (Abcam, ab121759), or to the readout probe on the FISH probe for six RNA targets, or to the readout sequence on the secondary amplification probe for barcode imaging (Bio-Synthesis Inc., Dataset S5) in hybridization buffer (10% ethylene carbonate in 2x SSC) was flowed into the flow cell and allowed to stand for 15 minutes, followed by washing with hybridization buffer. The dyes for these probes, Alexa 488, Cy5, or Alexa 750, were linked to the oligonucleotides via a cleavable disulfide bond (Biosynthesis, Dataset S5). Samples were imaged in anti-bleach buffer (for 50 mL anti-bleach buffer: 50 mg glucose oxidase (gluco-oxidase, Sigma, G2133), 50 mg (+ / -)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) (Sigma, 238813), 300 microliters catalase (Sigma, C100-500MG), 10% w / v glucose (Sigma, G8270), 5 mL 500 micromolar Trolox quinone, and 50 microliters murine RNase inhibitor). For each round of hybridization, fluorescence signals from four color channels (488 nm, 561 nm, 647 nm, and 750 nm if phenotypic imaging was included in that round) or three color channels (561 nm, 647 nm, and 750 nm if phenotypic imaging was not included in that round) were imaged. After each round, the dye on the readout probe was cleaved by 10% tris(2-carboxyethyl)phosphine (TCEP; Sigma, 646547-10X1ML), followed by the next round of hybridization of the readout probe.

[0246] For the quantitative and image registration reasons of the colocalization ratio between reporter gene signal and bar code signal, 561nm channel detection reporter gene mRNA signal is used in each round. By continuous rounds of hybridization, and in the 1-18 rounds, cleavable Cy5 and Alexa750 dye are utilized to use 647nm and 750nm channel imaging, bar code signal is measured, which allows all 36 numerical values ​​of 12-three bar codes to be imaged. By continuous rounds of hybridization, and in the 1-7 rounds, cleavable Alexa 488 dye is utilized to use 488nm channel imaging, the signal of SON and 6 RNA targets in phenotypic imaging is measured. For phenotypic imaging, images are collected with a slightly higher focal plane (2-3 micron), which is most suitable for the signal from nuclear interior.

[0247] For experiments measuring barcoding errors using two known phenotypes (expression of HA- or Myc-tagged reporter genes), Myc and HA tags were stained with Alexa 405-dye and Alexa 488-dye-labeled secondary antibodies and imaged in the 405 nm and 488 nm channels, respectively.

[0248] DAPI staining was imaged and used for cell segmentation and nuclear identification. For experiments measuring two known phenotypes (HA or Myc-tagged reporter genes), DAPI staining was imaged during the final imaging round. For experiments screening for factors regulating nuclear RNA localization, DAPI staining was imaged during the first imaging round. The sequences of the dye-labeled readout probes are listed in Dataset S5.

[0249] Transcriptional Inhibition: For transcriptional inhibition, 50 μM DRB (Sigma, D1916-10MG) was mixed in EMEM and incubated with cells for 1 hour before fixation.

[0250] Barcode decoding analysis. In order to correct the inconsistency in illumination, each image of the specified color channel is divided by the average intensity image of all images of the illumination color. Multiple rounds of images are registered using the uncleaved signal of reporter gene mRNA. Using DAPI staining as seed and cell autofluorescence (for evaluating barcode decoding accuracy and slow virus recombination experiments) or for the RNA staining containing polyadenylic acid (for screening the experiment of the factor regulating nuclear RNA localization) for cell boundary identification, cells are segmented by the watershed algorithm. Spot finding algorithm (spot finding algorithm) is used to identify the single molecule signal of reporter gene mRNA and barcode in all hybridizations. For experiments using 4- cameras for imaging, a segmentation algorithm is used to identify spots. Specifically, pixels whose intensity is greater than the brightness threshold are selected. The cluster of the selected pixels is identified by the bwareaopen function in MatLab. Clusters within the boundary area range (2-30 pixels) are retained. This area range is determined by visual inspection of the original image. In order to capture spots with intensity variations, this process is repeated using multiple brightness thresholds, for example, from 0.6x max (pixel intensity in FOV) to 0.3x max (pixel intensity in FOV), decreasing by 0.05x max (pixel intensity in FOV). The brightness threshold for each three-dimensional signal is manually determined. For each repetition, a lower brightness threshold will identify two types of clusters: (i) fuzzy clusters that cannot be detected at the higher brightness threshold of the previous round and (ii) larger clusters that completely include one or more clusters identified in the previous round. For any cluster of type (i), it is retained only if its area is within the above-mentioned allowable area range. For any cluster of type (ii), if its area is within the allowable area range, it is retained; otherwise, it is removed and the smaller cluster identified in the previous round that overlaps with this new cluster is retained instead. The centers of these clusters are identified by the regionprops function in MatLab.

[0251] Single molecule FISH spots were assigned to cells, and the colocalization ratio of each of the three values ​​of the three digits in the barcode was calculated as the number of reporter gene smFISH spots colocalized with the barcode smFISH signal divided by the total number of reporter gene smFISH spots in the cell. To determine the value of each three digits for each cell, cells were clustered using k-means clustering based on the three colocalization ratios of the three digits, and the three digits were assigned to each cluster based on which of the three average colocalization ratios was the highest in the cluster. The same process was repeated for all 12 digits so that each cell was assigned a 12-digit barcode. For each three digit value, the average colocalization ratio of the cell population assigned to that value was measured to be 0.4; while the average colocalization ratio resulting from random colocalization of probes with nonspecific binding, assessed from two cell populations that were not assigned that three digit value, was measured to be 0.1.

[0252] To decode cells based on the barcode signal alone (i.e., without considering colocalization between the barcode signal and the reporter gene signal), cells were clustered based on the number of barcode signal spots detected for the three three-dimensional values ​​within each cell. The cells were divided into three populations using the k-means clustering algorithm, and the three three-dimensional value was assigned to each population based on which of the three three-dimensional values ​​had the highest average number of spots. This same process was repeated for all 12 three-dimensional values.

[0253] To estimate the barcode misidentification rate, since only 0.4% of all possible barcodes are present in the library due to the bottleneck strategy, the probability that any incorrectly decoded barcode matches a barcode in the library is only 0.4%. Therefore, of the 57% of barcodes that are exact matches, only approximately p = 0.3% can come from barcode misidentification (solved from (p * 57%) / (1 - 57%) = 0.4% / (1 - 0.4%)).

[0254] Quantification of Myc and HA signals. To quantify HA and Myc expression in the nucleus, the nuclear border of each cell was used as a mask to measure the intensity of the corresponding Myc or HA channel. In order to allow HA and Myc expression to be clearly assigned to individual cells, thresholds for HA and Myc expression were first determined, above which HA or Myc tag expression could be detected with certainty. To determine these thresholds, the k-means clustering algorithm was used to cluster cells into two groups based on their non-thresholded HA and Myc tag staining intensities. This grouping allows the cells to be approximately divided into cells expressing HA and cells expressing Myc. In order to assess the background staining level of the HA tag, the mean and standard deviation of the HA intensity of the cells in the Myc-expressing clusters were calculated, and the threshold for the HA signal was calculated as the mean plus three standard deviations. The threshold for Myc expression was determined similarly to the HA-expressing clusters. Cells whose HA and Myc intensities were both below their respective thresholds or both above their respective thresholds were eliminated (197 out of 2336 cells). After removing these ambiguous cells, the remaining cells were clustered again using the k-means clustering algorithm to obtain the final grouping, as shown in Figure 5. Figure 2C As shown in .

[0255] Recombination rate calculation. The recombination rate a for the i-th sgRNA (with barcode or UMI) i Based on the following formula:

[0256] B i,day n =P i,day 2 *((1-a i )*S i +a i *C)

[0257]

[0258]

[0259] where n is the number of days after transduction, which in these experiments was equal to 21 or 28. iday 2 is the normalized protospacer read count determined by sequencing the i-th sgRNA on day 2 post-transduction (normalized by the total protospacer read count measured on day 2 post-transduction). P i,day n is the normalized protospacer read count determined by sequencing the i-th sgRNA on day n after transduction (normalized by the total protospacer read count measured on day n after transduction). B i,day n is the normalized cell number determined by barcode imaging or the normalized UMI count determined by sequencing (normalized by the total cell number or UMI count at day n post-transduction). iis the survival rate of the i-th sgRNA. C is the average survival rate of all sgRNAs in the library, which is calculated by taking into account the redundancy weight of different sgRNAs in the library. If recombination occurs, it is the average survival rate.

[0260] Phenotypic measurements are quantitative. Nuclear boundaries are determined by DAPI signal. Cells that the core is in contact with the edge of the imaging field are excluded from further analysis. In order to identify the cluster of MRP, pre-ribosomes and SON, the background intensity of the channel is subtracted, and clusters are identified using function regionprops (MatLab) and bwareaopen (MatLab), which is similar to the spot discovery algorithm for the experiment of utilizing 4-camera imaging. In detail, the pixel whose intensity is greater than the brightness threshold is selected. The cluster of the selected pixel is identified by the bwareaopen function. The cluster in the boundary area range (20-3000 pixels for SON, 100-5000 pixels for pre-ribosomes, and 100-6000 pixels for MRP) is retained. This area range is determined by visual inspection of the original image. In order to capture the relatively wide cluster of the variation of the staining level, multiple brightness thresholds are used to repeatedly carry out this process (from 0.9 x max (pixel intensity in the core) to 0.1 x max (pixel intensity in the core), decreasing by 0.05x max (pixel intensity in the core)). The number of the cluster of final mark and the area of ​​each cluster are measured using regionprops function.For MRP, preribosome and SON, the number of each cell calculation cluster, the average area of ​​cluster and cluster intensity (total signal in the cluster border divided by total cluster area) are defined as the total signal divided by the total cluster area in the cluster boundary. For quantitative nuclear speckle enrichment MALAT1, 7SK, U2 and the RNA comprising poly(A), the cluster boundary from SON dyeing is used as mask to measure MALAT1, 7SK, U2 in the described SON cluster boundary and the RNA signal comprising poly(A). In these RNAs, each nuclear speckle intensity is measured as the total signal of the RNA described in the described SON cluster boundary divided by the total area covered by the SON cluster. The signal intensity outside the spot is measured as the total signal of the RNA in the core but outside the nuclear speckle divided by the total area of ​​the core not in the nuclear speckle. Nuclear speckle enrichment is determined as the ratio of signal intensity outside nuclear speckle intensity and spot.

[0261] In order to identify the hits from this screening, the four repetitions of the experiment were merged. The above quantitative values ​​of each repetition (i.e., cluster number, cluster area, cluster intensity, and nuclear spot enrichment) were normalized by merging the mean value of all cells in each repetition before the test. The p value was calculated using the student's t test by testing the measured values ​​of cells carrying a targeting sgRNA relative to the measured values ​​of cells carrying all control non-targeting sgRNAs. When at least two sgRNAs targeting a specific gene showed a p value < 0.05, the gene was listed as a hit. SgRNAs with less than 40 cells were excluded from the analysis.

[0262] Dataset S1

[0263] A sgRNA library for evaluating lentiviral design for reduced recombination. This dataset contains oligonucleotide sequences for 159 sgRNAs targeting essential ribosomal genes and 51 protospacer sequences for non-targeting sgRNAs.

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273] Dataset S2

[0274] sgRNA library for genetic screening of factors regulating nuclear RNA localization. This dataset lists oligonucleotide sequences of 162 sgRNAs targeting selected candidate genes regulating nuclear RNA localization and the protospacer sequences of 5 non-targeting sgRNAs.

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282] Dataset S3

[0283] Features quantified and gene hits identified in a screen for factors regulating nuclear RNA localization. This dataset lists gene hits for individual phenotypic features quantified in the screen.

[0284]

[0285] Dataset S4

[0286] DNA oligonucleotide sequences used for library cloning and sequencing. This dataset lists the DNA oligonucleotide sequences used for library construction and next-generation sequencing (for determining barcode identity and barcode-sgRNA correspondence within the library, and for quantifying protospacer sequences and UMI abundance in recombination quantification).

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295] Dataset S5

[0296] FISH probe sequences for barcoding, reporter genes, and phenotypic imaging. This dataset includes separate lists of the following oligonucleotide probes:

[0297] Primary amplification probes for barcode imaging

[0298] Secondary amplification probes for barcode imaging

[0299] FISH probes for polyadenylated RNA

[0300] FISH probe for MALAT1

[0301] FISH probe for 7SK

[0302] FISH probes for MRP

[0303] FISH probes for pre-ribosomes

[0304] FISH probe for U2 snRNA

[0305] Oligonucleotide probes for FISH of reporter genes Puro-T2A-mCherry or mCherry-luciferase and SON antibody-linked probes

[0306] Readout probes for all of the above targets

[0307] Some probes are modified and the modifications are indicated in the probe sequence.

[0308]

[0309]

[0310]

[0311] Although several embodiments of the present invention have been described and illustrated herein, a person of ordinary skill in the art will readily conceive of various other means and / or structures for performing the functions described herein and / or obtaining the results and / or one or more advantages described herein, and each of these variations and / or modifications is considered to be within the scope of the present invention. More generally, those skilled in the art will readily understand that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications in which the teachings of the present invention are used. Those skilled in the art will recognize or be able to ascertain many equivalents to the specific embodiments of the present invention described herein using no more than routine experimentation. Therefore, it should be understood that the foregoing embodiments are given by way of example only, and that within the scope of the appended claims and their equivalents, the present invention may be implemented in a manner other than as specifically described and claimed. The present invention relates to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods is also included within the scope of the present invention, provided that such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent.

[0312] In the event that this specification and the documents incorporated by reference include conflicting and / or inconsistent disclosures, this specification shall prevail. If two or more documents incorporated by reference include conflicting and / or inconsistent disclosures, the document with the later effective date shall prevail.

[0313] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0314] Unless clearly indicated to the contrary, the indefinite articles "a" and "an" as used herein in the specification and claims should be understood to mean "at least one".

[0315] As used herein in the specification and claims, the phrase "and / or" should be understood to mean "either or both" of the connected elements, i.e., the elements are present in combination in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the connected elements. In addition to the elements expressly identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those elements expressly identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with an open-ended phrase such as "comprising" may refer to A alone (optionally including elements other than B) in one embodiment; to B alone (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in another embodiment; and so on.

[0316] As used herein in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" should be understood to be inclusive, i.e., including at least one, but also including more than one of a plurality of elements or a list of elements, and optionally, including additional unlisted items. Only terms that explicitly indicate the contrary, such as "only one of..." or "exactly one of..." or "consisting of..." when used in a claim, will refer to the inclusion of exactly one element of a plurality of elements or a list of elements. Generally, the term "or" as used herein should be interpreted as indicating an exclusive selection (i.e., "one or the other but not both") only when preceded by an exclusive term such as "either," "one of," "only one of," or "exactly one of..."

[0317] As used herein in the specification and claims, the phrase "at least one" with respect to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element explicitly listed in the list of elements and does not exclude any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than the elements explicitly identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those explicitly identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can, in one embodiment, mean at least one (optionally including more than one) A without B present (and optionally including elements in addition to B); in another embodiment, mean at least one (optionally including more than one) B without A present (and optionally including elements in addition to A); in another embodiment, mean at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements); and so on.

[0318] When the word "about" is used herein to refer to a number, it should be understood that another embodiment of the present invention includes the number not modified by the word "about."

[0319] It will also be understood that, unless expressly stated to the contrary, in any method claimed herein that includes more than one step or act, the order of the steps or acts of the method are not necessarily limited to the order in which the steps or acts of the method are recited.

[0320] In the claims, as well as in the foregoing description, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "having," "consisting of," and the like are to be construed as open-ended, i.e., meaning including, but not limited to, "consisting of." Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. Sequence Listing <110> President and Fellows of Harvard College <120> Imaging-based hybrid CRISPR screening <130> H0498.70693WO00 <140> Not yet allocated <141> This is the filing date of this application <150> US 62 / 841,715 <151> 2019-05-01 <150> US 62 / 836,578 <151> 2019-04-19 <160> 566 <170> PatentIn version 3.5 <210> 1 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 1 tcttgtggaa agccagaaac atggactact taccagggac acctgtttca gagctaagca 60 caagagtgc 69 <210> 2 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 2 tcttgtggaa agccagaaac atggcacaca cagagaactt aggggtttca gagctaagca 60 caagagtgc 69 <210> 3 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 3 tcttgtggaa agccagaaac atggctcacc tttggaaaac acaggtttca gagctaagca 60 caagagtgc 69 <210> 4 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 4 tcttgtggaa agccagaaac atggactgac cattcagaac agacgtttca gagctaagca 60 caagagtgc 69 <210> 5 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 5 tcttgtggaa agccagaaac atggcacctg cggatcttac gggcgtttca gagctaagca 60 caagagtgc 69 <210> 6 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 6 tcttgtggaa agccagaaac atggcctccc tctaggccgg aagggtttca gagctaagca 60 caagagtgc 69 <210> 7 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 7 tcttgtggaa agccagaaac atgggaagat tgaagccaga gaaagtttca gagctaagca 60 caagagtgc 69 <210> 8 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 8 tcttgtggaa agccagaaac atggacaacc tcttcaacac aaccgtttca gagctaagca 60 caagagtgc 69 <210> 9 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 9 tcttgtggaa agccagaaac atggctacga gagtacaagg tagtgtttca gagctaagca 60 caagagtgc 69 <210> 10 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 10 tcttgtggaa agccagaaac atggagacct tcttcttgcc acaggtttca gagctaagca 60 caagagtgc 69 <210> 11 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 11 tcttgtggaa agccagaaac atggatagca tagtggtcaa gcctgtttca gagctaagca 60 caagagtgc 69 <210> 12 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 12 tcttgtggaa agccagaaac atggagtcgg ctttcctttc caaggtttca gagctaagca 60 caagagtgc 69 <210> 13 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 13 tcttgtggaa agccagaaac atggatcttc cttcgaatgt gggagtttca gagctaagca 60 caagagtgc 69 <210> 14 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 14 tcttgtggaa agccagaaac atggacgcaa agctgtcatc gtgagtttca gagctaagca 60 caagagtgc 69 <210> 15 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 15 tcttgtggaa agccagaaac atggccaccg aggcctgcgc aagggtttca gagctaagca 60 caagagtgc 69 <210> 16 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 16 tcttgtggaa agccagaaac atggaaagtg ggaagtacgt cctggtttca gagctaagca 60 caagagtgc 69 <210> 17 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 17 tcttgtggaa agccagaaac atggagaggg atactcacac tccagtttca gagctaagca 60 caagagtgc 69 <210> 18 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 18 tcttgtggaa agccagaaac atggagggtt cgtagaagat tcaagtttca gagctaagca 60 caagagtgc 69 <210> 19 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 19 tcttgtggaa agccagaaac atggaacaaa gaaacatgtc agcagtttca gagctaagca 60 caagagtgc 69 <210> 20 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 20 tcttgtggaa agccagaaac atggcaatgg atttccggac gactgtttca gagctaagca 60 caagagtgc 69 <210> twenty one <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> twenty one tcttgtggaa agccagaaac atggaacaaa accagagtca tctggtttca gagctaagca 60 caagagtgc 69 <210> twenty two <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> twenty two tcttgtggaa agccagaaac atggcatggc cctacgctac cctagtttca gagctaagca 60 caagagtgc 69 <210> twenty three <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> twenty three tcttgtggaa agccagaaac atggaggcct tagagccaca gcgggtttca gagctaagca 60 caagagtgc 69 <210> twenty four <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> twenty four tcttgtggaa agccagaaac atggagcaag tgtacttggc gtgcgtttca gagctaagca 60 caagagtgc 69 <210> 25 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 25 tcttgtggaa agccagaaac atggcagcag atacctttac acccgtttca gagctaagca 60 caagagtgc 69 <210> 26 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 26 tcttgtggaa agccagaaac atggattacc agggatgttt ctgagtttca gagctaagca 60 caagagtgc 69 <210> 27 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 27 tcttgtggaa agccagaaac atgggactgg tgatgaatac aatggtttca gagctaagca 60 caagagtgc 69 <210> 28 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 28 tcttgtggaa agccagaaac atggacaggg ttgcggctgc aatggtttca gagctaagca 60 caagagtgc 69 <210> 29 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 29 tcttgtggaa agccagaaac atggcgtttg tcatcagaat cagagtttca gagctaagca 60 caagagtgc 69 <210> 30 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 30 tcttgtggaa agccagaaac atggcaccct ttacttctca ggacgtttca gagctaagca 60 caagagtgc 69 <210> 31 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 31 tcttgtggaa agccagaaac atggagactg ctgcctcata tccggtttca gagctaagca 60 caagagtgc 69 <210> 32 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 32 tcttgtggaa agccagaaac atggagcccc accagcaggt acacgtttca gagctaagca 60 caagagtgc 69 <210> 33 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 33 tcttgtggaa agccagaaac atggccgatg ttcttgtagt accggtttca gagctaagca 60 caagagtgc 69 <210> 34 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 34 tcttgtggaa agccagaaac atggaaacac tcaccgatct gtgagtttca gagctaagca 60 caagagtgc 69 <210> 35 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 35 tcttgtggaa agccagaaac atggcaacat agcagcatat ggtggtttca gagctaagca 60 caagagtgc 69 <210> 36 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 36 tcttgtggaa agccagaaac atggatcatc ctacccgaga tggtgtttca gagctaagca 60 caagagtgc 69 <210> 37 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 37 tcttgtggaa agccagaaac atggatcaac aatgccgaaa agaggtttca gagctaagca 60 caagagtgc 69 <210> 38 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 38 tcttgtggaa agccagaaac atggagctcc gcaacaagat agcagtttca gagctaagca 60 caagagtgc 69 <210> 39 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 39 tcttgtggaa agccagaaac atggaaagga tggaaaatac agccgtttca gagctaagca 60 caagagtgc 69 <210> 40 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 40 tcttgtggaa agccagaaac atggaactgg ttctacacgc gagcgtttca gagctaagca 60 caagagtgc 69 <210> 41 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 41 tcttgtggaa agccagaaac atggaaaaac acccgtggag ccgggtttca gagctaagca 60 caagagtgc 69 <210> 42 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 42 tcttgtggaa agccagaaac atggtacaaa gatgacatcc ggtggtttca gagctaagca 60 caagagtgc 69 <210> 43 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 43 tcttgtggaa agccagaaac atggcgtcat tcgaaacata gtgggtttca gagctaagca 60 caagagtgc 69 <210> 44 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 44 tcttgtggaa agccagaaac atggatcagt ctctgctgat cagggtttca gagctaagca 60 caagagtgc 69 <210> 45 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 45 tcttgtggaa agccagaaac atggaaatca ttatcttagc caccgtttca gagctaagca 60 caagagtgc 69 <210> 46 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 46 tcttgtggaa agccagaaac atggaaaaac gcaacaatca gatagtttca gagctaagca 60 caagagtgc 69 <210> 47 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 47 tcttgtggaa agccagaaac atgggttcat taaaatcgat ggcagtttca gagctaagca 60 caagagtgc 69 <210> 48 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 48 tcttgtggaa agccagaaac atggacctgc ctcacagtgc aggggtttca gagctaagca 60 caagagtgc 69 <210> 49 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 49 tcttgtggaa agccagaaac atggactgta gtatcagtca gtccgtttca gagctaagca 60 caagagtgc 69 <210> 50 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 50 tcttgtggaa agccagaaac atggaaattg aagttggtgg tggtgtttca gagctaagca 60 caagagtgc 69 <210> 51 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 51 tcttgtggaa agccagaaac atggacaaga aataccgtgc cctggtttca gagctaagca 60 caagagtgc 69 <210> 52 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 52 tcttgtggaa agccagaaac atgggcaaaa cttatgtgac cccggtttca gagctaagca 60 caagagtgc 69 <210> 53 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 53 tcttgtggaa agccagaaac atggcataaa tctcaagagg acctgtttca gagctaagca 60 caagagtgc 69 <210> 54 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 54 tcttgtggaa agccagaaac atgggacacc atgtggccac aaaggtttca gagctaagca 60 caagagtgc 69 <210> 55 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 55 tcttgtggaa agccagaaac atgggaagaa ctatgatccc cagagtttca gagctaagca 60 caagagtgc 69 <210> 56 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 56 tcttgtggaa agccagaaac atggggatgc gaagttcccg catggtttca gagctaagca 60 caagagtgc 69 <210> 57 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 57 tcttgtggaa agccagaaac atgggacccc aacgagatca aagtgtttca gagctaagca 60 caagagtgc 69 <210> 58 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 58 tcttgtggaa agccagaaac atgggccgga tgggacccga cgcggtttca gagctaagca 60 caagagtgc 69 <210> 59 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 59 tcttgtggaa agccagaaac atggctgccc cacaaaacca agcggtttca gagctaagca 60 caagagtgc 69 <210> 60 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 60 tcttgtggaa agccagaaac atgggtctcc tttggacctc atgcgtttca gagctaagca 60 caagagtgc 69 <210> 61 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 61 tcttgtggaa agccagaaac atggccgcca taacaaggac cgaagtttca gagctaagca 60 caagagtgc 69 <210> 62 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 62 tcttgtggaa agccagaaac atggctgcgc tatgactccc ggaggtttca gagctaagca 60 caagagtgc 69 <210> 63 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 63 tcttgtggaa agccagaaac atgggaatgc cagagaaggt cacagtttca gagctaagca 60 caagagtgc 69 <210> 64 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 64 tcttgtggaa agccagaaac atgggcacgt cacccacctt ccgggtttca gagctaagca 60 caagagtgc 69 <210> 65 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 65 tcttgtggaa agccagaaac atggcgtagc gcctcccgtg tccggtttca gagctaagca 60 caagagtgc 69 <210> 66 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 66 tcttgtggaa agccagaaac atggatttgc tcttaggttg tacggtttca gagctaagca 60 caagagtgc 69 <210> 67 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 67 tcttgtggaa agccagaaac atgggggata tccacagagt acctgtttca gagctaagca 60 caagagtgc 69 <210> 68 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 68 tcttgtggaa agccagaaac atggccgtgt cattgcccac acccgtttca gagctaagca 60 caagagtgc 69 <210> 69 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 69 tcttgtggaa agccagaaac atggaataga gtactatgct atgtgtttca gagctaagca 60 caagagtgc 69 <210> 70 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 70 tcttgtggaa agccagaaac atggcagatg tgcgcattga caccgtttca gagctaagca 60 caagagtgc 69 <210> 71 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 71 tcttgtggaa agccagaaac atggatttcc ttcagcgtaa ctgggtttca gagctaagca 60 caagagtgc 69 <210> 72 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 72 tcttgtggaa agccagaaac atgggtaaac aattctatta ccaggtttca gagctaagca 60 caagagtgc 69 <210> 73 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 73 tcttgtggaa agccagaaac atgggttaat aactgtgaga acacgtttca gagctaagca 60 caagagtgc 69 <210> 74 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 74 tcttgtggaa agccagaaac atggagcaac acagtcactc ctgggtttca gagctaagca 60 caagagtgc 69 <210> 75 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 75 tcttgtggaa agccagaaac atggcccagg cacagccgac gccggtttca gagctaagca 60 caagagtgc 69 <210> 76 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 76 tcttgtggaa agccagaaac atggcctcat tcgaccagtt ccgggtttca gagctaagca 60 caagagtgc 69 <210> 77 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 77 tcttgtggaa agccagaaac atgggccaaa cgtaccaaga aagtgtttca gagctaagca 60 caagagtgc 69 <210> 78 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 78 tcttgtggaa agccagaaac atggcctgct cacagcccga cgaagtttca gagctaagca 60 caagagtgc 69 <210> 79 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 79 tcttgtggaa agccagaaac atggcagact agtgctgagt cttggtttca gagctaagca 60 caagagtgc 69 <210> 80 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 80 tcttgtggaa agccagaaac atgggaggct tgtctatccc tcacgtttca gagctaagca 60 caagagtgc 69 <210> 81 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 81 tcttgtggaa agccagaaac atgggccaag aaggttgatg ctgggtttca gagctaagca 60 caagagtgc 69 <210> 82 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 82 tcttgtggaa agccagaaac atgggaactg aaattcgaat ggcggtttca gagctaagca 60 caagagtgc 69 <210> 83 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 83 tcttgtggaa agccagaaac atggagagag ccatcctcta taaggtttca gagctaagca 60 caagagtgc 69 <210> 84 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 84 tcttgtggaa agccagaaac atggcaccac agccttcccg cgaagtttca gagctaagca 60 caagagtgc 69 <210> 85 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 85 tcttgtggaa agccagaaac atggattgaa gacgtcattg cccagtttca gagctaagca 60 caagagtgc 69 <210> 86 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 86 tcttgtggaa agccagaaac atggggatgt agtgcagata gtctgtttca gagctaagca 60 caagagtgc 69 <210> 87 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 87 tcttgtggaa agccagaaac atggccagcg cgctacttac agtggtttca gagctaagca 60 caagagtgc 69 <210> 88 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 88 tcttgtggaa agccagaaac atggccggag tttgatgtgt aggggtttca gagctaagca 60 caagagtgc 69 <210> 89 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 89 tcttgtggaa agccagaaac atggcttgcg caggcgcttc agcagtttca gagctaagca 60 caagagtgc 69 <210> 90 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 90 tcttgtggaa agccagaaac atggcctcac aggcaggcta aacagtttca gagctaagca 60 caagagtgc 69 <210> 91 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 91 tcttgtggaa agccagaaac atggatatcc agaaagttta cctcgtttca gagctaagca 60 caagagtgc 69 <210> 92 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 92 tcttgtggaa agccagaaac atggagacat tgacctcacc aagagtttca gagctaagca 60 caagagtgc 69 <210> 93 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 93 tcttgtggaa agccagaaac atgggcgcgg cacctgtacc tccggtttca gagctaagca 60 caagagtgc 69 <210> 94 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 94 tcttgtggaa agccagaaac atggaccagt tcgaatgcct accagtttca gagctaagca 60 caagagtgc 69 <210> 95 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 95 tcttgtggaa agccagaaac atggtaggca ctgtcgcctt cccggtttca gagctaagca 60 caagagtgc 69 <210> 96 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 96 tcttgtggaa agccagaaac atggctgtgc ccgatgcgtg cccagtttca gagctaagca 60 caagagtgc 69 <210> 97 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 97 tcttgtggaa agccagaaac atggccaccc ggcccgtacc tcgagtttca gagctaagca 60 caagagtgc 69 <210> 98 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 98 tcttgtggaa agccagaaac atggagatgg ctactctgga gttggtttca gagctaagca 60 caagagtgc 69 <210> 99 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 99 tcttgtggaa agccagaaac atggcagacg aagcaagtaa ccatgtttca gagctaagca 60 caagagtgc 69 <210> 100 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 100 tcttgtggaa agccagaaac atggtaagat acttacaaac acacgtttca gagctaagca 60 caagagtgc 69 <210> 101 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 101 tcttgtggaa agccagaaac atggcataca cctgctcaca ggcggtttca gagctaagca 60 caagagtgc 69 <210> 102 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 102 tcttgtggaa agccagaaac atggagtggt gggaacgaca aacagtttca gagctaagca 60 caagagtgc 69 <210> 103 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 103 tcttgtggaa agccagaaac atggataagc aaaagcgtcc cagggtttca gagctaagca 60 caagagtgc 69 <210> 104 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 104 tcttgtggaa agccagaaac atggacagca caccgtaccg acaggtttca gagctaagca 60 caagagtgc 69 <210> 105 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 105 tcttgtggaa agccagaaac atgggcggac cagccgccgc agcagtttca gagctaagca 60 caagagtgc 69 <210> 106 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 106 tcttgtggaa agccagaaac atggtacaca gcgcaatggt aggtgtttca gagctaagca 60 caagagtgc 69 <210> 107 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 107 tcttgtggaa agccagaaac atggtcttgt tgatgcggat gacggtttca gagctaagca 60 caagagtgc 69 <210> 108 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 108 tcttgtggaa agccagaaac atggtcgcga caccctgtac gagggtttca gagctaagca 60 caagagtgc 69 <210> 109 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 109 tcttgtggaa agccagaaac atggttcatt tctccggatg ccaagtttca gagctaagca 60 caagagtgc 69 <210> 110 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 110 tcttgtggaa agccagaaac atggtcttct gcagttaaac acaggtttca gagctaagca 60 caagagtgc 69 <210> 111 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 111 tcttgtggaa agccagaaac atggtaccac acgaaggtgc gcgcgtttca gagctaagca 60 caagagtgc 69 <210> 112 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 112 tcttgtggaa agccagaaac atggtctttc tctaacagaa aaaggtttca gagctaagca 60 caagagtgc 69 <210> 113 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 113 tcttgtggaa agccagaaac atggttgtcg gacatacttc tggtgtttca gagctaagca 60 caagagtgc 69 <210> 114 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 114 tcttgtggaa agccagaaac atggtcctgg ccgggaaaac aagagtttca gagctaagca 60 caagagtgc 69 <210> 115 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 115 tcttgtggaa agccagaaac atgggaagtt cttcacccgc aggggtttca gagctaagca 60 caagagtgc 69 <210> 116 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 116 tcttgtggaa agccagaaac atggtgtacc cttccgctta cctggtttca gagctaagca 60 caagagtgc 69 <210> 117 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 117 tcttgtggaa agccagaaac atggtaaagc tgaagccaaa gcgagtttca gagctaagca 60 caagagtgc 69 <210> 118 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 118 tcttgtggaa agccagaaac atgggccgag cagtcaaatt ccaggtttca gagctaagca 60 caagagtgc 69 <210> 119 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 119 tcttgtggaa agccagaaac atggtttgcg attcttgctt cggtgtttca gagctaagca 60 caagagtgc 69 <210> 120 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 120 tcttgtggaa agccagaaac atggtggcag ctgtcacttt gcgggtttca gagctaagca 60 caagagtgc 69 <210> 121 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 121 tcttgtggaa agccagaaac atggtgagat gatcgacgtc atcggtttca gagctaagca 60 caagagtgc 69 <210> 122 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 122 tcttgtggaa agccagaaac atggtgcttt gtagaaaaag tcgcgtttca gagctaagca 60 caagagtgc 69 <210> 123 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 123 tcttgtggaa agccagaaac atgggcttca agaagcgtgc acctgtttca gagctaagca 60 caagagtgc 69 <210> 124 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 124 tcttgtggaa agccagaaac atggcttcca gctccttgac gttggtttca gagctaagca 60 caagagtgc 69 <210> 125 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 125 tcttgtggaa agccagaaac atggtattgt aggaaagcct acgtgtttca gagctaagca 60 caagagtgc 69 <210> 126 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 126 tcttgtggaa agccagaaac atggttacat cttagagagc ttgggtttca gagctaagca 60 caagagtgc 69 <210> 127 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 127 tcttgtggaa agccagaaac atgggtgtct taggctgtgg tccagtttca gagctaagca 60 caagagtgc 69 <210> 128 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 128 tcttgtggaa agccagaaac atgggtggct ttgccccgta cgaggtttca gagctaagca 60 caagagtgc 69 <210> 129 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 129 tcttgtggaa agccagaaac atggtttaga taactggagt gccagtttca gagctaagca 60 caagagtgc 69 <210> 130 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 130 tcttgtggaa agccagaaac atggtcggga tcgtcggtaa atacgtttca gagctaagca 60 caagagtgc 69 <210> 131 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 131 tcttgtggaa agccagaaac atgggttgca gcctcggaaa attggtttca gagctaagca 60 caagagtgc 69 <210> 132 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 132 tcttgtggaa agccagaaac atggtttgtt aggtcatcgt attggtttca gagctaagca 60 caagagtgc 69 <210> 133 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 133 tcttgtggaa agccagaaac atggtcatct tgtacatacc ctgcgtttca gagctaagca 60 caagagtgc 69 <210> 134 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 134 tcttgtggaa agccagaaac atgggttggt ggtgacaaga acgggtttca gagctaagca 60 caagagtgc 69 <210> 135 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 135 tcttgtggaa agccagaaac atggttcagc ttcgaaaggc aagggtttca gagctaagca 60 caagagtgc 69 <210> 136 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 136 tcttgtggaa agccagaaac atgggggcct actcacctgc tcgagtttca gagctaagca 60 caagagtgc 69 <210> 137 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 137 tcttgtggaa agccagaaac atggttatcc gaaatgtttc attggtttca gagctaagca 60 caagagtgc 69 <210> 138 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 138 tcttgtggaa agccagaaac atggggacga cgaccggctc aacagtttca gagctaagca 60 caagagtgc 69 <210> 139 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 139 tcttgtggaa agccagaaac atgggtaatg tgtccattcg aggggtttca gagctaagca 60 caagagtgc 69 <210> 140 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 140 tcttgtggaa agccagaaac atgggttgac atctgacgac gtgagtttca gagctaagca 60 caagagtgc 69 <210> 141 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 141 tcttgtggaa agccagaaac atgggactgg tgggatgaag gtaagtttca gagctaagca 60 caagagtgc 69 <210> 142 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 142 tcttgtggaa agccagaaac atgggctggt cgaggtccac gccggtttca gagctaagca 60 caagagtgc 69 <210> 143 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 143 tcttgtggaa agccagaaac atggtgacgt gcaactcaaa gaccgtttca gagctaagca 60 caagagtgc 69 <210> 144 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 144 tcttgtggaa agccagaaac atgggaaaag tactacacgc gcctgtttca gagctaagca 60 caagagtgc 69 <210> 145 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 145 tcttgtggaa agccagaaac atggtcaaca ccaacatcga tggggtttca gagctaagca 60 caagagtgc 69 <210> 146 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 146 tcttgtggaa agccagaaac atggtgacgg tatccaccca ttcggtttca gagctaagca 60 caagagtgc 69 <210> 147 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 147 tcttgtggaa agccagaaac atgggtgtgt gctgacttga taaggtttca gagctaagca 60 caagagtgc 69 <210> 148 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 148 tcttgtggaa agccagaaac atggtggtca tgaactttct agtggtttca gagctaagca 60 caagagtgc 69 <210> 149 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 149 tcttgtggaa agccagaaac atggtgcagc gaataggctg cacggtttca gagctaagca 60 caagagtgc 69 <210> 150 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 150 tcttgtggaa agccagaaac atggggatac gatagaaaat gtaagtttca gagctaagca 60 caagagtgc 69 <210> 151 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 151 tcttgtggaa agccagaaac atgggctgaa aaggtggcca ctaggtttca gagctaagca 60 caagagtgc 69 <210> 152 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 152 tcttgtggaa agccagaaac atggttccat ggtcaaaaaa tggcgtttca gagctaagca 60 caagagtgc 69 <210> 153 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 153 tcttgtggaa agccagaaac atggtgttcc tcaggaaaat gatggtttca gagctaagca 60 caagagtgc 69 <210> 154 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 154 tcttgtggaa agccagaaac atggttcact gcaatgtaat cctggtttca gagctaagca 60 caagagtgc 69 <210> 155 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 155 tcttgtggaa agccagaaac atggtacttt ctatgagaag cgtagtttca gagctaagca 60 caagagtgc 69 <210> 156 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 156 tcttgtggaa agccagaaac atgggccaag atcgtgaagc ccaagtttca gagctaagca 60 caagagtgc 69 <210> 157 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 157 tcttgtggaa agccagaaac atgggctggt tcgtaccaag acccgtttca gagctaagca 60 caagagtgc 69 <210> 158 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 158 tcttgtggaa agccagaaac atggtgggct ccggaacaaa cgtggtttca gagctaagca 60 caagagtgc 69 <210> 159 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 159 tcttgtggaa agccagaaac atggttggca gggagctcac tcaggtttca gagctaagca 60 caagagtgc 69 <210> 160 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 160 tcttgtggaa agccagaaac atggtccgtc tgcttcatga gcgggtttca gagctaagca 60 caagagtgc 69 <210> 161 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 161 tcttgtggaa agccagaaac atggtcctca cctaaagtgc aatagtttca gagctaagca 60 caagagtgc 69 <210> 162 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 162 tcttgtggaa agccagaaac atggtcctcg atagctggaa tccagtttca gagctaagca 60 caagagtgc 69 <210> 163 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 163 tcttgtggaa agccagaaac atggtcctgc caagaaacac ccttgtttca gagctaagca 60 caagagtgc 69 <210> 164 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 164 tcttgtggaa agccagaaac atggtcctgg ataccgcgtg gttagtttca gagctaagca 60 caagagtgc 69 <210> 165 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 165 tcttgtggaa agccagaaac atggtcgaga ggaaaaacac actggtttca gagctaagca 60 caagagtgc 69 <210> 166 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 166 tcttgtggaa agccagaaac atggtcgaga tgcgcagcag atgagtttca gagctaagca 60 caagagtgc 69 <210> 167 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 167 tcttgtggaa agccagaaac atggtcgatc gaggttgcat tcgggtttca gagctaagca 60 caagagtgc 69 <210> 168 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 168 tcttgtggaa agccagaaac atggtcgatg tagccccgcc caaggtttca gagctaagca 60 caagagtgc 69 <210> 169 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 169 tcttgtggaa agccagaaac atggtcgcaa ggaagccagc taaggtttca gagctaagca 60 caagagtgc 69 <210> 170 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 170 tcttgtggaa agccagaaac atggtcgcag cggcgtggga tcgggtttca gagctaagca 60 caagagtgc 69 <210> 171 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 171 tcttgtggaa agccagaaac atggtcgcgc ttgggttata cgctgtttca gagctaagca 60 caagagtgc 69 <210> 172 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 172 tcttgtggaa agccagaaac atggtcgcgg acatagggct ctaagtttca gagctaagca 60 caagagtgc 69 <210> 173 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 173 tcttgtggaa agccagaaac atggtcggaa gcaaacttct ggaggtttca gagctaagca 60 caagagtgc 69 <210> 174 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 174 tcttgtggaa agccagaaac atggtcggca tacgggacac acgcgtttca gagctaagca 60 caagagtgc 69 <210> 175 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 175 tcttgtggaa agccagaaac atggtcggct acaatctttg gcatgtttca gagctaagca 60 caagagtgc 69 <210> 176 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 176 tcttgtggaa agccagaaac atggtcggct acggcgtgga gaaggtttca gagctaagca 60 caagagtgc 69 <210> 177 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 177 tcttgtggaa agccagaaac atggtcggct cctgaagcca gtatgtttca gagctaagca 60 caagagtgc 69 <210> 178 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 178 tcttgtggaa agccagaaac atggtcgggc agtgagtaca atacgtttca gagctaagca 60 caagagtgc 69 <210> 179 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 179 tcttgtggaa agccagaaac atggtcgggg accacccacg atccgtttca gagctaagca 60 caagagtgc 69 <210> 180 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 180 tcttgtggaa agccagaaac atggtcgtaa acacacgacc aagtgtttca gagctaagca 60 caagagtgc 69 <210> 181 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 181 tcttgtggaa agccagaaac atggtctaaa gccgtcctga tgttgtttca gagctaagca 60 caagagtgc 69 <210> 182 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 182 tcttgtggaa agccagaaac atggtctacc tattgtggaa tttggtttca gagctaagca 60 caagagtgc 69 <210> 183 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 183 tcttgtggaa agccagaaac atggtctacg tgtagttgta catagtttca gagctaagca 60 caagagtgc 69 <210> 184 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 184 tcttgtggaa agccagaaac atggtctatt ttgtctgcgc agaagtttca gagctaagca 60 caagagtgc 69 <210> 185 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 185 tcttgtggaa agccagaaac atggtctcgt agcctaatgc gccagtttca gagctaagca 60 caagagtgc 69 <210> 186 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 186 tcttgtggaa agccagaaac atggtctctc ggagtggagc aacagtttca gagctaagca 60 caagagtgc 69 <210> 187 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 187 tcttgtggaa agccagaaac atggtctgaa aaataggccc aaccgtttca gagctaagca 60 caagagtgc 69 <210> 188 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 188 tcttgtggaa agccagaaac atggtctgac gattaatgct tctagtttca gagctaagca 60 caagagtgc 69 <210> 189 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 189 tcttgtggaa agccagaaac atggtctggc ttgacacgac cgttgtttca gagctaagca 60 caagagtgc 69 <210> 190 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 190 tcttgtggaa agccagaaac atggtctggc ttgcaccgtg tcatgtttca gagctaagca 60 caagagtgc 69 <210> 191 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 191 tcttgtggaa agccagaaac atggtgaacg cgtgtttcct tgcagtttca gagctaagca 60 caagagtgc 69 <210> 192 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 192 tcttgtggaa agccagaaac atggtgaacg gtgaagagat aggggtttca gagctaagca 60 caagagtgc 69 <210> 193 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 193 tcttgtggaa agccagaaac atggtgaagt ggggcgtcgg acacgtttca gagctaagca 60 caagagtgc 69 <210> 194 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 194 tcttgtggaa agccagaaac atggtgaatc gaatacaaac gatggtttca gagctaagca 60 caagagtgc 69 <210> 195 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 195 tcttgtggaa agccagaaac atggtgaatc gtaacctcgc cattgtttca gagctaagca 60 caagagtgc 69 <210> 196 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 196 tcttgtggaa agccagaaac atggtgacac attggctggg tgttgtttca gagctaagca 60 caagagtgc 69 <210> 197 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 197 tcttgtggaa agccagaaac atggtgacct ctgaggaatt cacagtttca gagctaagca 60 caagagtgc 69 <210> 198 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 198 tcttgtggaa agccagaaac atggtgacgc gatagagttg gcttgtttca gagctaagca 60 caagagtgc 69 <210> 199 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 199 tcttgtggaa agccagaaac atggtgacgc tccacgtccg gaccgtttca gagctaagca 60 caagagtgc 69 <210> 200 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 200 tcttgtggaa agccagaaac atggtgacta gctcttacat attcgtttca gagctaagca 60 caagagtgc 69 <210> 201 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 201 tcttgtggaa agccagaaac atggtgactc gggcaatatc ggttgtttca gagctaagca 60 caagagtgc 69 <210> 202 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 202 tcttgtggaa agccagaaac atggtgagca tgtcgggagt aactgtttca gagctaagca 60 caagagtgc 69 <210> 203 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 203 tcttgtggaa agccagaaac atggtgagca ttcgtagccc agcagtttca gagctaagca 60 caagagtgc 69 <210> 204 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 204 tcttgtggaa agccagaaac atggtgagcg gcctctaatt aatcgtttca gagctaagca 60 caagagtgc 69 <210> 205 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 205 tcttgtggaa agccagaaac atggtgagga tcatgtcgag cgccgtttca gagctaagca 60 caagagtgc 69 <210> 206 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 206 tcttgtggaa agccagaaac atggtgagtc ttactaggtc ctgtgtttca gagctaagca 60 caagagtgc 69 <210> 207 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 207 tcttgtggaa agccagaaac atggtgcaac cttccttttc aggagtttca gagctaagca 60 caagagtgc 69 <210> 208 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 208 tcttgtggaa agccagaaac atggtgcaag gacctggtat gaacgtttca gagctaagca 60 caagagtgc 69 <210> 209 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 209 tcttgtggaa agccagaaac atggtgcagg tctaggtccc aaaggtttca gagctaagca 60 caagagtgc 69 <210> 210 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 210 tcttgtggaa agccagaaac atggtgcagt cgcgctgagc gtcagtttca gagctaagca 60 caagagtgc 69 <210> 211 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 211 tcttgtggaa agccagaaac atggatcaac gactaccagc ccgggtttca gagctaagca 60 caagagtgc 69 <210> 212 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 212 tcttgtggaa agccagaaac atggagacgt gcactttgag cggagtttca gagctaagca 60 caagagtgc 69 <210> 213 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 213 tcttgtggaa agccagaaac atggagtgca aggatagaaa caccgtttca gagctaagca 60 caagagtgc 69 <210> 214 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 214 tcttgtggaa agccagaaac atggaaacaa aagcccatga atgtgtttca gagctaagca 60 caagagtgc 69 <210> 215 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 215 tcttgtggaa agccagaaac atggcaacat taaataccca atgagtttca gagctaagca 60 caagagtgc 69 <210> 216 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 216 tcttgtggaa agccagaaac atggcaacca caatctcagg acgagtttca gagctaagca 60 caagagtgc 69 <210> 217 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 217 tcttgtggaa agccagaaac atgggcaact tgtcacagac gcaggtttca gagctaagca 60 caagagtgc 69 <210> 218 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 218 tcttgtggaa agccagaaac atggcctgcc aagaaggatg tcaagtttca gagctaagca 60 caagagtgc 69 <210> 219 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 219 tcttgtggaa agccagaaac atggcgtgga cggagtgatt acgagtttca gagctaagca 60 caagagtgc 69 <210> 220 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 220 tcttgtggaa agccagaaac atggagtgat tgtgtgtcct accagtttca gagctaagca 60 caagagtgc 69 <210> 221 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 221 tcttgtggaa agccagaaac atggaagtct acttgtatct acgggtttca gagctaagca 60 caagagtgc 69 <210> 222 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 222 tcttgtggaa agccagaaac atggaagatt taatagctca agcagtttca gagctaagca 60 caagagtgc 69 <210> 223 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 223 tcttgtggaa agccagaaac atggacgtca gggatgtcct cgatgtttca gagctaagca 60 caagagtgc 69 <210> 224 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 224 tcttgtggaa agccagaaac atggaaacac aaaattcacg tccagtttca gagctaagca 60 caagagtgc 69 <210> 225 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 225 tcttgtggaa agccagaaac atggaggtgc caacacccat ccaggtttca gagctaagca 60 caagagtgc 69 <210> 226 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 226 tcttgtggaa agccagaaac atggatcatc tcacagttca accagtttca gagctaagca 60 caagagtgc 69 <210> 227 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 227 tcttgtggaa agccagaaac atggcgccca ggaatagtta ggaggtttca gagctaagca 60 caagagtgc 69 <210> 228 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 228 tcttgtggaa agccagaaac atggcccagg tcgaacatat ccaggtttca gagctaagca 60 caagagtgc 69 <210> 229 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 229 tcttgtggaa agccagaaac atggcaaaac attatactgg catggtttca gagctaagca 60 caagagtgc 69 <210> 230 <211> 69 <212> DNA <213> Artificial sequence <220> <223> Synthetic polynucleotides <400> 230 tcttgtggaa agccagaaac atggaacacc accgtacctt cccggtttca gagctaagca 60 caagagtgc 69 <210> 231 <211> 69 <212> DNA <213> Artificial sequence <220> <223>...

Claims

1. A high throughput screening method for imaging altered phenotypes and corresponding genotypes in a plurality of mammalian cells, the method comprising: (a) introducing DNA into the plurality of mammalian cells, the DNA comprising: a guide portion comprising a recognition sequence, a reporter gene portion, and an identification portion comprising a reading sequence, wherein the guide portion is operably linked to a first promoter, and the reporter gene portion and the identification portion are operably linked to a second promoter; (b) determining the location of RNA molecules expressed by the reporter gene portion of the introduced DNA within the plurality of mammalian cells by determining the reporter gene portion, wherein a labeled oligonucleotide hybridizes to the expressed RNA and is imaged; (c) determining a read sequence on the RNA molecule expressed by the introduced DNA comprising the reporter gene portion and the marker portion in the plurality of mammalian cells by exposing the mammalian cells to a read probe capable of binding to the read sequence; (d) co-localizing the binding of the readout probe with the position of the RNA molecule expressed by the reporter gene portion of the introduced DNA; (e) repeating (b), (c) and (d) multiple times using different read sequences; and (f) forming a codeword corresponding to the binding of the co-localized read probes, wherein a bit value of the codeword is based on binding of the read probe to the read sequence, and wherein the co-localization improves decoding accuracy of the generated codeword.

2. The method of claim 1, further comprising identifying a guide portion of a single cell based on the measured codeword.

3. The method of any one of claims 1 or 2, wherein the recognition sequence recognizes a DNA sequence.

4. The method of claim 1, wherein the recognition sequence recognizes an RNA sequence.

5. The method of claim 1, wherein the introduced DNA is derived from a nucleic acid library. The method of claim 5 , wherein the library is generated by mixed cloning.

7. The method of claim 1, wherein the identity of the associated pair of the guide moiety and the marker moiety on the DNA is determined by sequencing.

8. The method of claim 1, wherein the introduced DNA allows the association of the guide moiety and the tag moiety to occur.

9. The method of claim 1, wherein each read sequence represents a value of a position within a codeword.

10. The method of claim 1, wherein the read sequences are determined sequentially.

11. The method of claim 1, wherein the guide portion further comprises a Cas protein binding sequence.

12. The method of claim 11, wherein the guide portion allows the Cas protein to target DNA or RNA to interfere with the sequence or expression of a gene.

13. The method of claim 1, wherein the reporter gene portion encodes a protein that can be detected by fluorescence.

14. The method of claim 1, wherein the reporter gene portion encodes a fluorescent protein.

15. The method of claim 1, wherein the reporter gene portion encodes luciferase.

16. The method of claim 1, wherein the reporter gene portion encodes a protein that can be detected by immunoprecipitation.

17. The method of claim 1, wherein the reporter gene portion encodes a protein that can be detected by immunofluorescence.

18. The method of claim 1, wherein the reporter gene portion encodes a Myc tag.

19. The method of claim 1, wherein the reporter gene portion encodes an HA tag.

20. The method of claim 1, wherein the reporter gene moiety comprises a reporter gene.

21. The method of claim 1, wherein the identification moiety is present in the 3'UTR of the reporter gene.

22. The method of claim 1, wherein the reporter gene portion comprises a first promoter.

23. The method of claim 22, wherein the promoter is a promoter that drives transcription.

24. The method of any one of claims 22 or 23, wherein the promoter comprises a CMV promoter.

25. The method of claim 22, wherein the recognition sequence comprises a second promoter separated from the first promoter.

26. The method of claim 1, wherein the recognition sequence and the reporter gene portion are separated by less than 1000 bases.

27. The method of claim 1, wherein the recognition sequence and the reporter gene portion are separated by less than 100 bases within the DNA.

28. The method of claim 1, comprising determining one or more read sequences using fluorescence.

29. The method of claim 1, comprising determining the location of RNA comprising the reporter gene portion and the marker portion using smFISH targeted to the reporter gene portion.

30. The method of claim 1, comprising introducing the DNA into the plurality of mammalian cells using a virus.

31. The method of claim 30, wherein the virus is a lentivirus.

32. The method of claim 31, wherein the guide moiety and the tag moiety are positioned immediately 3' to a polypurine band sequence within the lentivirus.

33. The method of claim 32, wherein the guide portion replicates within the 5' region of the lentivirus.

34. The method of claim 1, wherein introducing the DNA into the plurality of mammalian cells comprises electroporating the DNA into the plurality of mammalian cells.

35. The method of claim 1, wherein the cells comprise cells in a tissue.

36. The method of claim 1, comprising introducing the DNA into the plurality of mammalian cells such that at least 50% of the cells contain no more than one type of introduced DNA.

37. The method of claim 1, comprising introducing the DNA into the plurality of mammalian cells such that at least 90% of the cells contain no more than one type of introduced DNA.

38. The method of claim 1, comprising introducing the DNA into the genome of the cell.

39. The method of claim 1, wherein the DNA further comprises a promoter.

40. The method of claim 1, wherein the read sequence defines a binary space of the number of bits of the codeword.

41. The method of claim 1, wherein the read sequence defines a ternary space of the number of bits of the codeword.

42. The method of claim 1, wherein determining the one or more read sequences comprises: For each bit number of the codeword, a readout probe corresponding to the bit number of the codeword is applied to the plurality of mammalian cells.

43. The method of claim 42, comprising sequentially applying and removing each of the readout probes to the plurality of mammalian cells.

44. The method of claim 43, wherein for at least some of the formed codewords, the codewords are matched with valid codewords, wherein: If no match is found, the codeword is discarded or error correction is applied to the codeword to form a valid codeword.

45. The method of claim 44, wherein the value of the number of bits of the codeword defines a set of potential codewords.

46. ​​The method of claim 45, wherein the set of potential codewords includes at least 10 2 A single sequence.

47. The method of claim 46, wherein the set of potential codewords includes at least 10 3 A single sequence.

48. The method of any one of claims 46 or 47, wherein the set of potential codewords comprises at least 10 4 A single sequence.

49. The method of claim 46, wherein the set of potential codewords includes at least 10 5 A single sequence.

50. The method of claim 46, wherein the set of potential codewords includes at least 10 6 A single sequence.

51. The method of claim 46, wherein a portion of the potential codewords are valid codewords.

52. The method of claim 51, comprising comparing the measured codeword to the valid codeword to determine an error in the codeword measurement.

53. The method of claim 44, wherein the valid codewords are a randomly selected subset of possible codewords.

54. The method of claim 53, wherein less than 10% of possible codewords are valid codewords.

55. The method of any one of claims 53 or 54, wherein less than 5% of possible codewords are valid codewords.

56. The method of claim 53, wherein less than 1% of possible codewords are valid codewords.

57. The method of claim 53, wherein less than 0.5% of possible codewords are valid codewords.

58. The method of claim 1, wherein the identification portion comprises N variable portions, N is at least 3, each variable portion having at least two possibilities.

59. The method of claim 58, wherein N is at least 5.

60. The method of any one of claims 58 or 59, wherein N is at least 10.

61. The method of claim 58, wherein N is at least 15.

62. The method of claim 58, wherein N is at least 20.

63. The method of claim 58, wherein the variable portions within the identification portion each have the same length.

64. The method of claim 58, wherein the variable portions within the identification portion each have a length of 5-50 nt.

65. The method of claim 58, wherein the variable portions within the identification portion each have a length of 15-25 nt.

66. The method of claim 1, wherein the identification portion comprises an error detection code.

67. The method of claim 1, wherein the identification portion comprises an error correction code.

68. The method of claim 66, wherein the error detection code comprises a Hamming code.

69. The method of claim 66, wherein the error detection code comprises an extended Hamming code.

70. The method of claim 66, wherein the error detection code comprises a Reed-Solomon code.

71. The method of claim 66, wherein the error detection code is not the same for all members of the error detection code.

72. The method of claim 67, wherein the error correcting code comprises a Hamming code.

73. The method of claim 67, wherein the error correcting code comprises an extended Hamming code.

74. The method of claim 67, wherein the error correcting code comprises a Reed-Solomon code.

75. The method of claim 67, wherein the error correction code is not the same for all members of the error correction code.

76. The method of claim 1, wherein the identification portion comprises at least 8 possible read sequences.

77. The method of claim 1, wherein the identification portion comprises at least 16 possible read sequences.

78. The method of claim 1, wherein the identification portion comprises no more than 32 possible read sequences.

79. The method of claim 1, wherein the identification portion comprises at least 32 possible read sequences.

80. A high throughput screening method for imaging altered phenotypes and corresponding genotypes in a plurality of mammalian cells, the method comprising: Introducing DNA into a plurality of mammalian cells, the DNA comprising: a guide portion comprising a recognition sequence, a reporter gene portion, and an identifier portion comprising a reader sequence, wherein the guide portion is operably linked to a first promoter, and the reporter gene portion and the identifier portion are operably linked to a second promoter; determining the location of RNA molecules expressed by the reporter gene portion of the introduced DNA within the plurality of mammalian cells by determining the reporter gene portion, wherein a labeled oligonucleotide hybridizes to the expressed RNA and is imaged; determining the read sequence within the plurality of mammalian cells by exposing the mammalian cells to a plurality of read probes each capable of binding to the read sequence, colocalizing the binding of the readout probe with the position of the RNA molecule expressed by the reporter gene portion of the introduced DNA; and A codeword is formed corresponding to the binding of the colocalized read probes, wherein a bit value of the codeword is based on binding of the read probe to the read sequence, and wherein the colocalization improves decoding accuracy of the generated codeword.

Citation Information

Patent Citations

  • Probe library construction

    US10240146B2

  • Systems and methods for determining nucleic acids

    US20170220733A1

  • Sub-diffraction limit image resolution and other imaging techniques

    US7838302B2

  • Photoconvertible fluorescent proteins

    WO2015160690A1

  • Systems and methods for determining nucleic acids

    WO2016018960A1